Jla wbqšY KwgwUi 18 A‡±vei 2016 Zwi‡L Abyôv‡Z 246 Zg mfvi Kvhweeiƒ

¯v¯¨ I cwievi Kj¨vY gšYvj‡qi mwPe Rbve ‰mq` gbRyj Bmjvg Gwu mfvcwZ‡Z Jla wbqšY KwgwUi 246 Zg mfv weMZ 18 A‡±vei 2016 ZwiL ‡ejv 11:00 NwUKvq gšYvj‡qi mfv K‡¶ Abyôv‡Z nq|

mfvq Kwমটির নিম্নবর্ণিত সদস্যগণ উপস্থিত ছিলেন (জ্যেষ্ঠতার ক্রমানুসারে নয়) ঃ

1| Rbve mykxgvi iÄb †NvI, cwZwbwa, evsjv‡`k dvgwmDwUK¨vjm B‡¤úvUvm G‡mvwm‡qkb, XvKv|
2| Aa¨vcK Wvt Kvgiæj nvmvb Lvb, DcvPvh, e½eÜztkL gyRe †gwW‡Kj wekwe`¨vjq, XvKv|
3| ‡gRi †Rbv‡ij †gvt Ave`yj Avjx wgqv, Kbmvj‡U›U wdwRwkqvb ‡Rbv‡ij, evsjv‡`k AvgW †dv‡mm †gwW‡Kj mwf‡mm|
4| Rbve L›`Kvi iwKeyj ingvb, gnvcwiPvjK, gv`K`e¨ wbqšY Awa`ßi, †ZRMvwu, XvKv|
5| Wvt GBPwe Gg †Mvjvg gvngy`, cwiPvjK, wiPvm †Uwbs GÛ Bfvjyqkb, jvBf ÷K wiPvm Bbw÷wUDU, c‡¶ gnvcwiPvjK, cwY m¤ú` Awa`ßi, XvKv|
6| Aa¨vcK Wvt †gvt BmgvBj Lvb, Wxb wPwKrmv Abyj`, XvKv wekwe`¨vjq I cwZwbwa, dvgv‡Kvjwf wefvM, XvKv †gwW‡Kj K‡jR|
7| Aa¨vcK dwi`v †eMg, wKwbK¨vj dv‡gmx I dvgv‡Kvjwf wefvM, XvKv wekwe`¨vjq|
8| Aa¨vcK Wvt RwKi †nvmvBb Mwje, Pg I †hŠb †ivM we‡klÁ, m¨vi mwjgyjvn †gwW‡Kj K‡jR, XvKv|
9| Rbve GmGg kwdD¾vgvb, gnvmwPe, evsjv‡`k Jla wkí mwgwZ, XvKv|
10| Rbve Ave`yj †gv³wi`i, mv‡eK gnvmwPe, evsjv‡`k Jla wkí mwgwZ Ges e¨e¯vcbv cwiPvjK, Bb‡mÞv dvgv wjt|
11| Wvt †gv‡gbyj nK, mv‡eK wmwbqi mn mfvcwZ, evsjv‡`k Jla wkí mwgwZ Ges e¨e¯vcbv cwiPvjK, †Rbv‡ij dvgwmDwUK¨vjm wjt|
12| Rbve Gg †gvQv‡ÏK †nv‡mb, cwZwbwa, evsjv‡`k dv‡gmx KvDwÝj, XvKv|
13| nvKxg †gvt BDmyd nvi‡b fBqv, BDbvbx we‡klÁ, evsjv‡`k BDbvbx I Avq‡ew`K †evW|
14| ‡gRi †Rbv‡ij †gvt ‡gv¯wdRyj ingvb, gnvcwiPvjK, Jla ckvmb Awa`ßi, XvKv|

mfvq Av‡jvP¨ welq mgn¨wbgi|c t

1| Jla wbqšY KwgwUi 245Zg mfvi Kvhweeiƒ wbwðZKiY cm‡½|

2| Jla wbqšY KwgwUi †UKwbK¨vj mve KwgwUi MZ 29-09-2016 Zwi‡L Abyôv‡Z mfvi myZwwikmg‡ni welq Av‡jvPbv I wm×vš MnY cm‡½:

K) ¯vbxq Drcv`‡bi Rb¨ bZzb 119 wU Jl‡ai †iwR‡÷k‡bi wbwg‡Ë `wLjKZ.Av‡e`‡bi myZwwikmg‡ni welq Av‡jvPbv I wm×vš MnY cm‡½|

L) Avg`vbxi Rb¨ bZzb 23 wU Jl‡ai †iwR‡÷k‡bi wbwg‡Ë `wLjKZ. Av‡e`‡bi myZwwikmg‡ni welq Av‡jvPbv I wm×vš MnY cm‡½|

M) ¯vbxq Drcv`‡bi Rb¨ bZzb ‡f‡Uwibvix Jla 6wU I f¨vKwmb 6 wUi †iwR‡÷k‡bi wbwg‡Ë `wLjKZ.Av‡e`‡bi mgvwikmg‡ni wel‡q Av‡jvPbv I wm×vš MnY cm‡½|

N) Avg`vbxi Rb¨ bZzb 15wU Jl‡ai †iwR‡÷k‡bi wbwg‡Ë `wLjKZ. Av‡e`‡bi mgvwikmg‡ni wel‡q Av‡jvPbv I wm×vš MnY cm‡½|

3| Jla wbqšY KwgwUi ‡gwW‡Kj wWfvBm gj¨vq‡bi wbwg‡Ë MwVZ †UKwbK¨vj mve KwgwUi MZ 10-08-2016 I 29-09-2016 Zwi‡L AbyôZ mfvq Avg`vbxi Rb¨ bZzb me‡gvU 27wU †gwW‡Kj wWfvBm-Gi †iwR‡÷k‡bi wbwg‡Ë `wLjKZ. Av‡e`‡bi mgvwikmg‡ni wel‡q Av‡jvPbv I wm×vš MnY cm‡½|

4| nvevj Jla GWfvBRix KwgwU (Jla wbqšY KwgwUi †UKwbK¨vj mve KwgwU)-Gi GK mfv weMZ 29-09-2016 Zwi‡L AbyôZ mfvq ¯vbxqfv‡e Drcv`‡bi Rb¨ bZzb 18wU nvevj Jl‡ai †iwR‡÷k‡bi wbwg‡Ë `wLjKZ.Av‡e`b Gi Dci gZvgZ c`vb cm‡½|

5| wWwmwm 244Zg mfvq †iwR‡÷kb ewZjKZ. Rosiglitazone 2 mg I 4mg Ges Pioglitazone 30 mg I 45 mg-Gi K¤‡bkb Jla¸wji †iwR‡÷kb ewZjKiY cm‡½ |

6| Glimepiride 2mg + Metformin BP 500mg Bilayer Tablet-Gi Abyfgv`‡bi wel‡q Av‡jvPbv I wm×vš MnY cm‡½|

7| **wewea Av‡jvPbv t**

K) Jla ckvmb Awa`ßi KZ„K BwZc‡e †iwR‡÷kb c`vbKZ.K¤‡bkb Jl‡ai †hš¿KZv wifD cm‡½|

L) Jl‡ai gj¨ ew„× cwZ‡iv‡a KiYxq wbaviY cm‡½|

<u>mfvi Av‡jvPbv I wm×vš t</u>

mfvcwZ Dcw¯Z সকলকে স্বাগত জানিয়ে সভার কার্যক্রম শুরু করেন। অতঃপর তিনি সদস্য-mwPe ‡gRi †Rbv‡ij †gvt ‡gv¯wdRyi ingvb, gnvcwiPvjK, Jla ckvmb Awa`ßi‡K Av‡jvP¨mPx Abyôvqx welqmgn Dc¯vcb Kivi Rb¨ Abyfiva K‡ib|

1| **Jla wbqšY KwgwUi 245 Zg mfvi KvhweeiYx wbwðZKiY cm‡½|**

weMZ 23-06-2016 Zwi‡L AbyôZ Jla wbqšY KwgwUi 245 Zg mfvi KvhweeiYx mfvq Dc¯vcb Kiv nq| Kvhweeiyx mwVKfv‡e wjwce× n‡q‡Q e‡j m`m¨MY gZ cKvk K‡ib|

সভায় সর্বসম্মতিক্রমে ২৪৫ তম সভার কার্যবিবরণী নিশ্চিত করা হয়।

2| **¯vbxq Drcv`b I Avg`vbxi Rb¨ wnDg¨vb I †f‡Uwibvix Jl‡ai wel‡q Av‡jvPbv I wm×vš MnY cm‡½ t**

K) ¯vbxq Drcv`‡bi Rb¨ †iwR‡÷k‡bi wbwg‡Ë `wLjKZ.119wU bZzb Jla mfvq Dc¯vcb Kiv n‡j m`m¨MY Jla¸wji Jla wbqšY KwgwUi †UKwbK¨vj mve-KwgwUi mgvwi‡ki Av‡jv‡K বিস্তারিত আলোচনাক্রমে ঊ³ Jla¸‡jvi g‡a¨ 49wU Jl‡ai Abyhvqx`b, ‡WvR mgšq K‡i †idv‡iÝmn cÖKvq `wLj 01 wU, ¯wMZ 24wU (wWwmwm Gi 245 I 244 Zg mfvq Jla¸wji Av‡e`b bvgÄyi nIqvq cPwjZ wbqgvbyhvqx G¸‡jv cieZx` mfv c‡i Dc¯vcb Kiv n‡e) Ges Aewkó 45wU Jla bvgÄyi K‡ib (Annex-A)|

L) Avg`vbxi Rb¨ †iwR‡÷k‡bi wbwg‡Ë `wLjKZ.23wU Jla mfvq Dc¯vcb Kiv n‡j m`m¨MY Jla¸wji Jla wbqšY Kwgwui †UKwbK¨vj mve-Kwgwui mgvwi‡ki Av‡jv‡K we¯wiZ আলোচনাক্রমে ঊ³ Jlamg‡ni g‡a¨ 13wU Jl‡ai Abyhvqx`b Ges 10wU Jl‡ai c‡qvRb ‡bB weavq Av‡e`b bvgÄyi K‡ib (Annex-B)|

M) ¯vbxq Drcv`‡bi Rb¨ Av‡ew`Z ‡f‡Uwibvix Jl‡ai †iwR‡÷k‡bi wbwg‡Ë `wLjKZ. ‡f‡Uwibvix Jla 6wU I f¨vKwmb 6 wUi g‡a¨ m`m¨MY Jla¸wji Jla wbqšY Kwgwui †UKwbK¨vj mve-Kwgwui mgvwi‡ki Av‡jv‡K we¯wiZ Av‡jvPbv K‡i 01wU Jla Ges 06wU f¨vKwm‡bi ‡iwR‡÷kb Abyhvqx`b Ges 05wU Jl‡ai Av‡e`b bvgÄyi K‡ib (Annex-C)|

N) Avg`vbxi Rb¨ ‡f‡Uwibvix Jl‡ai †iwR‡÷k‡bi wbwg‡Ë `wLjKZ.15wU Jl‡ai wel‡q mfvq m`m¨MY Jla¸wji Jla wbqšY Kwgwui †UKwbK¨vj mve-Kwgwui mgvwi‡ki Av‡jv‡K বিস্তারিত আলোচনাক্রমে 07wU Jla Avg`vbx †iwR‡÷k‡bi Rb¨ Abyhvqx`b K‡ib Ges Aewkó 08wU Jla c‡qvRb ‡bB weavq Av‡e`b bvgÄyi K‡ib (Annex-D)|

3| **Avg`vbxi wbwg‡Ë †iwR‡÷k‡bi Rb¨ Av‡ew`Z 27wU †gwW‡Kj wWfvBm t**

†UKwbK¨vj mve-Kwgwui wm×vš t ‡gwW‡Kj wWfvBm gj¨vq‡bi wbwg‡Ë MwVZ Jla wbqšY Kwgwui †UKwbK¨vj mve Kwgwui MZ 10-08-2016 I 29-09-2016 Zwi‡L Abyôv‡Z mfvq Avg`vbxi Rb¨ me‡gvU 27wU †gwW‡Kj wWfvBm (Annex-E)-Gi Dc¯vcb Kiv n‡j Jla¸wji Jla wbqšY Kwgwui †gwW‡Kj wWfvB‡mi gj¨vq‡bi wbwg‡Ë MwVZ †UKwbK¨vj mve-Kwgwui mgvwi‡ki Av‡jv‡K we¯wiZ Av‡jvPbv †k‡l 24(PweÿY) wUi Abyhvqx`v‡bi mgvwik, 01wUi Av‡e`b ¯wMZ Ges DuraGraft Vascular Conduit Solution wUi wel‡q wb‡¤v³ wm×vš MnxZ nq-

1. Av‡e`bKvix cwZôvb‡K †gwW‡Kj wWfvBmwUi BDRvi WvUv Ges wKwbK¨vj WvUv `wLj Ki‡Z n‡e|

2. †gwW‡Kj wWfvBmwUi c‡qvRbxqZv wel‡q wb¤ewYZ 02Rb KwWqvK mvRb Gi gZvg‡Zi wfwË‡Z cieZx‡Z wm×vš MnY Kiv n‡e-

K. we‡MwWqvi †Rbv‡ij ^mq` Avwmd BKevj, wefvMxq cavb, KwWl‡jwR wefvM, wmGgGBP, XvKv|

L. Wvt jyqdi ingvb, KwWqvK mvRb, j¨veGBW KwWqvK nvmcvZvj, avbgwÛ, XvKv |

GQvov Sterile Kollagen sheet bvgxq †gwW‡Kj wWfvBmwU Av‡e`b ¯wMZ Kiv nq| Sterile Kollagen sheet bvgxq †gwW‡Kj wWfvBmwU KwgwUi cieZx mfvq gj¨vq‡bi wbwg‡Ë wb‡¤wjwLZ e¨e¯v MnY Ki‡Z n‡e t

K) Avg`vbxi Rb¨ Av‡e`bKvix cwZôvb‡K †gwW‡Kj wWfvBmwUi cixÿv we‡kl‡bi wbwg‡Ë c‡qvRbxq cwigvY bgybv Jla ckvmb Awa`ß‡i `wLj Kivi wb‡`kbv c`vb Kiv hvB‡Z cv‡i |

L) ¯wMZKZ.†gwW‡Kj wWfvBmwUi m¤ú‡K gZvgZ Mn‡Yi Rb¨ cieZx mfvq Aa¨vcK Avevwmi Kvjvg AvRv`, cwiPvjK, evb BÝwUwUDU, XvKv †gwW‡Kj K‡jR- †K Dcw¯Z _vKvi Rb¨ Abyiva Kiv †h‡Z cv‡i|

K) Powdered Medical Gloves Gi ¯vbxq Drcv`b I Avg`vbxi wbwg‡Ë †iwR‡÷kb c`vb Ges evRvi RvZKi‡bi wel‡q Av‡jvPbv I wm×vš MnY cm‡½ t

†UKwbK¨vj mve-KwgwUi Av‡jvPbv t Powdered Medical Gloves e¨envi Kivi d‡j wewfb ক্ষতিকর পার্শ্বপ্রতিক্রিয়া যেমন: Severe airway inflammation, Hypersensitivity reactions and allergic reactions (including asthma), allergic rhinitis, conjuntivitis, and dyspenia, granuloma and adhesion formation _vKvq Gi ewZj Kivi wel‡q USFDA সম্প্রতি রুল প্রণয়ন করার কার্যক্রম শুরু করেছে। এমতাবস্থায়, evsjv‡`‡k Powdered Medical Gloves †gwW‡Kj wWfvBmwU †iwR‡÷kb c`vb ev Gi e¨envi ewZj Kivi wel‡q mfvq Dc¯vb Kiv হলে বিস্থারিত আলোচনাক্রমে নিম্নলিখিত সিদ্ধান্ত গৃহীত হয়-

†UKwbK¨vj mve-KwgwUi wm×vš t

1. USFDA KZ„K c`Ë Warning wU D³ †gwW‡Kj wWfvBm Avg`vbxKviK, Drcv`bKvix, বিক্রয়কারী ও ব্যবহারকারীকে অবহিত করতে হবে।
2. cwi_exi wewfb †`‡k Powdered Medical Gloves wUi eZgvb Ae¯v m¤ú‡K KwgwUi m`m¨MY Av‡iv Z_¨ DcvË msMn Kivi ci AvMvgx 02 (`ªæ) gvm c‡i GKwU mfv Avnevb K‡i c`wUi †`‡k Pvjyev ewZj Kivi wel‡q wm×vš Mp„xZ n‡e|
3. eyqU I GgAvBGmwU Powdered Medical Gloves †gwW‡Kj wWfvBmwU m¤ú‡K GKwU mv‡f cwiPvjbv Ki‡e|
4. Powdered Medical Gloves wUi †iwR‡÷kb Pvjyi vLv †h‡Z cv‡i|

mfvi wm×vš t †UKwbK¨vj mve-KwgwUi myZwikmgn Abyjgv`b Kiv nj|

4| ¯vbxqfv‡e Drcv`‡bi Rb¨ 18wU nvevj Jl‡ai †iwR‡÷k‡bi Rb¨ Av‡jvPbv I wm×vš MnY cm‡½t

mfvi Av‡jvPbv I wm×vš t

weMZ 29-09-2016 Zwi‡L Abyôv‡b mfvq 18wU nvevj Jl‡ai Av‡e`b mfvq Dc¯vcb Kiv n‡j Jla¸wji Jla wbqšY KwgwUi nvevj GWfvBRix KwgwUi mycwi‡ki Av‡jv‡K we¯wiZ আলোচনাক্রমে ১৮wU nvevj Jla †iwR‡÷k‡bi wbwg‡Ë Abyôv`b K‡ib (Annex-F)|

5| wWwmwm 244Zg mfvq †iwR‡÷kb ewZjKZ. Rosiglitazone 2 mg I 4mg Ges Pioglitazone 30 mg I 45 mg-Gi Kw¤‡bkb Jla¸wji †iwR‡÷kb ewZjKiY cm‡½t

Jla wbqšY KwgwUi 244Zg mfvq we‡klÁ KwgwUi gZvg‡Zi wfwË‡Z Rosiglitazone 2mg I 4mg Ges Pioglitazone 30 mg I 45 mg ‡R‡bwi‡Ki JlaMwji †iwR‡÷kb ewZj Kiv nq| AZtci Jla ckvmb Awa`ßi KZ…K ¯§viK bs-wWG/29-2/09(Ask)/12025, ZwiLt 20/08/2015 Gi gva¨‡g D³ ‡R‡bwi‡Ki Kw¤‡bk‡bi (1) Rosiglitazone 2mg + Metformin HCl 500mg (2) Rosiglitazone 2mg + Metformin HCl 1000mg (3) Rosiglitazone 4mg + Metformin HCl 500mg (4) Rosiglitazone 4mg + Metformin HCl 1000mg (5) Rosiglitazone 4mg + Glimepride 1mg (6) Rosiglitazone 4mg + Glimepride 2mg (7) Pioglitazone 30mg + Glimepride 2mg (8) Pioglitazone 30mg + Glimepride 4mg Jla¸wji Drcv`b I evRviRvZKiY ¯wMZ Kiv n‡q‡Q|

D³ Kw¤‡bkY RvZxq †R‡bwi‡Ki Jla¸wji †iwR‡÷kb ewZj Kivi wel‡q wm×vš Mn‡Yi Rb¨ mfvq Dc¯vcb Kiv nq|

mfvi Av‡jvPbv t Rosiglitazone 2mg I 4mg Ges Pioglitazone 30 mg I 45 mg ‡R‡bwi‡Ki Kw¤‡bkb Jl‡ai †iwR‡÷kb ewZ‡ji wel‡q wm×vš MnY Rb¨ mfvq Dc¯vcb করা হলে, বিস্তারিত আলোচনাক্রমে Kw¤‡bkb Jla¸‡jv †iwR‡÷kb ewZ‡ji wel‡q mevB GKgZ cKvk K‡ib|

mfvi wm×vš t (1) Rosiglitazone 2mg + Metformin HCl 500mg (2) Rosiglitazone 2mg + Metformin HCl 1000mg (3) Rosiglitazone 4mg + Metformin HCl 500mg (4) Rosiglitazone 4mg + Metformin HCl 1000mg (5) Rosiglitazone 4mg + Glimepride 1mg (6) Rosiglitazone 4mg + Glimepride 2mg (7) Pioglitazone 30mg + Glimepride 2mg (8) Pioglitazone 30mg + Glimepride 4mg Jla¸‡jvi †iwR‡÷kb ewZj Kiv nj|

6| **Glimepiride 2mg + Metformin BP 500mg Bilayer Tablet–Gi Abyjgv`‡bi wel‡q Av‡jvPbv I wm×vš MnY cm‡½|**

Jla wbqšY Kwgwi 243Zg mfvq †gmvm mv‡bwd G‡fbwUm evsjv‡`k wjwg‡UW KZ„K Av‡ew`Z Glimepiride 2mg + Metformin BP 500mg Bilayer Tablet Jlawi Safety, Efficacy & Usefullness m¤ú‡K 3 (wZb) Rb we‡klÁi gZvgZ Mn‡Yi wm×vš Mp„xZ nq-

(1) Aa¨vcK Wvt †gvt Rwjj Avbmvix, wefvMxq cavb, G‡ÛvKvB‡bvjwR wefvM, XvKv †gwW‡Kj K‡jR, XvKv|
(2) Aa¨vcK Wvt †gvt dwi`Dïxb, †Pqvig¨vb, G‡Ûvc¬B‡bvjwR wefvM, weGmGgGgBD Ges
(3) Aa¨vcK Wvt nv‡Riv gvnZve, evi‡Wg nvmcvZvj, XvKv|

we‡klÁMY Jlawi ‡`‡k c‡qvRbxqZv we‡ePbv K‡i Abyjgv`‡bi mgvwik K‡ib|

বিশেষজ্ঞগনের মতামত সভায় উপস্থাপন করা হলে বিস্তারিত আলোচনাক্রমে †gmvm mv‡bwd G‡fbwUm evsjv‡`k wjwg‡UW KZ„K Av‡ew`Z Glimepiride 2 mg+ Metformin BP 500mg Bilayer Tablet (Glimepiride BP 2mg + Metformin BP 500mg)–bvgxq Jlawi Abyjgv`b Kiv nq|

7| **wewea Av‡jvPbv t**

K) **BwZc‡e †iwR‡÷kb c`vbKZ.K¤‡bkb Jl‡ai †hŠw³KZv c¥we‡ePbv/wiwfD cm‡½ t**

mfvi Av‡jvPbv t Kwgwi mfvcwZ mfv‡K AewnZ K‡ib †h, K¤‡bkb Jl‡ai c‡qvRbxqZv I †hŠw³KZvi wel‡q wewfb cwÎKvq mse„` cKwkZ n‡"Q| সদস্যগণ আলোচনাক্রমে উল্লেখ করেন †h, Jla wbqšY Kwgwi Fixed Dosage Combination (FDC) Jla Abyjgv`‡bi wel‡q me mgq mZK wQj| Z_wc BwZc‡e †hmg¯ Fixed Dosage Combination (FDC) Jl‡ai Abyjgv`b †`qv n‡q‡Q, Hmg¯ K¤‡bkb Jla¸‡jvi g‡a¨ †hmg¯ Jla c‡qvRbxqZv gvÎ¨vqbcwK envj ev ewZ‡ji wel‡q wm×vš Mn‡Yi Rb¨ cieZx †UKwbK¨vj mve Kwgwi mfvq Av‡jvPbv K‡i Jla wbqšY Kwgwi mfvq Dc¯vcb Kiv ‡h‡Z cv‡i|

mfvi wm×vš t BwZc‡e †iwR‡÷kb c`vbKZ. Fixed Dosage Combination (FDC) Jla¸‡jvi c‡qvRbxqZv I †hŠw³KZv c¥we‡ePbvi Rb¨ cieZx †UKwbK¨vj mve Kwgwi mfvq Dc¯vcb Ki‡Z n‡e|

L) **Jl‡ai gj¨ e¨¨× cwZ‡iv‡a KiYxq wbaviY cm‡½|**

mfvi Av‡jvPbv I wm×vš t mfvi mfvcwZ e‡jb †h, mv¤úwZK mg‡q Jl‡ai gj¨ e¨¨× m¤ú‡K we¨fb ^`wbK cwÎKvq we¨fb wi‡cvU cKwkZ n‡"Q| Jl‡ai gj¨ e¨¨× wel‡q fwel¨r KiYxq wbavi‡Yi Rb¨ †UKwbK¨vj mve-Kwgwi cieZx mfvq Dc¯vcb Kiv †h‡Z cv‡i|

Ab¨ †Kvb Av‡jv"¨ wel‡q bv _vKvq mfvcwZ g‡nv`q Dcw¯Z mKj‡K ab¨ev` Ávcb K‡i mfvi mgwß †NvlYv K‡ib|

‡gRi †Rbv‡ij †gvt ‡gv¯wdRjyi ingvb
gnvcwiPvjK
Jla ckvmb Awa`ßi
I
m`m¨-mwPe
Jla wbqšY Kwgwi|

‰mq` gbRjyj Bmjvg
mwPe
¯v¯¨ I cwievi Kj¨vY gšYvjq
I
mfvcwZ
Jla wbqšY Kwgwi|

Annex-A : Products for Locally manufacture (Human)

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RMbwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
1.	Beacon Pharmaceutical Ltd.	L-Ornithine-L-Aspartate INN 150mg Tablet L-Ornithine-L-Aspartate INN **Amino acid**	For the treatment of concomitant diseases and sequelae of acute and chronic liver diseases (e.g. liver cirrhosis) with the symptoms of latent and manifest hepatic Encephalopathy.	**Contraindication**: Hypersensitivity to Lornithine-L-aspartate or any other excipients of these products. Severe renal insufficiency (a serum creatinine level in excess of 3 mg/100 ml can be regarded as the guide value). **Side effect**: Uncommon nausea, vomiting, stomach ache, flatulence, diarrhoea; very rare pain in the limbs. E110 can trigger allergic reactions.	3gm/Sachet Granules **And** 5gm/10ml Ampoule Injection		Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj
2.	Square Formulations Ltd., Gorai, Tangail	Diphenhydramine Citrate 38mg + Ibuprofen 200mg Tablet Diphenhydramine Citrate USP 38mg + Ibuprofen DC 85 Ph. Grade 235.3mg contains Ibuprofen BP 200mg Tablet **Analgesic + Antihistamine**	Indicated for the sleeplessness due to minor aches and pains.Diphenhydramin is an antihistamine that causes drowsiness and ibuprofen reduces the inflammation and helps relieve inor aches and pains in adults and children not over than 12 years.	Contraindications: Aspirin allergy. Immediately before or after cardiac surgery. Side Effects: Upset stomach, nausea, vomiting, headache, diarrhea, constipation, dizziness, or drowsiness may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.If your doctor has prescribed this medication, remember that he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.This medication may raise your blood pressure.	Diphenhydramine 50mg Tablet		c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB wea|q Av‡e`b bv gÄyi Kiv †h‡Z cv‡i	c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB wea|q Av‡e`b bv gÄyi Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvlbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-Kvgv‡Ui mfvi wm×vš	mfvi wm×vš
3.	Sanofi Bangladesh Limited	Ketoprofen 100mg + Omeprazole 20mg Modified Release Capsule Ketoprofen BP 100mg + Omeprazole BP 20mg **Analgesic + Antiulcerant**	Symptomatic treatment of rheumatoid arthritis, ankylosing spondylitis and osteoarthritis in patients with a previous history or who are at risk of developing NSAID associated gastric ulcers or duodenal ulcers.	**Contraindications:** Hypersensitivity to ketoprofen or to omeprazole or to any of the excipients listed. Last trimester of pregnancy. History of asthma induced by administration of ketoprofen or similar acting substances, such as other non-steroidal anti-inflammatory agents (NSAIDs) or acetylsalicylic acid. Severe hepatic failure. Severe renal failure. Severe heart failure. Cerebrovascular bleeding or other active bleeding. Concomitant use with St. John's wort or atazanavir sulphate. Combination therapy with clarithromycin should not be used in patients with hepatic impairment. Active peptic ulcer, or any history of gastrointestinal bleeding, ulceration or perforation. **Side-effects:** Common: Drowsiness, Headache, Spinning sensation, Difficulty sleeping (insomnia), Disturbances of the gut such as diarrhoea, constipation, nausea, vomiting, flatulence or abdominal pain. Uncommon: Skin reaction, such as itching, rash, increased sweating, photosensitivity, Changes in mood, Visual disturbances, such as blurred vision, loss of focus, Change in taste, Sensation of ringing or other noise in the ears (tinnitus), Changes in the	New	UKMHRA	c‡qvRb ‡bB wea|q Av‡e`b bv gÄy¨ Kiv †h‡Z cv‡i |	c‡qvRb ‡bB wea|q Av‡e`b bv gÄy¨ Kiv nj |

				levels of liver enzymes, Hair loss (alopecia), Swollen ankles, feet or hands (peripheral oedema). Rare: Pain in the muscles and joints, muscle weakness, Pins and needles (paraesthesia), Heart failure, High blood pressure, Lightheadedness or feeling faint, Confusion, Hallucinations, Ulceration in the stomach or intestine, Bleeding from the stomach or intestine, Kidney, liver or blood disorders, Brownish-black discoloration of the tongue, if also taking the antibiotic clarithromycin. Very rare: Decreased numbers of white blood cells or platelets in the blood (leucopenia or thrombocytopenia), Decreased numbers of all types of blood cells in the blood (agranulocytosis or pancytopenia), Decreased level of sodium in the blood (hyponatraemia), Inflammation of the liver (hepatitis), Dry mouth or inflammation of the mouth (stomatitis), Kidney inflammation (interstitial nephritis), Agitation, Depression, Abnormal enlargement of breasts in men (gynaecomastia), Severe skin reactions.				
4.	Sanofi Bangladesh Limited	Ketoprofen 150mg + Omeprazole 20mg Modified Release Capsule Ketoprofen BP 150mg + Omeprazole BP 20mg **Analgesic + Antiulcerant**	Do	Do		UKMHRA	*c‡qvRb ‡bB wea|q Av‡e`b bv gÄy¨K iv †h‡Z cv‡i |*	*c‡qvRb ‡bB wea|q Av‡e`b bv gÄy¨K iv nj |*

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
5.	Sanofi Bangladesh Limited	Ketoprofen 200mg + Omeprazole 20mg Modified Release Capsule Ketoprofen BP 200mg + Omeprazole BP 20mg **Analgesic + Antiulcerant**	Do	Do		UKMHRA	c‡qvRb ‡bB weavq Av‡e`b bv gÄy Kiv †h‡Z cv‡i	c‡qvRb ‡bB weavq Av‡e`b bv gÄy Kiv nj
6.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Paracetamol 250mg/5ml Suspension Paracetamol BP 250mg/5ml Suspension **Analgesic and Antipyretic**	It is indicated for the treatment of mild to moderate pain and as an antipyretic. It can be used in many conditions including headache, toothache, earache, teething, sore throat, colds & influenza, aches and pains and post-immunisation fever.	**Contraindications:** Hypersensitivity to Paracetamol or any of the excipients. **Side Effects:** Adverse effects of paracetamol are rare but hypersensitivity including skin rash may occur. Very rare cases of serious skin reactions have been reported. Very rarely there have been reports of blood dyscrasias including thrombocytopenia and agranulocytosis, but these were not necessarily causally related to paracetamol. Most reports of adverse reactions to paracetamol related to overdosage and overusage of the drug	120 mg/ 5 ml Oral suspension	MHRA	wWwmwm 245Zg mfvq Av‡e`b bvgÄy Kiv nq weavq Av‡e`bU ¯wMZ Kiv †h‡Z cv‡i	wWwmwm 245Zg mfvq Av‡e`b bvgÄy Kiv nq weavq Av‡e`bU ¯wMZ Kiv nj
7.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Paracetamol 3.25gm + Ibuprofen 2.0gm/100ml Suspension Paracetamol BP 3.25gm + Ibuprofen BP 2.0gm/100ml **Analgesic and Antipyretic**	For the temporary relief of mild to moderate pain associated with migrane, heachache, backache, period pain, dental pain, rheumatic and muscular pain, pain of non serious arthritis, cold and flu symptoms, sore throat, and fever. This product is suitable for pain which requires stronger analgesia than ibuprofen or paracetamol.	Contraindications: This product is contraindicated: •In patients with a known hypersensitivity to Ibuprofen, Paracetamol or any other excipients. •In patients with a history of hypersensitivity reactions (e.g. bronchospasm, angioedema, asthma, rhinitis, or urticaria) associated with acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs).	120 mg/ 5 ml Oral suspension Ibuprofen 100 mg/5 ml Suspension		c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄy Kiv †h‡Z cv‡i	c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄy Kiv nj

				•In patients with a history of, or an existing gastrointestinal ulceration/perforation or bleeding, including that associated with NSAIDs. •Patients with defects in coagulation. •In patients with severe hepatic failure, severe renal failure or severe heart failure. •In concomitant use with other NSAID containing products, including cyclo-oxygenase-2 (COX-2) specific inhibitors and doses of acetylsalicylic acid above 75 mg daily – increased risk of adverse reactions. •In concomitant use with other Paracetamol-containing products – increased risk of serious adverse effects. •During the last trimester of pregnancy due to risk of premature closure of the foetal ductus arteriosus with possible pulmonary hypertension **Side effects:** Clinical trials with this product have not indicated any other undesirable effects other than those for Ibuprofen or Paracetamol alone. Common side effects are Disturbances of the gut such as nausea, vomiting, abdominal pain, indigestion, diarrhoea. Uncommon side effects are headache, dizziness, flatulence, constipation, skin reactions such as itching, stomach or duodenal ulcer.				

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-Kgv‡Ui mfvi wm×vš	mfvi wm×vš
8.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Paracetamol 325mg + Ibuprofen 400mg Tablet Paracetamol BP 325mg + Ibuprofen BP 400mg **Analgesic and Antipyretic**	-Do-	-Do-	Ibuprofen 400mg Tablet		c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄy Kiv †h‡Z cv‡i	c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄy Kiv nj
9.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Elemental Calcium 400mg + Simethicone 60mg Tablet Calcium Carbonate (Heavy) BP 1000.00mg eq. to 400mg Elemental Calcium + Simethicone 100 DC Ph. Gr. 100mg eq. to Simethcone USP 60mg **Antacid**	For the relieve of acid digestion, heartburn, sour stomach, upset of stomach associated with these symptoms, bloating and pressure commonly referred to as gas.	**Contraindications:** Constipation, diarrhoea. **Side effects:** Constipation, diarrhoea.	Elemental Calcium 500mg Tablet Simethicone 40mg Tablet		wWmwm 245Zg mfvq Av‡e`b bvgÄy Kiv nq weavq Av‡e`bU ¯wMZ Kiv †h‡Z cv‡i	wWmwm 245Zg mfvq Av‡e`b bvgÄy Kiv nq weavq Av‡e`bU ¯wMZ Kiv nj
10.	Aristopharma Ltd, Shampur-Kadamtali I/A, Dhaka-1204.	Ketotifen 2 mg Tablet Ketotifen Fumarate BP 2.760 mg Eq.to Ketotifen 2 mg **Antiasthmatic**	Preventive treatment of bronchial asthma especially when associated with atopic symptoms. Ketotifen is not effective in aborting established attacks of asthma. Ketotifen is not a substitute for corticosteroid treatment (inhaled or systemic) when corticosteroid is indicated in the treatment of asthma. Prevention and treatment of multisystem allergic disorders eg, chronic urticaria, atopic dermatitis, allergic rhinitis and conjunctivitis.	**Contra-indication :** Known hypersensitivity to ketotifen or to any of the excipients of ketotifen SRO.Epilepsy or history of seizures **Side Effects:** Most Common- Headache and inflammation of nose. Eye- Allergic reactions, burning or stinging, inflammation, discharge from eyes, dry eyes, eye pain, eyelid disorder, itching, increased tears, dilation of the pupils, oversensitivity to light and rash.	1 mg Tablet, 0.02g/100 ml Syrup, 0.025g/100ml Eye Drops,		c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄy Kiv †h‡Z cv‡i	c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄy Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
11.	a) Incepta Pharmaceuticals Ltd, Savar b) Beacon Pharmaceuticals Ltd.	Mepolizumab 100 mg/Vial Lyophilized Powder for Injection Mepolizumab INN 100mg/Vial **Antiasthmatic**	It is an interleukin-5 antagonist monoclonal antibody (IgG1 kappa) indicated for add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. ***Limitations of Use:*** •Not for treatment of other eosinophilic conditions. •Not for relief of acute bronchospasm or status asthmaticus.	**Contraindication:** History of hypersensitivity to mepolizumab or excipients in the formulation. **Side effect:**Most common adverse reactions (incidence greater than or equal to 5%) include headache, injection site reaction, back pain, and fatigue	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj
12.	a) Incepta Pharmaceuticals Ltd, Savar b) Beacon Pharmaceuticals Ltd.	Reslizumab 100 mg/10ml Injection Reslizumab INN 100mg/10ml **Antiasthmatic**	It is an interleukin-5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype. ***Limitations of Use:*** It is not indicated for: Treatment of other eosinophilic conditions. Relief of acute bronchospasm or status asthmatics.	**Contraindication:** Known hypersensitivity to reslizumab or any of its excipients **Side effect:** The most common adverse reaction (incidence greater than or equal to 2%) includes oropharyngeal pain.	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj
13.	Square Pharmaceuticals Ltd., (Dhaka Unit) Kaliakoir, Gazipur	Ceftriaxone 1000mg + Sulbactam 500mg/Vial Injection Ceftriaxone Sodium (Sterile) USP 1190.00mg eq. to Ceftriaxone 1000mg + Sulbactam Sodium (Sterile) USP 549.520mg eq. to Sulbactam 500mg/Vial **Antibiotic**	-do-	-do-	Ceftriaxone 1000mg/Vial Injection		c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄyi Kiv †h‡Z cv‡i	c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄyi Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-Kgv‡Ui mfvi wm×vš	mfvi wm×vš
14.	Square Pharmaceuticals Ltd., (Dhaka Unit) Kaliakoir, Gazipur	Ceftriaxone 250mg + Sulbactam 125mg/Vial Injection Ceftriaxone Sodium (Sterile) USP 297.50mg eq. to Ceftriaxone 250.00mg + Sulbactam Sodium (Sterile) USP 137.380mg eq. to Sulbactam 125mg/Vial **Antibiotic**	It is indicated for the treatment of following infection when caused by susceptible bacteria: Meningitis, For the treatment of Nosocomial Infection surgical propphylaxis, Urinary Tract Infection, Skin and soft tissue infections like Cellulites, erysepalis etc, Cholecystitis Osteomyelitis, Sexually Transmitted Diseases (Ghonorrhoea, Chancroid, Syphilis), Chronic Suppurative bacterial otitis media, Infection in dialysis unit	**Contraindications:** Ceftriaxone & Sulbactam for Injection is contraindicated in patients with known allergy to Cephalosporin group of antibiotics. Hypersensitivity to penicillin may pre-dispose the patient to the possibility of allergic cross-reactions **Adverse effects:** The following side effects, reported to occur during Ceftriaxone therapy, may be seen with the combination as well: Gastrointestinal: Diarrhoea, nausea & vomiting (less frequent), stomatitis, and glossitis. Hepatic: Elevations of SGOT/SGPT. Hematological: Eosinophilia, thrombocytopenia, leukopenia, granulocytopenia, hematoma or bleeding. Hemolytic anemia is observed less frequently.	Ceftriaxone 250mg/Vial Injection		c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB wea|q Av‡e`b bv gÄ¨Kiv †h‡Z cv‡i|	c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB wea|q Av‡e`b bv gÄ¨Kiv nj|
15.	Square Pharmaceuticals Ltd., (Dhaka Unit) Kaliakoir, Gazipur	Ceftriaxone 250mg + Tazobactam 31.250mg/Vial Injection Ceftriaxone Sodium (Sterile) USP 297.500mg eq. to Ceftriaxone 250mg + Tazobactam USP 31.25mg as Tazobactam Sodium (Sterile) 33.531mg/Vial Injection **Antibiotic**	Indicated for the treatment of the following infections Lower Respiratory Tract Infections, Acute Bacterial Otitis Media, Skin and Skin Structure Infections, Urinary Tract Infections, Uncomplicated Gonorrhea, Pelvic Inflammatory Disease, Bacterial Septicemia, Bone and Joint Infections, Intra-Abdominal Infections, Surgical Prophylaxis	Contraindication: Contraindicated in patients with known allergy to the cephalosporin or beta lactam class of antibiotics. Side Effects: Most common adverse reactions are pain, induration, tenderness, pruritus, eosinophilia, thrombocytosis, leukopenia, diarrhea & headache or dizziness was reported occasionally.	Ceftriaxone 250mg/Vial Injection		c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB wea|q Av‡e`b bv gÄ¨Kiv †h‡Z cv‡i|	c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB wea|q Av‡e`b bv gÄ¨Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-Kvgvwi mfvi wm×vš	mfvi wm×vš
16.	Square Pharmaceuticals Ltd., (Dhaka Unit) Kaliakoir, Gazipur	Ceftriaxone 500mg + Sulbactam 250mg/Vial Injection Ceftriaxone Sodium (Sterile) USP 595.00mg eq. to Ceftriaxone 500mg + Sulbactam Sodium (Sterile) USP 274.760mg eq. to Sulbactam 250mg/Vial **Antibiotic**	-do-	-do-	Ceftriaxone 500mg/Vial Injection		c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB wea|q Av‡e`b bv gÄy Kiv †h‡Z cv‡i |	c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB wea|q Av‡e`b bv gÄy Kiv nj |
17.	Square Pharmaceuticals Ltd., (Dhaka Unit) Kaliakoir, Gazipur	Ceftriaxone 500mg + Tazobactam 62.500mg/Vial Ceftriaxone Sodium (Sterile) USP 595mg eq. to Ceftriaxone 500mg + Tazobactam USP 62.50mg as Tazobactam Sodium (Sterile) 67.062mg/Vial **Antibiotic**	Indicated for the treatment of the following infections 1.Lower Respiratory Tract Infections, 2.Acute Bacterial Otitis Media, 3.Skin and Skin Structure Infections, 4.Urinary Tract Infections, 5.Uncomplicated Gonorrhea, 6.Pelvic Inflammatory Disease, 7.Bacterial Septicemia, 8.Bone and Joint Infections, 9.Intra-Abdominal Infections, 10.Surgical Prophylaxis	Contraindication: Contraindicated in patients with known allergy to the cephalosporin or beta lactam class of antibiotics. Side Effects: Most common adverse reactions are pain, induration, tenderness, pruritus, eosinophilia, thrombocytosis, leukopenia, diarrhea & headache or dizziness was reported occasionally.	Ceftriaxone 500mg/Vial Injection		c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB wea|q Av‡e`b bv gÄy Kiv †h‡Z cv‡i |	c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB wea|q Av‡e`b bv gÄy Kiv nj |
18.	Aristopharma Ltd, Shampur-Kadamtali I/A, Dhaka-1204.	Fusidic Acid Hemihydrate 1.017 g Eq..to Fusidic Acid Anhydrous 1gm/100gm Viscous Eye Drops Fusidic Acid Hemihydrate (Sterile & Micronized) BP 1.017 g Eqv.to Fusidic Acid Anhydrous 1g/100g	It is indicated for the treatment of superficial infections of the eye and its adnexa (ie., conjunctivitis) caused by fusidic acid susceptible strains of the designated bacteria in adults and children (≥2 years of age): Staphylococcus aureus, Streptococcus pneumoniae and Haemophilus influenzae.	**Contraindication:** Fusidic Acid Viscous Eye Drops (multi-dose preserved preparation and unit dose unpreserved preparation) are contraindicated in patients with hypersensitivity to fusidic acid or any of the other components of the preparations. The component benzalkonium chloride in the preserved preparation can be	2% Cream & 250 mg/5 ml Suspension	BNF-71 Page: 982	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |

		Antibiotic	Enterobacteriaciae and Pseudomonas are resistant to fusidic acid.	allergenic. A Preservative free unit dose formulation of Fusidic Acid is available for patients with known or suspected hypersensitivity to benzalkonium chloride. **Side-effect:** Like other medicines, Fusidic Acid eye drops can cause some side effects. In deciding to prescribe Fusidic Acid for you, your doctor has weighed the risk of taking Fusidic Acid against the benefit it is expected to have for you. Side effects not listed in this leaflet may occur in some patients.				
19.	Sanofi Bangladesh Limited	Metronidazole 400mg + Diloxanide Furoate 500mg Tablet Metronidazole BP 400mg + Diloxanide Furoate BP 500mg Antibiotic	It is indicated in the treatment of acute and chronic intestinal amoebiasis, including the amoebic cyst carriers' hepatitis, amoebic liver abscess and other systemic infections caused by E. histolytica and giardiasis.	**Contraindications:** History of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema Hypersensitivity, blood dyscrasias, active CNS disease, serious neurological disease, seizures, severe hepatic failure, 1st trimester pregnancy, lactation. **Side-effects:** Seizures, headache, dizziness, peripheral neuropathies, unpleasant metallic taste, furred tongue, glossitis, pseudomembranous colitis, GI disturbances, rash, urticaria, pruritus, paraesthesias, superinfection; transient leucopaenia, thrombocytopenia. Raised liver enzyme values, cholestatic hepatitis, and jaundice.	New		*c‡qvRbxq ‡idv‡iY Ges K¡¤‡bkb¡U †`‡k c‡qvRb ‡bB ¯^ea©vq Av‡e`b bv gÄyi Kiv †h‡Z cv‡i |*	*c‡qvRbxq ‡idv‡iY Ges K¡¤‡bkb¡U †`‡k c‡qvRb ‡bB ¯^ea©vq Av‡e`b bv gÄyi Kiv nj |*

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvlbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-Kvgvwi mfvi wm×vš	mfvi wm×vš
20.	Aristopharma Ltd, Shampur-Kadamtali I/A, Dhaka-1204.	Moxifloxacin 0.50gm /100g Sterile Eye Ointment Moxifloxacin Hydrochloride BP 0.5454gm eq.to Moxifloxacin 0.50gm/100gm **Antibiotic**	Moxifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram –negative bacteria. It functions by inhibiting DNA gyrase, a type II topoisomerase, and topoisomerase IV enzymes necessary to separate bacteria DNA, thereby inhibiting cell replication. It is indicated for the treatment of ocular bacteria infection.	**Contraindication:** Moxifloxacin ophthalmic ointment is contraindicated in patients with a history of hypersensitivity to moxifloxacin, to other quinolones, or to any of the components in this medication. **Side effects:** The most frequently reported Ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing.	400mg Tablet 0.5g/100 Eye Drop 0.16% IV Infusion		wWwmwm 245Zg mfvq Av‡e`b bvgÄyÿ Kiv nq weavq Av‡e`bU ¯wMZ Kiv †h‡Z cv‡i	wWwmwm 245Zg mfvq Av‡e`b bvgÄyÿ Kiv nq weavq Av‡e`bU ¯wMZ Kiv nj
21.	ACI Ltd., Narayanganj	Nitrofurantoin 25 mg SR Capsule Nitrofurantoin 25% w/w SR Pellets Ph.Grade 100 mg Eqv. to Nitrofurantoin BP 25 mg SR Capsule **Antibiotic**	It is indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of *Escherichia coli* or *Staphylococcus saprophyticus.* It is not indicated for the treatment of pyelonephritis or perinephric abscesses.	**Contraindications:** Anuria, oliguria, or significant impairment of renal function are contraindications. Treatment of this type of patient carries an increased risk of toxicity because of impaired excretion of the drug. Because of the possibility of hemolytic anemia due to immature erythrocyte enzyme systems (glutathione instability), the drug is contraindicated in pregnant patients at term (38-42 weeks gestation), during labor and delivery, or when the onset of labor is imminent. For the same reason, the drug is contraindicated in neonates under one month of age. Nitrofurantoin is contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with nitrofurantoin. Nitrofurantoin is also contraindicated in those patients with known hypersensitivity to	Nitrofurantoin 100mg & 50mg Capsule		c‡qvRb ‡bB weavq Av‡e`b bv gÄyÿ Kiv †h‡Z cv‡i	c‡qvRb ‡bB weavq Av‡e`b bv gÄyÿ Kiv nj

				nitrofurantoin. **Side effects**: In clinical trials of **Nitrofurantoin**, the most frequent clinical side effects that were reported as possibly or probably drug-related were nausea, headache, and flatulence**.**				
22.	Incepta Pharmaceuticals Ltd, Savar	Sodium Fusidate 500mg/Vial Powder for IV Infusion Sodium Fusidate BP 500mg eq. to Fusidic Acid 488 mg/Vial **Antibiotic**	It is indicated in the treatment of all staphylococcal infections due to susceptible organisms such as: cutaneous infections, osteomyelitis, pneumonia, septicaemia, wound infections, endocarditis, and superinfected cystic fibrosis. Sodium Fusidate should be administered intravenously whenever oral therapy is inappropriate, which includes cases where absorption from the gastro-intestinal tract is unpredictable.	**Contraindication:** Hypersensitivity to fusidic acid and its salts, or to any of the excipients. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. **Side effect:** Like all medicines, sodium fusidate infusion can cause side effects, although not everybody gets them. Approximately 3 out of 10 people may experience side effects with sodium fusidate infusion, but many of these are where the medicine is given into the vein.	Sodium Fusidate 250mg Tablet		*c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB wea©vq Av‡e`b bv gÄyi Kiv †h‡Z cv‡i |*	*c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB wea©vq Av‡e`b bv gÄyi Kiv nj |*
23.	Beacon Pharmaceutical Ltd.	Cytarabine 1gm/10ml Injection Cytarabine USP 1gm/Vial Injectable Injection **Anticancer**	It is indicated for the intrathecal treatment of lymphomatous meningitis.	**Contraindication:** Hypersensitive to cytarabine or any component of the formulation with active meningeal infection **Side effect:** Most common adverse reactions (incidence ≥20%) are headache, arachnoiditis, confusion, abnormal gait , convulsions, weakness, pyrexia, fatigue, nausea, vomiting, constipation, and back pain	500mg/5ml Injection	USFDA	*Abyjgv`b Kiv ‡h‡Z cv‡i |*	*Abyjgv`b Kiv nj |*

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rlbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-Kvgv‡Ui mfvi wm×vš	mfvi wm×vš
24.	Beacon Pharmaceutical Ltd.	Lenvatinib 4mg Capsule Lenvatinib Mysylate INN 4.90mg eq. to Lenvatinib 4mg **Anticancer**	It is a kinase inhibitor that is indicated for: • Differentiated Thyroid Cancer (DTC): single agent for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC. • Renal Cell Cancer (RCC): in combination with everolimus, for patients with advanced RCC following one prior anti-angiogenic therapy	**Contra-indication:** None **Side effect**: In DTC, the most common adverse reactions (incidence greater than or equal to 30%) for Lenvatinib are hypertension, fatigue, diarrhea, arthralgia/myalgia, decreased appetite, weight decreased, nausea, stomatitis, headache, vomiting, proteinuria, palmar-plantar erythrodysesthesia syndrome, abdominal pain, and dysphonia. (6.1) In RCC, the most common adverse reactions (greater than 30%) for Lenvatinib + everolimus are diarrhea, fatigue, arthralgia/myalgia, decreased appetite, vomiting, nausea, stomatitis/oral inflammation, hypertension, peripheral edema, cough, abdominal pain, dyspnea, rash, weight decreased, hemorrhagic events, and proteinuria	New	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj
25.	Beacon Pharmaceutical Ltd.	Lenvatinib 10mg Capsule Lenvatinib Mysylate INN 12.25mg eq. to Lenvatinib 10mg **Anticancer**	Do	Do	New	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rlbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	A|‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-Kvgvwi mfvi wm×vš	mfvi wm×vš
26.	Beacon Pharmaceutical Ltd.	Obinutuzumab 1000mg/40ml Injection Obinutuzumab INN 1000mg/40ml **Anticancer**	it is a CD20-directed cytolytic antibody and is indicated: • in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia. • in combination with bendamustine followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.	**Contra-indication:** None **Side effect**: The most common adverse reactions (incidence ≥ 10%) were: • CLL: infusion reactions, neutropenia, thrombocytopenia, anemia, pyrexia, cough, nausea, and diarrhea. • Indolent NHL: infusion reactions, neutropenia, nausea, fatigue, cough, diarrhea, constipation, pyrexia, thrombocytopenia, vomiting, upper respiratory tract infection, decreased appetite, arthralgia, sinusitis, anemia, asthenia and urinary tract infection.	New	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj
27.	Beacon Pharmaceutical Ltd.	Pomalidomide 4mg Capsule Pomalidomide INN 4mg **Anticancer**	it is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy	**Contra-indication:** Pregnancy **Side-effect**: Most common adverse reactions (≥30%) included fatigue and asthenia, neutropenia, anemia, constipation, nausea, diarrhea, dyspnea, upperrespiratory tract infections, back pain, and pyrexia	New	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rlbv‖iK bvg	‖b‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	A|‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UK‖bK`vj mve-K‖g‖Ui mfvi ‖m×vš	mfvi ‖m×vš
28.	Beacon Pharmaceutical Ltd.	Ramucirumab 100mg/10ml Injection Ramucirumab USP 100mg/10ml **Anticancer**	it is a human vascular endothelial growth factor receptor 2 antagonist indicated • as a single agent or in combination with paclitaxel, for treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. • in combination with docetaxel, for treatment of metastatic nonsmall cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Ramucirumab • in combination with FOLFIRI, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.	**Contra-indication:** None **Side effect**:The most common adverse reactions observed in single-agent RAMUCIRUMAB-treated patients at a rate of ≥10% and ≥2% higher than placebo were hypertension and diarrhea. • The most common adverse reactions observed in patients treated with RAMUCIRUMAB plus paclitaxel at a rate of ≥30% and ≥2% higher than placebo plus paclitaxel were fatigue, neutropenia, diarrhea, and epistaxis. • The most common adverse reactions observed in patients treated with RAMUCIRUMAB plus docetaxel at a rate of ≥30% and ≥2% higher than placebo plus docetaxel were neutropenia, fatigue/asthenia, and stomatitis/mucosal inflammation. • The most common adverse reactions observed in patients treated with ramucirumab plus FOLFIRI at a rate of ≥30% and ≥2% higher than placebo plus FOLFIRI were diarrhea, neutropenia, decreased appetite, epistaxis, and stomatitis.	New	USFDA	Abjgv`b Kiv ‡h‡Z cv‡i |	Abjgv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rlbv‖iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UK‖bK`vj mve-K‖g‖Ui mfvi wm×vš	mfvi wm×vš
29.	Beacon Pharmaceutical Ltd.	Temozolomide 5mg Capsule Temozolomide USP 5mg **Anticancer**	It is an alkylating drug indicated for the treatment of adult patients with: • Newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and then as maintenance treatment. • Refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine.	**Contraindication:** Known hypersensitivity to any temozolomide component or to dacarbazine (DTIC) **Side effect:** The most common adverse reactions (≥10% incidence) are: alopecia, fatigue, nausea, vomiting, headache, constipation, anorexia, convulsions, rash, hemiparesis, diarrhea, asthenia, fever, dizziness, coordination abnormal, viral infection, amnesia, and insomnia. • The most common Grade 3 to 4 hematologic laboratory abnormalities (≥10% incidence) that have developed during treatment with temozolomide are: lymphopenia, thrombocytopenia, neutropenia, and leukopenia. • Allergic reactions have also been reported.	100mg & 250mg capsule	USFDA	Abjgv`b Kiv ‡h‡Z cv‡i	Abjgv`b Kiv nj
30.	Beacon Pharmaceutical Ltd.	Venetoclax 10mg Tablet Venetoclax INN 10mg **Anticancer**	It is a BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy	**Contra-indication:** Concomitant use of VENCLEXTA with strong inhibitors of CYP3A at initiation and during ramp-up phase is contraindicated **Side effect**: The most common adverse reactions (≥20%) were neutropenia, diarrhea, nausea, anemia, upper respiratory tract infection, thrombocytopenia, and fatigue.	New	USFDA	Abjgv`b Kiv ‡h‡Z cv‡i	Abjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rlbl iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKlbK¨vj mve-Kglwi mfvi wm×vš	mfvi wm×vš
31.	Beacon Pharmaceutical Ltd.	Venetoclax 50mg Tablet Venetoclax INN 50mg **Anticancer**	Do	Do	New	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i |	Abyjgv`b Kiv nj |
32.	Beximco Pharmaceuticals Ltd., Tongi,Gazipur	Aspirin 100mg+ Glycine 45mg Tablet Aspirin USP 100mg+ Glycine USP 45mg **Anticoagulants, Antiplatelets & Fibrinolytics Agent**	The combinations of drugs lower the risk of stroke and heart attacks. Aspirin and glycine reduces the stickiness of platelets, making them less likely to form a clot and helping to prevent blocking of blood vessels. and more effective in the prevention of strokes and ischemic attacks. Transient ischaemic attacks, secondary prevention of MI; prophylaxis against stroke, vascular occlusion & DVT.	**Contraindications**: Hypersensitivity to salicylates or NSAIDs. Pregnancy & lactation. Active GI ulceration, haemophilia or other bleeding disorders. **Side-effects:** GI disturbances, GI mucosal erosion, ulceration, haematemesis & melaena.	Aspirin 75mg, 100mg & 300mg Tablet, Aspirin 75mg+Clopidogrel 75mg Tablet Glycine 1.5gm/100ml Irrigation Solution	Marketed in Germany, Poland, Spain, Czech Republic, Italy	lWlmlm 244Zg mfvq Av‡e`b bvgÄyi Kiv nq lealq Av‡e`bl U ¯lMZ Kiv †h‡Z cv‡i |	lWlmlm 244Zg mfvq Av‡e`b bvgÄyi Kiv nq lealq Av‡e`bl U ¯lMZ Kiv nj |
33.	Drug International Ltd., Gazipur	Primidone 250 mg Tablet Primidone USP 250 mg **Anticonvulsant**	It is used alone or concomitantly with other anticonvul sants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy.	**Contraindications**: It is contraindicated in: 1) patients with porphyria and 2) patients who are hypersensitive to phenobarbital. **Side Effects:** The most frequently occurring early side effects are ataxia and vertigo. These tend to disappear with continued therapy, or with reduction of initial dosage. Occasionally, the following have been reported: nausea, anorexia, vomiting, fatigue, hyperirritability, emotional disturbances, sexual impotency, diplopia, nystagmus, drowsiness, and	New	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i |	Abyjgv`b Kiv nj |

				morbilliform skin eruptions. Granulocytopenia, agranulocytosis, and red-cell hypoplasia and aplasia, have been reported rarely. These and, occasionally, other persistant or severe side effects may necessitate Withdrawal of the drug. Megaloblastic anemia may occur as a rare idiosyncrasy to Mysoline and to other anticonvulsants. The anemia responds to folic acid without necessity of discontinuing medication.				
34.	a) Incepta Pharmaceuticals Ltd, Savar b) Delta Pharma Ltd. c) Drug International Ltd. e) Pacific Pharmaceuticals Ltd	Linagliptin 5mg + Metformin HCl 1000mg Extended release tablet Linagliptin INN 5mg + Metformin HCl BP 1000mg **Antidiabetic**	It is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment withboth linagliptin and metformin is appropriate ***Important Limitations*** Not for treatment of type 1 diabetes or diabetic ketoacidosis Has not been studied in patients with a history of pancreatitis	**Contraindication:** Severe renal impairment (eGFR below 30 mL/min/1.73 m2 Metabolic acidosis, including diabetic ketoacidosis History of hypersensitivity reaction to linagliptin, such as anaphylaxis, angioedema, exfoliative ski conditions, urticaria, or bronchial hyperreactivity Hypersensitivity to metformin **Side effect:** Adverse reactions reported in ≥5% of patients treated with Linagliptin + metformin HCL and more commonly than in patients treated withplacebo are nasopharyngitis and diarrhea. Hypoglycemia was more commonly reported in patients treated with the combination of Linagliptin + metformin HCL and SU compared with those treatedwith the combination of SU and metformin	Linagliptin 2.5 mg + Metformin Hydrochloride 500 mg Tablet Linagliptin 2.5 mg + Metformin Hydrochloride 850 mg Tablet Linagliptin 2.5 mg + Metformin Hydrochloride 1000 mg Tablet	USFDA	*c‡qvRb ‡bB wea‡q Av‡e`b bv gÄyi Kiv †h‡Z cv‡i |*	*c‡qvRb ‡bB wea‡q Av‡e`b bv gÄyi Kiv nj |*
35.	Square Formulations Ltd., Gorai, Tangail	Metformin Hydrochloride 500mg + Glimepiride 2mg Tablet Metformin Hydrochloride BP 500mg + Glimepiride Ph. Eur 2mg **Antidiabetic**	For the management of Type 2 diabetes mellitus when diet, exercise and single agent (glimepiride or metformin alone) do not results in adequet glycemic control.	Contraindication: In patients hypersensitive to glimepiride, other sulfonylureas, other sulfonamides, or any of the excipients of it. In pregnant women, in breast-feeding women. Side effects: Hypoglycemia, nausea, vomiting, abdominal pain and diarrhea, itching, urticarial.	Glimepiride 1.0mg + Metformin BP 500mg Bilayer Tablet		*c‡qvRb ‡bB wea‡q Av‡e`b bv gÄyi Kiv †h‡Z cv‡i |*	*Abyjgv`b Kiv nj |*

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvlbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	A|‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
36.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Vildagliptin 50mg + Metformin Hydrochloride 1000mg Tablet Vildagliptin INN 50mg + Metformin Hydrochloride BP 1000mg **Antidiabetic**	Type 2 diabetes mellitus not controlled by Metformnin alone or by metformin in combination with either a sulfonylurea or insulin.	**Contraindications:** Known hypersensitivity to vildagliptin or metformin hydrochloride or to any of the excipients, renal dysfunction should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials. **Side effects:** Dizziness, headache & Nausea.	50 mg/500 mg & 50mg/850 mg Tablet	BNF 71 Page: 609	c‡qvRb ‡bB wea|q A|‡e`b b| gÄy Ki| †h‡Z c|‡i |	c‡qvRb ‡bB wea|q A|‡e`b b| gÄy Ki| nj |
37.	Aristopharma Ltd, Shampur-Kadamtali I/A, Dhaka-1204.	Rolapitant 90 mg Film Coated Tablet Rolapitant Hydrochloride INN 100mg Eq.to Rolapitant 90 mg **Antiemetic**	It is used as an antiemetic agent in adults for the prevention of delayed nausea and vomiting associated with initial and repeat coursed of emetogenic chemotherapy.	**Contraindication:** Rolapitant is contraindicated in patients receiving thioridazine, a CYP2D6 substrate. A significant increase in plasma concentrations of thioridazine may result in QT prolongation and Torsades de Pointes. **Side Effects:** Most common adverse reactions (≥ 5%) are : Cisplatin based highly emetogenic chemotherapy , neutropenia and hiccups. Moderately emetogenic chemotherapy and combinations of anthracycline and cyclophosphamide, decreased appetite, neutropenia and dizziness.	New	USFDA	Abyjgv`b Ki| ‡h‡Z c|‡i |	Abyjgv`b Ki| nj |
38.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Simethicone 80mg Tablet Simethicone DC 100 Ph. Grade 133.333mg eq. to Simethicone USP 80mg **Antiflatulent**	It is indication for the treatment of • *Flatulence, abdominal distention, fullness, gas and windy colic* Simethicone USP 80 mg is an excellent and effective antiflatulent. It is used for relief of the painful symptoms of excess gas in the digestive tract. Such gas is frequently caused by excessive swallowing of air or by eating foods	**Contraindications:** No contraindication is reported to this medication **Side effects :** Simethicone is physiologically inert and no adverse effect has been noted after oral ingestion.	40 mg Tablet		c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB wea|q A|‡e`b b| gÄy Ki| †h‡Z c|‡i |	c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB wea|q A|‡e`b b| gÄy Ki| nj |

			that disagree. • *Large bowel preparation* Addition of Simethicone USP 80 mg to a polyethylene glycol bowel preparation produces symptomatic improvement prior to investigation in the management of accidental ingestion of foaming detergents. • *Treatment of poisoning* Simethicone USP 80 mg has an anecdotal use as an antifoaming agent in the management of accidental ingestion of foaming detergents.					
39.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Amlodipine Besilate 5.0mg + Valsartan 160mg + Hydrochlorothiazide 12.5 mg Tablet Amlodipine Besilate BP 6.94 mg eq. to 5 mg Amlodipine + Valsartan USP 160 mg + Hydrochlorothiazide USP 12.5 mg **Antihypertensive**	Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single-component formulation or as a dual-component formulations or as dual-component and a single-component formulation.	**Contraindication:** Hypersensitivity to amlodipine, valsartan, HCTZ, other sulfonamides or to any of the excipients. Exforge HCT is contraindicated in pregnancy. **Side effects:** Headache, fatigue, oedema, flushing.	Amlodipine 5mg + Valsartan 160mg Tablet	USFDA	*wWwmwm 245Zg mfvq Avwe`b bvgÄy Kiv nq weavq Avwe`bwU ¯wMZ Kiv †hŠZ cvwi|*	*wWwmwm 245Zg mfvq Avwe`b bvgÄy Kiv nq weavq Avwe`bwU ¯wMZ Kiv nj|*
40.	a) Incepta Pharmaceuticals Ltd, Savar b) Delta Pharma Ltd. c) Drug International Ltd., Gazipur	Nebivolol 5 mg + Valsartan 80 mg Tablet Nebivolol Hydrochloride INN 5.45 eq. to Nebivolol 5 mg + Valsartan USP 80mg **Antihypertensive**	It is a beta adrenergic blocker and an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.	**Contraindication:** Severe bradycardia Heart block greater than first degree Patients with cardiogenic shock Decompensated cardiac failure Sick sinus syndrome (unless a permanent pacemaker is in place) Patients with severe hepatic impairment (Child-Pugh >B) Hypersensitivity to any component of this product Do not co-administer aliskiren with NEBIVOLOL/VALSARTAN in patients with diabetes **Side effect:**No adverse reactions were observed more frequently on NEBIVOLOL/VALSARTAN than on placebo	Nebivolol 2.5mg & 5mg Tablet Valsartan 40mg, 80mg & 160mg Tablet	USFDA	*c‡qvRb ‡bB weavq Avwe`b bv gÄy Kiv †hŠZ cvwi|*	*c‡qvRb ‡bB weavq Avwe`b bv gÄy Kiv nj|*

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RMbwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KgwUi mfvi wm×vš	mfvi wm×vš
41.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Nebivolol 5mg + Hydrochlorothiazide 12.5mg Tablet Nebivolol Hydrochloride INN 5.45mg eq. to 5mg Nebivolol + Hydrochlorothiazide BP 12.5mg **Antihypertensive & Diuretic**	• Nebivolol is a cardiovascular drug belonging to the group of selective beta-blocking agents (i.e. with a selective action on the cardiovascular system). It prevents increased heart rate and controls heart pumping strength. It also widens blood vessels, which helps to lower your blood pressure. • Hydrochlorothiazide is a diuretic that acts by increasing the amount of urine you produce. It is a one-tablet combination of nebivolol and hydrochlorothiazide and is used for the treatment of raised blood pressure (hypertension). It is used instead of the two separate products for those patients who are already taking them together.	Contraindication: -Hypersensitivity to the active substances or to any of the excipients. -Hypersensitivity to other sulphonamide-derived substances (since hydrochlorothiazide is a sulphonamide-derived medicinal product). - Liver insufficiency or liver function impairment. - Anuria, severe renal insufficiency (creatinine clearance < 30 ml/min.). - Acute heart failure, cardiogenic shock or episodes of heart failure decompensation requiring i.v. inotropic therapy. - Sick sinus syndrome, including sino-atrial block. - Second and third degree atrioventricular block (without a pacemaker). - Bradycardia (heart rate < 60 bpm prior to start therapy). - Hypotension (systolic blood pressure < 90 mmHg). - Severe peripheral circulatory disturbances. - History of bronchospasm and bronchial asthma. - Untreated phaeochromocytoma. - Metabolic acidosis. - Refractory hypokalaemia, hypercalcaemia, hyponatraemia and symptomatic hyperuricaemia Side Effects: The following side effects have been reported with nebivolol:	Nebivolol 5mg & 2.5mg Tablet	MHRA	wWwmwm 244Zg mfvq Av‡e`b bvgÄyÿ Kiv nq weavq Av‡e`bU ¯wMZ Kiv †h‡Z cv‡i	wWwmwm 244Zg mfvq Av‡e`b bvgÄyÿ Kiv nq weavq Av‡e`bU ¯wMZ Kiv nj

				Common side effects (affecting more than 1 person in every 100 treated but fewer than 1 person in every 10 treated): headache, dizziness, tiredness, an unusual burning, pricking, tickling, or tingling sensation, diarrhea, constipation, nausea, shortness of breath, swollen hands or feet. Uncommon side effects (affecting more than 1 person in every 1,000 treated, but fewer than 1 person in every 100 treated): slow heartbeat or other heart complaints, low blood pressure, cramp-like leg pains on walking, abnormal vision, impotence, feelings of depression, digestive difficulties, gas in stomach or bowel, vomiting, skin rash, itchiness, breathlessness such as in asthma, due to sudden cramps in the muscles around the airways (bronchospasm), nightmares. Very rare side effects (affecting fewer than 1 person in every 10,000 treated): fainting, worsening of psoriasis (a skin disease characterised by scaly pink patches). The following side effects have been reported only in some isolated cases: - whole-body allergic reactions, with generalised skin eruption (hypersensitivity reactions); rapid-onset swelling, especially around the lips, eyes, or of the tongue with possible sudden difficulty breathing (angioedema). The following side effects have been reported with hydrochlorothiazide: Allergic reactions - whole-body allergic reaction (anaphylactic reaction) Heart and circulation				

				- heart rhythm disturbances, palpitations - changes in the electrocardiogram - sudden fainting when standing upright, formation of blood clots in veins (thrombosis) and embolism, circulatory collapse (shock) Blood - changes in the number of blood cells, such as: decreased white blood cells, decreased blood platelets, decreased red blood cells; impaired production of new blood cells by the bone marrow - altered levels of body fluids (dehydration) and blood chemicals, in particular decreased potassium, decreased sodium, decreased magnesium, decreased chlorine and increased calcium - increased uric acid levels, gout, increased blood glucose, diabetes, metabolic alkalosis (a disorder of metabolism), increased blood cholesterol and/or triglycerides Stomach and gut - lack of appetite, dry mouth, nausea, vomiting, stomach discomfort, abdominal pain, diarrhoea, fewer bowel movements (constipation), absence of bowel movements (ileus paralytic), flatulence - inflammation of the glands that produce saliva, inflammation of the pancreas, increased blood amylase level (a pancreatic enzyme) - yellowing of the skin (jaundice), inflammation of the gall bladder Chest - respiratory distress, lung inflammation (pneumonitis), formation of fibrous tissue in the lungs (interstitial lung disease), fluid accumulation in the lung				

				(pulmonary oedema) Nervous system - vertigo (spinning sensation) - convulsions, depressed level of consciousness, coma, headache, dizziness - apathy, confusional state, depression, nervousness, restlessness, sleep disturbances - unusual burning, pricking, tickling, or tingling skin sensations - muscle weakness (paresis) Skin and hair - itchiness, purple spots/blotches on the skin (purpura), hives (urticaria), increased sensitivity of your skin to sunlight, rash, facial rash and/or patchy redness that can cause scarring (cutaneous lupus erythematosus), inflammation of blood vessels with consequent death of tissue (vasculitis necrotising), peeling, redness, loosening, and blistering of the skin (toxic epidermal necrolysis) Eyes and ears - yellow vision, blurred vision, worsening of myopia, decreased tear production Joint and muscles - muscle spasm, muscle pain Urinary - Kidney dysfunction, acute kidney failure (reduced urine production and build-up of fluid and wastes in your body), inflammation of the connective tissue within the kidneys (interstitial nephritis), sugar in the urine. Sexual - Erection disturbances General/Other - General weakness, tiredness, fever, thirst				

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
42.	a) ACI Ltd., Narayanganj b) Incepta Pharmaceuticals Ltd, Savar	Lifitegrast 5.0 gm/100 ml Ophthalmic Solution Lifitegrast INN 5.0gm/100 ml **Antiinflammatory**	It is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the treatment of the signs and symptoms of dry eye disease.	**Contraindications:** None **Side effects:** The most common side effects following the use of Lifitegrast were instillation site irritation, dysgeusia and decreased visual acuity.	New	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj
43.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Paracetamol 500mg + Ibuprofen 200mg Tablet Paracetamol BP 500mg + Ibuprofen BP 200mg **Antiinflammatory & Analgesic**	-Do-	-Do-	New	MHRA	wWwmwm 244Zg mfvq Av‡e`b bvgÄyi Kiv nq weavq Av‡e`bvU ¯wMZ Kiv †h‡Z cv‡i	wWwmwm 244Zg mfvq Av‡e`b bvgÄyi Kiv nq weavq Av‡e`bvU ¯wMZ Kiv nj
44.	Beacon Pharmaceutical Ltd.	Apremilast INN 30mg Tablet Apremilast INN 30mg **Antipsoriatic arthritis**	Apremilast is indicated for: ✓ Adult patients with active psoriatic arthritis ✓ Patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy	**Contraindication**: Contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation **Side-effect:** Diarrhea, Nausea, Headache Upper respiratory tract infection, Vomiting Nasopharyngitis, Upper abdominal pain	10mg Tablet	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj
45.	General Pharmaceuticals Ltd., kaliakair, Gazipur	Cariprazine 1.5mg Capsule Cariprazine Hydrochloride INN 1.628mg eq. to Cariprazine 1.50mg **Antipsychotic**	a) Treatment of schizophrenia b) Acute treatment of manic or mixed episodes associated with bipolar I disorder	**Contraindication:** Known hypersensitivity to Cariprazine Hydrochloride Side Effect: a) Schizophrenia: extrapyramidal symptoms and akathisia b) Bipolar mania: extrapyramidal symptoms, akathisia, dyspepsia	New	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj
46.	General Pharmaceuticals Ltd., kaliakair, Gazipur	Cariprazine 3.00mg Capsule Cariprazine Hydrochloride INN 3.255mg eq. to Cariprazine 3.00mg **Antipsychotic**	a) Treatment of schizophrenia b) Acute treatment of manic or mixed episodes associated with bipolar I disorder	Contraindication: Known hypersensitivity to Cariprazine Hydrochloride **Side Effect:** a) Schizophrenia: extrapyramidal symptoms and akathisia b) Bipolar mania: extrapyramidal symptoms, akathisia, dyspepsia	New	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rlbwi K bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi mfvi wm×vš	mfvi wm×vš
47.	General Pharmaceuticals Ltd., kaliakair, Gazipur	Cariprazine 4.50mg Capsule Cariprazine Hydrochloride INN 4.883mg eq. to Cariprazine 4.50mg **Antipsychotic**	a) Treatment of schizophrenia b) Acute treatment of manic or mixed episodes associated with bipolar I disorder	**Contraindication:** Known hypersensitivity to Cariprazine Hydrochloride **Side Effect:** a) Schizophrenia: extrapyramidal symptoms and akathisia b) Bipolar mania: extrapyramidal symptoms, akathisia, dyspepsia	New	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj
48.	General Pharmaceuticals Ltd., kaliakair, Gazipur	Cariprazine 6.00mg Capsule Cariprazine Hydrochloride INN 6.510mg eq. to Cariprazine 6.00mg **Antipsychotic**	a) Treatment of schizophrenia b) Acute treatment of manic or mixed episodes associated with bipolar I disorder	**Contraindication:** Known hypersensitivity to Cariprazine Hydrochloride **Side Effect:** a) Schizophrenia: extrapyramidal symptoms and akathisia b) Bipolar mania: extrapyramidal symptoms, akathisia, dyspepsia	New	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj
49.	Aristopharma Ltd, Shampur-Kadamtali I/A, Dhaka-1204.	Levosulpiride 25 mg Tablet Levosulpiride INN 25 mg **Antipsychotic**	It is an antipsychotic and prokinetic (gastroprokinetic) agent, for the treatment of gastroesophageal reflux disease, various forms of dyspepsia, diabetic gastroparesis, vomiting and nausea.	**Contraindications:** Levosulpiride is contraindicated in conditions like epilepsy, hyperprolactinaemia, breast feeding, and hypersensitivity to any component of product, gastrointestinal hemorrhage and Pheochromocytoma. **Side effects**: The symptomatic adverse Reactions produced by Levosulpiride are more or less tolerable and if they become severe, they can be treated symptomatically, these include sedation, hypotension, and dyskinesia pheochromocytoma.	New		wWmmm 245Zg mfvq Av‡e`b bvgÄyi Kiv nq weavq Av‡e`bU ¯wMZ Kiv †h‡Z cv‡i	wWmmm 245Zg mfvq Av‡e`b bvgÄyi Kiv nq weavq Av‡e`bU ¯wMZ Kiv nj

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-Kvgvi mfvi wm×vš	mfvi wm×vš
50.	Beacon Pharmaceutical Ltd.	Paliperidone 150mg/1.5ml Pre-filled Syringe suspension Paliperidone Palmitate INN 234.0mg eq. to 150mg Paliperidone **Antipsychotic**	It is an atypical antipsychotic indicated for • Treatment of schizophrenia. • Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants.	**Contraindication:** Known hypersensitivity to paliperidone, risperidone, or to any excipients in Paliperidone **Side effect:** The most common adverse reactions (incidence ≥ 5% and occurring at least twice as often as placebo) were injection site reactions, somnolence/sedation, dizziness, akathisia, and extrapyramidal disorder.	3mg&, 6mg& 9mg ER Tablet	USFDA	Jla wUi †WvR mgšq K‡i c‡qvRbxq †idv‡iÝmn cÖvivq `wLj Kiv wb‡`kbv c`vb Kiv †h‡Z cv‡i	Jla wUi †WvR mgšq K‡i c‡qvRbxq †idv‡iÝmn cÖvivq `wLj Kiv wb‡`kbv c`vb Kiv nj	
51.	Incepta Pharmaceuticals Ltd, Savar	Pimavanserin 17 mg Tablet Pimavanserin Tartrate INN 20 mg eq. to Pimavanserin 17 mg **Antipsychotic**	It is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.	**Contraindication: None** **Side effect:**Most common adverse reactions (≥5% and twice the rate of placebo): peripheral edema and confusional state	New	USFDA	Abÿgv`b Kiv ‡h‡Z cv‡i	Abÿgv`b Kiv nj	
52.	Beacon Pharmaceutical Ltd.	Pimavanserin 17mg Tablet Pimavanserin Tartrate INN 20mg eq. to Pimavanserin 17mg **Antipsychotic**	It is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis	**Contraindication:** None **Side effect:** The following serious adverse reactions are discussed elsewhere in the labeling: Increased Mortality in Elderly Patients with Dementia-Related Psychosis.	New	USFDA	Abÿgv`b Kiv ‡h‡Z cv‡i	Abÿgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
53.	Aristopharma Ltd, Shampur-Kadamtali I/A, Dhaka-1204. Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Rabeprazole Sodium 20mg/Vial Lyophilized Injection Rabeprazole Sodium (Injectable Grade) INN 20 mg / Vial **Antiulcerant**	It is an alternative in patients for whom oral administration of Rabeprazole is not indicated. Rabeprazole Injection is indicated in the treatment of: * Active duodenal ulcer with bleeding or severe erosions. * Active gastric ulcer with bleeding or severe erosions. *Short-term treatment of erosive or ulcerative gastroesophageal reflux disease (GERD) * Prevention of acid-aspiration during surgery. *Prevention of stress-induced mucosal injury in critical care. *Pathological hypersecretory conditions, including Zollinger-Ellison syndrome.	**Contraindication:** Rabeprazole is contraindicated in patients with known hypersensitivity to Rabeprazole, substituted benzimidazoles or to any component of the formulation. **Side-effect :** It is an altemative in whom oral administration of Rabeprazole is not indicated. Symptomatic response to therapy with Rabeprazole does not preclude the presence of gastric malignancy. In case of discoloration of content, please do not use and discard the vial.*Pregnancy*: There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. *Lactation*: Since many drugs are excreted in milk, caution should be excercised when Rabeprazole is administered to a nursing mother.*Paediatric use*: The safely and effectiveness of Rabeprazole in Paediatric patients has not been established. *Geriatric use*: No overall differences in safety or effectiveness were observed between these subjects & younger subjects.	Rabeprazole 20 mg Tablet & Capsule		wWwmwm 245Zg mfvq Av‡e`b bvgÄyb Kiv nq weavq Av‡e`bwU ¯wMZ Kiv †h‡Z cv‡i	wWwmwm 245Zg mfvq Av‡e`b bvgÄyb Kiv nq weavq Av‡e`bwU ¯wMZ Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
54.	a) Incepta Pharmaceuticals Ltd, Savar b) Beacon Pharmaceutical Ltd. c) Julphar Bangladesh Ltd., Faridpur, sreepur, Gazipur	Sofosbuvir 400 mg + Velpatasvir 100 mg Tablet Sofosbuvir INN 400 mg + Velpatasvir INN 100 mg **Antiviral**	It is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adult patients with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection: •without cirrhosis or with compensated cirrhosis •with decompensated cirrhosis for use in combination with ribavirin	**Contraindication:** It combination regimen is contraindicated in patients for whom ribavirin is contraindicated. **Side effect:** The most common adverse reactions (incidence greater than or equal to 10%, all grades) observed with treatment with SOFOSBUVIR + VELPATASVIR for 12 weeks are headache and fatigue. (6.1) The most common adverse reactions (incidence greater than or equal to 10%, all grades) observed with treatment with its and ribavirin for 12 weeks in patients with decompensated cirrhosis are fatigue, anemia, nausea, headache, insomnia and diarrhea.	Sofosbuvir 400mg Tablet Ledipasvir 90mg + Sofosbuvir 400 mg Tablet	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj
55.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Etizolam 0.5mg Tablet Etizolam INN 0.5mg **Anxiolytics**	It is a thienobenzodiazepine with anxiolytic, sedative-hypnotic and antidepressant properties.This drug treats generalized anxiety disorder which is associated with depression. The other clinical usages of this drug are insomnia, panic disorders with agoraphobia and secondary psycho-somatic illnesses like tension type headache, irritable bowel syndrome and hypertension. It treats and improves the anxiety by acting on benzodiazepine receptors in the hypothalamus and cerebral limbic system	Contraindications: Contraindicated in patient with acute narrow-angle glaucoma; eye pressure myasthenia gravis; resp depression; coma; acute pulmonary insufficiency; sleep apnoea syndrome; severe hepatic impairment. Chronic psychosis. Phobic or obsessional states; may precipitate suicide or aggressive behavior, not to be used alone to treat depression or anxiety associated with depression. Porphyria. Pregnancy and lactation. Neonates. **Side effects:** Drowsiness, sedation, muscle weakness and ataxia. Less frequently, vertigo, headache, confusion, depression, slurred speech or dysarthria, changes in libido, tremor, visual disturbances, urinary retention or incontinence, GI disturbances, changes in salivation and amnesia.	New		c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄy Kiv †h‡Z cv‡i	c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄy Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
56.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Etizolam 1mg Tablet Etizolam INN 1mg **Anxiolytics**	It is a thienobenzodiazepine with anxiolytic, sedative-hypnotic and antidepressant properties.This drug treats generalized anxiety disorder which is associated with depression. The other clinical usages of this drug are insomnia, panic disorders with agoraphobia and secondary psycho-somatic illnesses like tension type headache, irritable bowel syndrome and hypertension. It treats and improves the anxiety by acting on benzodiazepine receptors in the hypothalamus and cerebral limbic system	Contraindications: Contraindicated in patient with acute narrow-angle glaucoma; eye pressure myasthenia gravis; resp depression; coma; acute pulmonary insufficiency; sleep apnoea syndrome; severe hepatic impairment. Chronic psychosis. Phobic or obsessional states; may precipitate suicide or aggressive behavior, not to be used alone to treat depression or anxiety associated with depression. Porphyria. Pregnancy and lactation. Neonates. **Side effects:** Drowsiness, sedation, muscle weakness and ataxia. Less frequently, vertigo, headache, confusion, depression, slurred speech or dysarthria, changes in libido, tremor, visual disturbances, urinary retention or incontinence, GI disturbances, changes in salivation and amnesia.	New		wWwmwm 245Zg mfvq Av‡e`b bvgÄy Kiv nq weavq Av‡e`bwU ¯wMZ Kiv †h‡Z cv‡i	wWwmwm 245Zg mfvq Av‡e`b bvgÄy Kiv nq weavq Av‡e`bwU ¯wMZ Kiv nj
57.	Beacon Pharmaceutical Ltd.	Obeticholic Acid 10 mg Tablet Obeticholic Acid INN 10mg **Bile acid analogue**	It a farnesoid X receptor (FXR) agonist, is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA	**Contra-indication:** Patients with complete biliary obstruction. **Side effect**: Most common adverse reactions (≥ 5%) are: pruritus, fatigue, abdominal pain and discomfort, rash, oropharyngeal pain, dizziness, constipation, arthralgia, thyroid function abnormality, and eczema	New	USFDA	c‡qvRb ‡bB weavq Av‡e`b bv gÄy Kiv †h‡Z cv‡i	c‡qvRb ‡bB weavq Av‡e`b bv gÄy Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvlbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-Kgv‡Ui mfvi wm×vš	mfvi wm×vš
58.	a) Beacon Pharmaceutical Ltd. b) Julphar Bangladesh Ltd., Faridpur, sreepur, Gazipur	Obeticholic Acid 5mg Tablet Obeticholic Acid INN 5mg **Bile acid analogue**	It a farnesoid X receptor (FXR) agonist, is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA	**Contra-indication:** Patients with complete biliary obstruction **Side effect**: Most common adverse reactions (≥ 5%) are: pruritus, fatigue, abdominal pain and discomfort, rash, oropharyngeal pain, dizziness, constipation, arthralgia, thyroid function abnormality, and eczema	New	USFDA	c‡qvRb ‡bB wea|q Av‡e`b bv gÄy Kiv †h‡Z cv‡i |	c‡qvRb ‡bB wea|q Av‡e`b bv gÄy Kiv nj |
59.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Piracetam 800mg + Citicoline 500mg Tablet Piracetam BP 800mg + Citicoline Sodium INN 522.527mg eqv. to Citicoline 500mg **CNS Agent**	It is used as a nootropic or cognitive enhancer and improves learning and memory performance. It is used to treatm head trauma, Parkinson's disease, Glucoma, ADHD (Attention Deficit Hyperactivity Disorder) and Cerebrovascular Disease i.e stroke	Contraindication: It is contraindicated in patients with hypersensitivity to either Citicoline or Piracetam patients with severe renal impairment, hepatic impairment and Cerebral hemorrage Side effect: Most common adverse reactions during treatment: nausea, vomiting, and headache.	Piracetam 800mg Tablet		c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB wea|q Av‡e`b bv gÄy Kiv †h‡Z cv‡i |	c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB wea|q Av‡e`b bv gÄy Kiv nj |
60.	Beacon Pharmaceutical Ltd.	Tetrabenazine 25mg Tablet Tetrabenazine INN 25mg **CNS Agent**	It is indicated for the treatment of chorea associated with Huntington's disease.	**Contraindication**: Depression, Parkinsonism, Phaeochromocytoma, Prolactin-dependent tomours **Side-effect:** The following risks are discussed in greater detail in other sections of the labeling: Depression and suicidality, Akathisia, restlessness and agitation, Parkinsonism, Sedation and somnolence Dysphagia	12.5mg	BNF-71 Page No-358	Abygv`b Kiv ‡h‡Z cv‡i |	Abygv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †Rmbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKmbK`vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
61.	Incepta Pharmaceuticals LTd, (Dhamrai Unit.)	Clobetasol Propionate 0.05gm/100gm solution for Spray Clobetasol Propionate BP/Ph.Eur. 0.5mg/100gm **Corticosteroid**	It is a corticosteroid indicated for the topical treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older. ***Limitations of Use:*** Do not use on the face, axillae or groin. Do not use if atrophy is present at the treatment site. Do not use for rosacea or perioral dermatitis.	**Contraindication:** No information provided **Side effect:** In controlled, clinical trials with Clobetasol Propionate Spray, 0.05%, the most common adverse reactions (incidence > 2%) were burning, pruritus, nasopharyngitis, upper respiratory tract infection.	0.05% Scalp Lotion	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj
62.	General Pharmaceuticals Ltd., kaliakair, Gazipur	Desoximetasone 0.25% Cream Desoximetasone USP 0.25gm/100gm **Corticosteroid**	Topical corticosteroids are high potency corticosteroids indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.	Contra-indication: None Side-effecty : The most common Side effects are reactions (≥ 1%) at application site dryness, application site irritation and application site pruritus.	New	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj
63.	**Aristopharma Ltd,** Shampur-Kadamtali I/A, Dhaka-1204.	Dexamethasone 4 mg Film Coated Tablet Dexamethasone USP 4 mg **Corticosteroid**	It is indicated and widely used drug for the pretreatment for chemotherapy to reduce delayed inflammation and side effects from chemotherapy associated medications.	**Contra-indication :** Contraindications include Hypersensitivity to Dexamethasone, systemic infections unless specific anti-infective therapy is given, and live virus immunization. **Side Effects :** The common side effects are stomach upset, headache, dizziness, menstrual changes, trouble sleeping, increased appetite, or weight. Serious side effects occur: signs of infection (e. g., fever, persistent sore throat), bone/joint pain, increased thirst/urination, fast/slow/irregular heartbeat, eye pain/pressure, vision problems, heartburn, black stools, vomit that looks like coffee grounds, puffy face, swelling of the ankles/feet, stomach/abdominal pain, pain/redness/swelling of arms/legs, tiredness, mental/mood changes the blood cells, kidneys, and other parts of the body.	0.5mg Tablet	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rlbl‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKlbK`vj mve-Kvgl‡Ui mfvi wm×vš	mfvi wm×vš
64.	**Aristopharma Ltd,** Shampur-Kadamtali I/A, Dhaka-1204 Square Pharmaceuticals Ltd., (Dhaka Unit) Kaliakoir, Gazipur	Dexamethasone Phosphate 0.10 gm + Moxifloxacin 0.50gm/100gm Sterile Ophthalmic Solution Dexamethasone Sodium Phosphate USP 0.1093 gm Eq.to Dexamethasone Phosphate 0.10gm + Moxifloxacin Hydrochloride BP 0.5454gm Eq.to Moxifloxacin 0.50gm/100gm **Corticosteroid + Antibiotic**	It is indicated forsteroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and Where bacterial infection or a risk of bacterial ocular infection exists. The combination can also be used for post-operative inflammation and any other ocular inflammation associated with infection.	**Contraindication:** It is contraindicated in epithelial herpes simplex keratitis (Dendritic keratitis), vaccinia, varicella, and in many other viral diseases of the conjunctiva and cornea, Mycobacterial infection of the eye and fungal diseases of ocular structures and in individuals hypersensitive to any of the components of the medication. **Side effects:** The most frequently reported drug-related undesirable effects seen with Moxifloxacin are conjunctival irritation, increased lacrimation, keratitis and papillary conjunctivitis	Moxifloxacin 0.5gm/100ml Eye Drop Dexamethasone 0.10 gm/100ml Eye Drop		wWwmwm 245Zg mfvq Av‡e`b bvgÄyÿ Kiv nq weavq Av‡e`bU ¯wMZ Kiv †h‡Z cv‡i	wWwmwm 245Zg mfvq Av‡e`b bvgÄyÿ Kiv nq weavq Av‡e`bU ¯wMZ Kiv nj
65.	Square Formulations Ltd., Gorai, Tangail	Pancrelipase 435mg (Amylase 39,150 USP Units + Lipase 10,440 USP Units + Protease 39,150 USP Units) Tablet Pancrelipase USP 435mg (Amylase 39,150 USP Units + Lipase 10,440 USP Units + Protease 39,150 USP Units) **Enzyme**	It is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.	Contraindication: Not yet found **Warnnigns:** Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PANCREAZE exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day). To avoid irritation of oral mucosa, do not chew PANCREAZE or retain in the mouth Exercise caution when prescribing PANCREAZE to patients with gout, renal impairment, or hyperuricemia. There is theoretical risk of viral transmission with all pancreatic enzyme products including PANCREAZE. Exercise caution when	New	USFDA	c‡qvRb ‡bB weavq Av‡e`b bv gÄyÿ Kiv †h‡Z cv‡i	c‡qvRb ‡bB weavq Av‡e`b bv gÄyÿ Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RMbwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
66.	Square Formulations Ltd., Gorai, Tangail	Pancrelipase 870mg (Amylase 78,300 USP Units + Lipase 20,880 USP Units + Protease 78,300 USP Units) Tablet Pancrelipase USP 870mg (Amylase 78,300 USP Units + Lipase 20,880 USP Units + Protease 78,300 USP Units) **Enzyme**	It is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.	Contraindication: Not yet found Warnnigns: Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PANCREAZE exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day). To avoid irritation of oral mucosa, do not chew PANCREAZE or retain in the mouth Exercise caution when prescribing PANCREAZE to patients with gout, renal impairment, or hyperuricemia. There is theoretical risk of viral transmission with all pancreatic enzyme products including PANCREAZE. Exercise caution when administering pancrelipase t	New	USFDA	c‡qvRb ‡bB wea|q Av‡e`b bv gÄ¨y Kiv †h‡Z cv‡i |	c‡qvRb ‡bB wea|q Av‡e`b bv gÄ¨y Kiv nj |
67.	Incepta Pharmaceuticals Ltd, Savar	Alvimopan 12 mg Capsule Alvimopan INN 12 mg **Gastrointestinal Agent**	Alvimopan is an opioid antagonist indicated to accelerate the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection with primary anastomosis.	**Contraindication:** Patients who have taken therapeutic doses of opioids for more than 7 consecutive days prior to taking Alvimopan **Side effect:** The most common adverse reaction (incidence ≥1.5%) is occurring with a higher frequency than placebo among Alvimopan-treated patients undergoing surgeries that included a bowel resection was dyspepsia.	New	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i |	Abyjgv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rlbl iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	A\‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKlbK¨vj mve-Kvgl Ui mfvi wm×vš	mfvi wm×vš
68.	Beacon Pharmaceutical Ltd.	Alvimopan 12mg Hard Gelatin Capsule Alvimopan Dihydrate INN 13.017mg eq to Alvimopan 12mg **Gastrointestinal Agent**	Alvimopan is an opioid antagonist indicated to accelerate the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection with primary anastomosis.	**Contraindication:** Patients who have taken therapeutic doses of opioids for more than 7 consecutive days prior to taking Alvimopan. **Side effect:** The most common adverse reaction (incidence ≥1.5%) was occurring with a higher frequency than placebo among Alvimopan treated patients undergoing surgeries that included a bowel resection was dyspepsia.	New	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj
69.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Famotidine 10mg + Calcium Carbonate (Heavy) 800mg + Magnesium Hydroxide 165mg Tablet Famotidine USP 10mg + Calcium Carbonate BP (Heavy) 800mg + Magnesium Hydroxide USP 165mg **Gastrointestinal agent**	It is used to treat heartburn and other symptoms caused by too much acid in the stomach (acid indigestion). It is an H2 (histamine) blocker and antacid combination. It works by neutralizing stomach acid and reducing stomach acid production.	Contraindication: Hypersensitivity to Famotidine, Calcium Carbonate, Magnesium Hydroxide or other acid reducers. Severe renal or hepatic impairment. **ADR/Side effects:** Headache, Constipation, Diarrhea	New	USFDA	c‡qvRb ‡bB weavq A\‡e`b bv gÄyi Kiv †h‡Z cv‡i	c‡qvRb ‡bB weavq A\‡e`b bv gÄyi Kiv nj
70.	Incepta Pharmaceuticals Ltd, Savar	Methylnaltrexone Bromide 12mg/0.6ml Prefilled syringe Injection Methylnaltrexone Bromide INN/In-house 12mg/0.6ml **Gastrointestinal Agent**	It is indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. **Limitation of Use:** methylnaltrexone bromide beyond four months has not been studied.	**Contraindication:** It is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction **Side effect:** The most common (≥5%) adverse reactions reported with methylnaltrexone bromide are abdominal pain, flatulence, nausea, dizziness, diarrhea and hyperhidrosis.	New	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RMbwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgwUi mfvi wm×vš	mfvi wm×vš
71.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Sodium Alginate 250mg + Sodium Bicarbonate 106.500mg + Calcium Carbonate (Heavy) 187.500mg Tablet Sodium Alginate USP 250mg + Sodium Bicarbonate BP 106.500mg + Calcium Carbonate (Heavy) BP 187.500mg **Gastrointestinal agent**	It is indicated for the treatment of gastro-oesophageal reflux i.e. acid regurgitation, heartburn, indigestion and for symptoms of excess stomach acid (hyperacidity) It acts in a dual mechanism mood, quickly neutralizes excess stomach acid and also forms a protective layer over stomach content	Contraindications: Hypersensitivity to the active substances or to any of the excipients, including the esters of hydroxybenzoates (parabens). Side effects: Very rarely (<1/10,000) patients sensitive to the ingredients may develop allergic manifestations such as urticaria or bronchospasm, anaphylactic or anaphylactoid reactions	Potassium Bicarbonate 100 mg + Sodium Alginate 500 mg Tablet	MHRA (Gaviscon Double Action Tablet)	wWwmwm 245Zg mfvq Av‡e`b bvgÄyÿ Kiv nq weavq Av‡e`bwU ¯wMZ Kiv †h‡Z cv‡i	wWwmwm 245Zg mfvq Av‡e`b bvgÄyÿ Kiv nq weavq Av‡e`bwU ¯wMZ Kiv nj	
72.	Drug International Ltd., Gazipur	Sodium Alginate 5.0 gm + Sodium Bicarbonate 2.67gm + Calcium Carbonate 1.60gm/100ml Oral Suspension Sodium Alginate BP 5gm + Sodium Bicarbonate BP 2.67gm + Calcium Carbonate BP 1.60gm / 100ml **Gastrointestinal Agent**	For the management of gastric reflux, reflux oesophagitis, hiatus hernia, heartburn (including heartburn of pregnancy) and similar gastric distress.	**Contraindications**: It is contraindicated in patients with known to have hypersensitivity to the drug. **Side Effects:** The most common side effects are constipation,diarrhea, severe allergic reactions		BNF-71 , Page-60	wWwmwm 245Zg mfvq Av‡e`b bvgÄyÿ Kiv nq weavq Av‡e`bwU ¯wMZ Kiv †h‡Z cv‡i	wWwmwm 245Zg mfvq Av‡e`b bvgÄyÿ Kiv nq weavq Av‡e`bwU ¯wMZ Kiv nj	
73.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Sodium Alginate 5.0gm + Sodium Bicarbonate 2.130gm + Calcium Carbonate (light) 3.250gm/100ml Suspension Sodium Alginate USP 5.0gm + Sodium Bicarbonate BP 2.130gm + Calcium Carbonate (light) BP 3.250gm/100ml **Gastrointestinal agent**	It is indicated for the treatment of gastro-oesophageal reflux i.e. acid regurgitation, heartburn, indigestion and for symptoms of excess stomach acid (hyperacidity). It acts in a dual mechanism mood, quickly neutralizes excess stomach acid and also forms a protective layer over stomach content	**Contraindications:** Hypersensitivity to the active substances or to any of the excipients, including the esters of hydroxybenzoates (parabens). **Side effects:** Very rarely (<1/10,000) patients sensitive to the ingredients may develop allergic manifestations such as urticaria or bronchospasm, anaphylactic or anaphylactoid reactions	Potassium Bicarbonate 100mg + Sodium Alginate 500 mg/5 ml Suspension	MHRA (Gaviscon Double Action)	c‡qvRb ‡bB weavq Av‡e`b bv gÄyÿ Kiv †h‡Z cv‡i	c‡qvRb ‡bB weavq Av‡e`b bv gÄyÿ Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RIbwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KgwUi mfvi wm×vš	mfvi wm×vš
74.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Deflazacort 12mg Tablet Deflazacort INN 12mg **Glucocorticoid**	-Do-	-Do-	6mg & 24mg Tablet		c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄ¨ Kiv †h‡Z cv‡i	c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄ¨ Kiv nj
75.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Deflazacort 1mg Tablet Deflazacort INN 1mg **Glucocorticoid**	-Do-	-Do-	6mg & 24mg Tablet		wWmwm 245Zg mfvq Av‡e`b bvgÄ¨ Kiv nq weavq Av‡e`bwU ¯wMZ Kiv †h‡Z cv‡i	wWmwm 245Zg mfvq Av‡e`b bvgÄ¨ Kiv nq weavq Av‡e`bwU ¯wMZ Kiv nj
76.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Deflazacort 30mg Tablet Deflazacort INN 30mg **Glucocorticoid**	-Do-	-Do-	6mg & 24mg Tablet		wWmwm 245Zg mfvq Av‡e`b bvgÄ¨ Kiv nq weavq Av‡e`bwU ¯wMZ Kiv †h‡Z cv‡i	wWmwm 245Zg mfvq Av‡e`b bvgÄ¨ Kiv nq weavq Av‡e`bwU ¯wMZ Kiv nj
77.	Julphar Bangladesh Ltd., Faridpur, sreepur, Gazipur	Deflazacort 6mg/5ml Suspension Deflazacort INN 6mg/5ml **Glucocorticoid**	Asthma and other airway Diseases, Rheumatoid arthritis, juvenile chronic arthritis, pemphigus, uveitis, nephritic, syndrome,Immune suppression in transplantation, anaphylaxis, severe,hypersensitivity reactions, dermatomyositis, mixed connective, tissue disease, polyarteritis nodosa, bullous pemphigoid, ulcerative colitis, optic neuritis, autoimmune haemolytic anaemia, idiopathic, thrombocytopenic, purpura, acute and lymphatic leukaemia, malignant lymphoma.	**Contraindications:** Systemic infection; live virus vaccines in those receiving immunosuppressive doses. **Side Effects:** GI disturbances, musculoskeletal, endocrine, neuropsychiatric, ophthalmic, fluid and electrolyte disturbances; susceptible to infection, impaired healing, hypersensitivity, skin atrophy, striae, telangiectasia, acne, myocardial rupture following recent MI, thromboembolism.	6mg Tablet		c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄ¨ Kiv †h‡Z cv‡i	c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄ¨ Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rlbl iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKlbK¨vj mve-Kgl Ui mfvi wm×vš	mfvi wm×vš
78.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Lafutidine 5mg Tablet Lafutidine INN 5mg **H_2 Receptor Blocker**	Gastric ulcers, duodenal ulcers and stomal ulcers. -Gastric mucosal lesions (erosion, hemorrhage, redness or edema) associated with acute gastritis and acute exacerbation of chronic gastritis. - Preanesthetic medication.	**Contraindications:** Patients with a history of drug hypersensitivity to any of the ingredients in the product. **Side effects:** Adverse reactions (including abnormal changes in labotaroty tests) were observed in 32 (2.5%) of the 1,287 patients evaluated at the time of approval. The main adverse reactions were constipation in 3 patients (0.2%). Abnornal changes in laboratory tests were observed in 22 patients.	New	[STOGAR Tablet 5] UCB Japan Co. Ltd.	wWmwm 244Zg mfvq Av‡e`b bvgÄyÿ Kiv nq weavq Av‡e`bU ¯wMZ Kiv †h‡Z cv‡i	wWmwm 244Zg mfvq Av‡e`b bvgÄyÿ Kiv nq weavq Av‡e`bU ¯wMZ Kiv nj
79.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Lafutidine 10mg Tablet **H_2 Receptor Blocker** Lafutidine INN 10mg **H_2 Receptor Blocker**	-Do-	-Do-	New	[STOGAR Tablet 10] UCB Japan Co. Ltd.	wWmwm 244Zg mfvq Av‡e`b bvgÄyÿ Kiv nq weavq Av‡e`bU ¯wMZ Kiv †h‡Z cv‡i	wWmwm 244Zg mfvq Av‡e`b bvgÄyÿ Kiv nq weavq Av‡e`bU ¯wMZ Kiv nj
80.	Incepta Pharmaceuticals Ltd, Savar	Methoxy Polyethylene Glycol-Epoetin Beta 75mcg/0.3 ml Prefilled Syringe Methoxy Polyethylene Glycol-Epoetin Beta INN 75mcg/0.3 ml **Hematopoietic**	Methoxy Polyethylene Glycol-Epoetin Beta is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia associated with chronic kidney disease (CKD in adult patients on dialysis and patients not on dialysis.	**Contraindication:** •Uncontrolled hypertension. •Pure red cell aplasia (PRCA) that begins after treatment with Methoxy Polyethylene Glycol-Epoetin Beta or other erythropoietin protein drugs •History of serious allergic reactions to Methoxy Polyethylene Glycol-Epoetin Beta, including anaphylaxis **Side effect:** The most common adverse reactions (≥10%) are hypertension, diarrhea, and nasopharyngitis.	New	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rlbl‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	A\‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKlbK`vj mve-Kgl‡Ui mfvi wm×vš	mfvi wm×vš
81.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Progesteron 32mg/mL Cream Progesteron BP 32mg/ml **Hormone**	It is indicated in progesterone-deficient conditions. Progesterone deficiency is associated with natural or surgical menopause, premenstrual syndrome (PMS), breast cancer, ovarian cysts, uterine fibroids, endometrial hyperplasia and associated estrogen-dependent malignancies, fibrocystic breasts, post-patrum depression, repeat first-term miscarriages and endometriosis.	It should not be used by women with any of the following conditions: • Severe liver disease i.e. cholestatic jaundice, Rotor syndrome or Dubin-Johnson syndrome • Any unexplained abnormal vaginal bleeding • History of herpes gestationis • Jaundice of pregnancy • Known sensitivity to progesterone cream or any of its individual components	100mg & 200mg Soft Gelatin Capsule	ProFeme 3.2% w/v Cream TGA Australia	c‡qvRb ‡bB wea\q A\‡e`b bv gÄy Kiv †h‡Z cv‡i	c‡qvRb ‡bB wea\q A\‡e`b bv gÄy Kiv nj
82.	a) Incepta Pharmaceuticals Ltd, Savar b) Beacon Pharmaceuticals Ltd.	Anakinra 100 mg/0.67ml Prefilled Syringe Injection Anakinra INN 100mg/0.67ml **Immunomodulator**	Anakinra is an interleukin-1 receptor antagonist indicated for: **Rheumatoid Arthritis (RA)** Reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs (DMARDs) **Cryopyrin-Associated Periodic Syndromes (CAPS)** •Treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID).	**Contraindication:** Known hypersensitivity to E coli-derived proteins, Anakinra, or to any component of the product **Side effect:** Rheumatoid Arthritis (RA) Most common adverse reactions (incidence ≥ 5%) are injection site reaction, worsening of rheumatoid arthritis, upper respiratory tract infection, headache, nausea, diarrhea, sinusitis, arthralgia, flu like-symptoms, and abdominal pain NOMID. The most common AEs during the first 6 months of treatment (incidence >10%) are injection site reaction, headache, vomiting, arthralgia, pyrexia, and nasopharyngitis	New	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rlbw`iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	A|‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgwUi mfvi wm×vš	mfvi wm×vš
83.	Incepta Pharmaceuticals Ltd, Savar	Naloxegol 12.5 mg Tablet Naloxegol Oxalate INN 14.20 mg eq. to Naloxegol 12.5 mg **laxative**	It is an opioid antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.	**Contraindication:** Patients with known or suspected gastrointestinal obstruction and at increased risk of recurrent obstruction Concomitant use with strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) • Known serious or severe hypersensitivity reaction to Naloxegol Oxalate or any of its excipients **Side effect:**The most common adverse reactions in clinical trials (≥3%) are: abdominal pain, diarrhea, nausea, flatulence, vomiting, and headache	25mg Tablet	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj
84.	Incepta Pharmaceuticals Ltd, Savar	Monobasic Sodium Phosphate Monohydrate 19.0gm + Dibasic Sodium Phosphate Heptahydrate 7.0gm/118ml Solution Monobasic Sodium Phosphate Monohydrate BP 19.0 gm + Dibasic Sodium Phosphate Heptahydrate BP 7.0gm/118ml **laxatives**	Useful as laxatives in the relief of occasional constipation and as part of a bowel cleansing regimen in preparing the colon for surgery, x-ray or endoscopic examination.	**Contraindication:** Do not use in patients with Congestive heart failure, Clinically significant impairment of renal function, Known or suspected gastrointestinal obstruction, Megacolon (congenital or acquired), Paralytic ileus, Perforation, Active inflammatory bowel disease, Imperforate anus, Dehydration, Generally in all cases where absorption capacity is increased or elimination capacity is decreased, Children under 2 years of age, Hypersensitivity to active ingredients or to any of the excipients of the product. **Side effect:** Hypersensitivity, Pruritis, Dehydration, Hyperphosphatemia, Hypocalcemia Hypokalemia, Hypernatremia, Metabolic Acidosis, Nausea, Vomiting, Abdominal Pain, Abdominal Distension, Diarrhea Gastrointestinal Pain, Chills, Blistering, Stinging, Anal discomfort Proctalgia	New		c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB wea|q A|‡e`b bv gÄyÝ Kiv †h‡Z cv‡i	c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB wea|q A|‡e`b bv gÄyÝ Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
85.	Beximco Pharmaceuticals Ltd., Tongi ,Gazipur	Fenofibric Acid 135mg Delayed/Sustained Release Capsule Choline Fenofibrate Delayed/Sustained Release Pellets Ph.Grade 225.00mg eq.to Fenofibric Acid INN 135mg **Lipid Lowering Agent**	Choline Fenofibrate is indicated for the treatment of mixed dyslipidemia, treatment of severe hypertriglyceridemia, treatment of primary hypercholesterolemia	**Contraindications:** It is contraindicated in: Gallbladder disease, liver disease, renal dysfunction, including patients receiving dialysis, nursing mothers & patients with hypersensitivity to Fenofibric acid or Fenofibrate. **Side-effects:** The most common adverse events reported during clinical trials with fenofibrate (≥ 2% and at least 1% greater than placebo) were abnormal liver tests, increased AST, increased ALT, increased CPK, and rhinitis.	New	USFDA (Delayed Release)	Abygv`b Kiv ‡h‡Z cv‡i	Abygv`b Kiv nj
86.	General Pharmaceuticals Ltd., kaliakair, Gazipur	Ferric Citrate 1000mg Tablet Ferric Citrate INN 1000mg eq. to Ferric Iron 210mg **Minerals**	For the control of serum phosphorus levels in patients with chronic kidney disease on dialysis	**Contraindication:** Iiron overload syndromes (e.g., hemochromatosis) **Side effect:** Auryxia included diarrhea, discolored feces, constipation, nausea, and vomiting	New	USFDA	Abygv`b Kiv ‡h‡Z cv‡i	Abygv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvniK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
87.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Vitamin C 100mg + Pantothenic Acid 7.5mg + Iron 5mg + Lutein 500mcg + Vit A 2666IU + Vit D3200IU + Vit E 22.5IU + Vit K1 30mcg + Folic Acid 200mcg + Vit B1 1.4mg + VIt B2 1.75mg + Niacinamide 20mg + Pyridoxine 2mg + Vit B12 2.5mcg + Biotin 62.5mcg + Magnesium 100mg + Zinc 5mg + Manganese 2mg + Calcium 0.55mg + Dicalcium Phosphate Anhydrous 549.322mg + Molybdenum 5mg + Selenium 30mcg + Copper 0.50mg + Iodine 100mcg + Chromium 40mcg Tablet Ascorbic Acid 96% (Powder) BP 104.167mg eqv. to Vitamin C 100mg + Calcium Pantothenate 100% BP 8.151mg eqv. to Pantothenic Acid 7.5mg + Dried Ferrous Sulfate 86% BP 15.815mg eqv. to Iron 5mg + Lutein 5% USP 11.500mg eqv. to Lutein 500mcg + Beta Carotene 10% BP 48mg eqv. to Vit A 2666IU + Dried Vitamin D3 BP 2mg eqv. to Vit D3200IU + Dried	It helps to maintain healthy immunity, energy level and metabolism and also ensures all the necessary nutrition to keep one's fit for daily activities.	**Contraindication:** This multivitamin and multiminerals is contraindicated in patients with known hypersensitivity to any of it's component of the formulation.	New		c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB wea|q Av‡e`b bv gÄý Kiv †h‡Z cv‡i |	c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB wea|q Av‡e`b bv gÄý Kiv nj |

		Vitamin E Acetate 50% BP 45mg eqv. to Vit E 22.5IU + Vitamin K1 5% SD USP 600mcg eqv. to Vit K1 30mcg + Folic Acid BP 200mcg + Thiamine Hydrochloride BP 1.569mg eqv. to Vit B1 1.4mg + Riboflavin Sodium Phosphate BP 2.224mg eqv. to Vlt B2 1.75mg + Niacinamide BP 20mg + Pyridoxine Hydrochloride BP 2mg + Cyanocobalamin 1% BP 0.250mg eqv. to Vit B12 2.5mcg + Biotin BP 62.5mcg + Magnesium Oxide BP 165.840mg eqv. to Magnesium 100mg + Zinc Oxide BP 6.223mg eqv. to Zinc 5mg + Manganese Sulphate Monohydrate BP 6.152 eqv. to Manganese 2mg + Calcium Carbonate BP 1.376mg eqv. to 0.55mg Calcium + Dicalcium Phosphate Anhydrous BP 549.322mg eqv. to Phosphorus 125mg & 161.45mg Calcium + Sodium Molybdate Dihydrate 100% BP 12.607mg eqv. to Molybdenum 5mg + Sodium Selenate USP 71.790mg eqv. to Selenium 30mcg +Coper (II) Oxide BP 0.626mg eqv. to Copper 0.50mg + Potassium Iodide BP 130.810mcg eqv. Iodine 100mcg + Chromic Chloride Hexagydrate USP 205mcg eqv. to Chromium 40mcg						

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
88.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Benzydamine Hydrochloride 0.150gm/100ml Mouth Wash Benzydamine Hydrochloride 0.150gm/100ml **NSAID**	Painful inflammatory conditions of oropharynx.	**Contraindications:** Patients allergic (hypersensitive) to Benzydamine Hydrochloride or other component of mouthwash should not use the preparation. Contact with eye should be avoided. If accidentally get into eyes, they should be immediately washed with cold water. **Side effects:** • Severe allergic reaction which may include a red and lumpy skin rash, difficulty breathing, swelling of face, mouth, lips or eyelids, unexplained high temperature (fever) • Itchy rash, sometimes with pale, raised areas of skin with red edges (urticaria). • Your skin becoming more sensitive to sunlight than normal causing an itchy, red, scaly rash, sometimes with blisters. • A stinging feeling in mouth – the mouthwash may be diluted with water if you experience stinging. This should help to reduce the stinging effect.	New	BNF 71 Page: 1022	Abygv`b Kiv ‡h‡Z cv‡i	Abygv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RMbwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi mfvi wm×vš	mfvi wm×vš
89.	Delta Pharma Ltd.	Ticagrelor INN 60 mg film coated Tablet Ticagrelor INN 60 mg **Platelet Aggregation Inhibitor**	Ticagrelor is a P2Y12 platelet inhibitor indicated to reduce the rate of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). For at least the first 12 months following ACS, it is superior to Clopidogrel. Ticagrelor also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS.	**Contra-indications:** Use of this drug is contraindicated: ● History of intracranial hemorrhage ● Active pathological bleeding ● Hypersensitivity to Ticagrelor or any component of the product. **Side-effects:** Most common adverse reactions are bleeding 12% and dyspnea 14%.	90 mg Tablet	USFDA	Abygv`b Kiv ‡h‡Z cv‡i	Abygv`b Kiv nj
90.	Square Pharmaceuticals Ltd., (Dhaka Unit) Kaliakoir, Gazipur	Itopride HCl 50mg Tablet Itopride HCl INN 50 mg **Prokinetic-Antiemetic**	It is indicated in the treatment of gastrointestinal symptoms of functional, nonulcer dyspepsia (chronic gastritis) i.e, sensation of bloating, early satiety, upper abdominal pain or discomfort, anorexia, heartburn, nausea and vomiting.	Contraindications: It is contraindicated in patients with history of hypersensitivity to any ingredients of this product. Side effects: In clinical trials the most common adverse reactions observed were diarrhea, headache, and abdominal pain. Abnormalities in laboratory data were leucopenia, increased prolactin, increased AST (GOT), and increased ALT (GPT) etc.	New		wWmmm 244Zg mfvq Av‡e`b bvgÄyi Kiv nq weavq Av‡e`bU ¯wMZ Kiv †h‡Z cv‡i	wWmmm 244Zg mfvq Av‡e`b bvgÄyi Kiv nq weavq Av‡e`bU ¯wMZ Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
91.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Fluoxetine Hydrochloride 400mg/100ml Oral Solution Fluoxetine Hydrochloride BP 0.4472gm eq. to 400mg Fluoxetine/100ml **Selective serotonin reuptake inhibitors**	This is indicated for the treatment of major depressive disorder and Obsessive Compulsive Disorder	**Contraindications:** It is contraindicated in patients known to be hypersensitive to it.. **MAO inhibitors :** There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, it should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI. Since fluoxetine and its major metabolite have very long elimination half-lives, at least 5 weeks [perhaps longer, especially if fluoxetine has been prescribed chronically and/or at higher doses should be allowed after stopping this medicine before starting an MAOI. Pimozide: Concomitant use in patients taking pimozide is contraindicated. Thioridazine: Thioridazine should not be administered with it or within a minimum of 5 weeks after this medicine has been discontinued. Side Effects: Most common adverse reactions are Headache, Nausea, Insomnia, Nervousness, Anxiety, Somnolence, Dizziness, Tremor, and Diarrhea.	20mg Tablet	USFDA	Abygv`b Kiv ‡h‡Z cv‡i	Abygv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
92.	Incepta Pharmaceuticals LTd, (Dhamrai Unit.)	Nicotine 4 mg Chewing Gum Nicotine Polacrilex USP 9.38 mg eq. to Nicotine 4mg **Smoking cessation Agent**	It is used to control nicotine withdrawal symptoms and cravings associated with smoking cessation.	**Contraindication:** Check with your physician if you have any of the following conditions: Severe Uncontrolled High Blood Pressure, Heart Attack, Recent Heart Attack, Type of Angina Where Chest Pain Occurs at Rest, Angina, Unpredictable Severe Constricting Chest Pain, Life-Threatening Irregular Heart Rhythm, Occasional Numbness, Prickling, or Tingling of Fingers and Toes, Buerger's Disease, Throat Irritation, Disease of Joint Connecting the Jaw with the Temple Bone, Inflammation of the Esophagus, Ulcer from Stomach Acid, Liver Problems, Pregnancy, Tumor of Adrenal Gland Causing High Blood Pressure, Overactive Thyroid Gland, Type 1 Diabetes Mellitus **Allergies:** **Nicotine** **Side effect:**Side effects include: increase heart rate, increased blood pressure, oral irritation, dental pain, hiccups, heartburn, nausea, and	2mg Tablet	USFDA	Ab¨gv`b Kiv ‡h‡Z cv‡i	Ab¨gv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
93.	**Aristopharma Ltd,** Shampur-Kadamtali I/A, Dhaka-1204	Hydroquinone 2.0 g + Tretinoin (Micronized) 0.025g + Mometasone Furoate 0.10g /100gm Cream Hydroquinone (Micronized) USP 2.0 gm + Tretinoin (Micronized) USP 0.025 gm + Mometasone Furoate (Micronized) USP 0.1gm/100 gm **Steroid**	Hydroquinone, Tretinoin and Mometasone Furoate Combination Cream is indicated for gradual bleaching of hyper pigmentation skin condition such as cholasma, melasma, freckles. senile lentigines and other unwanted areas of melanin hyper pigmentation.	**Contra-indication:** Prior history of allergic reaction to Hydroquinone, Tretinoin and Mometasone Combination Cream. The safety of Hydroquinone, Tretinoin and Mometasone Furoate Combination Cream during pregnancy and children (12 years and under) has not been established. Caution to be exercised when Hydroquinone, Tretinoin and Mometasone Furoate Combination Cream is administered to nursing woman. **Side Effects:** Strictly for external use only. Important to avoid contact with eye and mucous membranes. Exposure to sunlight or UV light will cause regimentation of bleached area.	Fluocinolone 0.01% + Hydroquinone 4% + Tretinoin 0.05% Cream		c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄy¨ Kiv †h‡Z cv‡i	c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄy¨ Kiv nj
94.	Drug International Ltd., Gazipur	Sucralose 8.00mg/Sachet Sucralose USP 8.00mg/Sachet **Sweetener**	Sucralose is a sweetening agent. It is indicated for diabetes, obese & health conscious people. It's a sweetener made from sugar, about 600 times sweeter and safer than normal sugar.	**Contraindications**: It is contraindicated in patients with hypersensitivity to sucralose. **Side Effects:** The most commonly reported side effects are: migraines, dizziness, intestinal cramping, rashes, acne, headache, bloating, chest pain, and tinnitus, gum bleeding.	8mg Tablet & 6.5mg/Sachet		c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄy¨ Kiv †h‡Z cv‡i	c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄy¨ Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-Kvgvwi mfvi wm×vš	mfvi wm×vš
95.	Square Pharmaceuticals Ltd., (Dhaka Unit) Kaliakoir, Gazipur	Phenylephrine Hydrochloride 10mg/ml Injection Phenylephrine Hydrochloride USP 10mg/ml **Vasopressor**	It is intended for the maintenance of an adequate level of blood pressure during spinal and inhalation anesthesia and for the treatment of vascular failure in shock, shock-like states, and drug-induced hypotension, or hypersensitivity. It is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.	Contraindication: None Side effect: Most common adverse reactions during treatment: nausea, vomiting, and headache.	Phenylephrine Hydrochloride 2.5% Eye Drops	BNF-71 Page: 168	wWmmm 245Zg mfvq Av‡e`b bvgÄyÿ Kiv nq weavq Av‡e`bU ¯wMZ Kiv †h‡Z cv‡i	wWmmm 245Zg mfvq Av‡e`b bvgÄyÿ Kiv nq weavq Av‡e`bU ¯wMZ Kiv nj	
96.	Beacon Pharmaceutical Ltd.	Calcifediol 30 mcg Hard Gelatin Extended Release Capsule Calcifediol BP 30 mcg **Vatamin D3 Analogue**	Calcifediol is a vitamin D3 analog indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30ng/ml **Limitations of Use:** Calcifediol is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.	**Contraindication:** None **Side effect:** The most common adverse reactions (≥3% and more frequent than placebo) were anemia, nasopharyngitis, increased blood creatinine, dyspnea, congestive heart failure and constipation.	New	USFDA	Abygv`b Kiv ‡h‡Z cv‡i	Abygv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
97.	Incepta Pharmaceuticals LTd, (Dhamrai Unit.)	Calcifediol 30 mcg Extended Release Capsule Calcifediol BP 30 mcg **Vitamin D3**	It is a vitamin D3 analog indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/ml ***Limitations of Use:*** It is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.	**Contraindication:** None **Side effect:** The most common adverse reactions (≥3% and more frequent than placebo) were anemia, nasopharyngitis, increased blood creatinine, dyspnea, congestive heart failure and constipation.	New	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj
98.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Biotin 3mg Capsule Biotin BP 3mg **Vitamin H or coenzyme R**	Biotin deficiency (prophylaxis and treatment) The B vitamins are indicated for prevention and treatment of vitamin B deficiency. Vitamin B deficiency may occur as a result of inadequate nutrition or intestinal malabsorption but does not occur in healthy individuals receiving an adequate balanced diet. Simple nutritional deficiency of individual B vitamins is rare since dietary inadequacy usually results in multiple deficiencies. For prophylaxis of biotin deficiency, dietary improvement, rather than supplementation, is advisable. For treatment of biotin deficiency, supplementation is preferred. Biotin deficiency may lead to dermatitis, alopecia, hypercholesterolemia, and cardiac abnormalities. Requirements may be increased and/or supplementation may be necessary in the following conditions (based on documented biotin deficiency): ▪ Biotinidase deficiency	**Contraindications:** None known. **Side Effects:** Biotin may not have any known side effects through normal use, but that does not mean that an excess use of the vitamin does not have its drawbacks. Even with using too much of the vitamin, there aren't many side effects reported. Even in cases where extremely high doses were given (either by mouth or IV) there aren't many instances of side effects.These few instances have arisen over the years: One documented case involved a very high dose of vitamin B7 (biotin) along with vitamin B5 that caused a lifethreatening condition called eosinophilic pleuropericardial effusion. The condition promptly subsided once the treatment with vitamin B7 and vitamin B5 was stopped. There is a possibility that the combination of the two vitamins in high doses caused the condition, but it could have also been something completely unrelated. In animal studies, pregnant rats were given high doses of biotin. The test results showed that the placenta of the fetal rats decreased in size which increased the possibility of miscarriage. It is not known why or how	New		c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄyÝ Kiv †h‡Z cv‡i	c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄyÝ Kiv nj

			▪ Gastrectomy ▪ Seborrheic dermatitis of infancy ▪ Administration of large amounts of the biotin antagonist, avidin, which is found in raw egg whites, has also been found to cause biotin deficiency. ▪ Some unusual diets (e.g., reducing diets that drastically restrict food ▪ selection) may not supply minimum daily requirements of biotin ▪ Supplementation may be necessary in patients receiving total parenteral nutrition (TPN) or undergoing rapid weight loss or in those with malnutrition, because of inadequate dietary intake. ▪ <u>Unaccepted</u> Biotin has not been proven effective in the treatment of acne, seborrheic eczema, or alopecia.	this occurred and is unknown if the same problem could happen in human mothers.				
99.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Biotin 5mg Capsule Biotin BP 5mg **Vitamin H or coenzyme R**	Do	Do	New		*c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB wea|q Av‡e`b bv gÄ¥Kiv †h‡Z cv‡i |*	*c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB wea|q Av‡e`b bv gÄ¥Kiv nj |*

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
100.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	Ascorbic Acid 60mg + Vitamin E 30 IU + Lutein 5mg + Zeaxanthin 1mg + Elemental Copper 2mg + Elemental Zinc 15mg Capsule Ascorbic Acid (Coated) Ph. Grade 66.00mg contains Ascorbic Acid BP 60mg + Dry Vitamin E 50% (Acetate) Ph. Grade 66.00mg contains vitamin E USP 30 IU + Lutein Ph.Grade 115.00mg contains Lutein USP 5mg + Zeaxanthin Ph.Grade 23.00mg contains Zeaxanthin 1mg + Cupric Oxide Powder Ph.Grade 2.503mg eq. to Elemental Copper 2mg + Zinc Oxide BP 18.670mg eq. to Elemental Zinc 15mg **Vitamins and Minerals**	It is indicated for Age-related Eye Disease. This is an advanced new antioxidant supplement formulated to provide nutritional support for the eye. The formulation contains essential antioxidant vitamins, minerals, Lutein & Zeaxanthin.	**Contraindications:** No contraindication is reported to this medication **Side effects :** No adverse effect has been noted	New		c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB wea|q Av‡e`b bv gÄý Kiv †h‡Z cv‡i |	c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB wea|q Av‡e`b bv gÄý Kiv nj |
101.	a) Concord Pharmaceuticals Ltd., Naraynganj, Bangladesh b) Julphar Bangladesh Ltd., Faridpur, sreepur, Gazipur	Flibanserin 100 mgTablet Flibanserin INN 100 mg **Multifunctional serotonin agonist antagonist (MSAA)**	It is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty.	**Contraindicaion:** • Alcohol • Moderate or strong cytochrome P450 3A4 (CYP3A4) inhibitors • Hepatic impairment **Side effects:** Most common adverse reactions (incidence ≥2%) are dizziness, somnolence, nausea, fatigue, insomnia, and dry mouth.	New	USFDA	wWwmwm 245Zg mfvq Av‡e`b bvgÄý Kiv nq wea|q Av‡e`bwU ¯wMZ Kiv †h‡Z cv‡i |	wWwmwm 245Zg mfvq Av‡e`b bvgÄý Kiv nq wea|q Av‡e`bwU ¯wMZ Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
102.	Concord Pharmaceuticals Ltd., Naraynganj, Bangladesh	L Methyl Folate 300 mcg Tablet L Methyl Folate INN 300 mcg **Anti-Anemic**	L-methylfolate is a prescription medicine used as Dietary management of low plasma or low red blood cell folate in certain patients. It may also be used for other conditions as determined by your doctor.	**Contraindicaion:** L-Methyl Folate Tablets is contraindicated in patients with known hypersensitivity to any of the components contained in this product. **Side effects:** A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), dizziness, trouble breathing.	New		c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄyÝ Kiv †h‡Z cv‡i	c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄyÝ Kiv nj
103.	Concord Pharmaceuticals Ltd., Naraynganj, Bangladesh	L Methyl Folate 600 mcg Tablet L Methyl Folate INN 600 mcg **Anti-Anemic**	L-methylfolate is a prescription medicine used as Dietary management of low plasma or low red blood cell folate in certain patients. It may also be used for other conditions as determined by your doctor.	**Contraindicaion:** L-Methyl Folate Tablets is contraindicated in patients with known hypersensitivity to any of the components contained in this product. **Side effects:** A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), dizziness, trouble breathing.	New		c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄyÝ Kiv †h‡Z cv‡i	c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄyÝ Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
104.	Concord Pharmaceuticals Ltd., Naraynganj, Bangladesh	Sumatriptan 85mg + Naproxen Sodium 500mg Tablet Sumatriptan Succinate USP 118.98mg + Naproxen Sodium USP 500mg **Anti-Migraine**	Acute treatment of migraine with or without aura in adults and children ≥12yrs old.	**Contraindicaion:** Aspirin allergy or triad syndrome (asthma, rhinitis, nasal polyps), hypotension with prior NSAID or aspirin use. History, symptoms, or signs of ischemic cardiac (eg, MI, angina pectoris, silent myocardial ischemia), cerebrovascular (eg, stroke, TIA), or peripheral vascular (eg, ischemic bowel disease, Raynaud) syndromes. Vasospastic coronary artery disease (CAD). Uncontrolled hypertension (HTN). Significant underlying cardiovascular disease. Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders. Basilar or hemiplegic migraine. Coronary artery bypasses surgery. Severe hepatic impairment. Within 24hrs of ergot-type drugs (eg, methysergide, dihydroergotamine) or other 5-HT_1agonists. During or within 2 weeks after discontinuing MAO-type a inhibitors. 3rd trimester of pregnancy. **Side effects:** Dizziness, somnolence, paresthesia, nausea, dyspepsia, dry mouth, GI ulcers/bleed, abdominal pain, chest or neck/throat/jaw discomfort/pain, fatigue, rash (discontinue if occurs). See labeling re: risk of cardiovascular events.	New	USFDA	wWwmwm 245Zg mfvq Av‡e`b bvgÄyÿ Kiv nq weavq Av‡e`bwU ¯wMZ Kiv †h‡Z cv‡i	wWwmwm 245Zg mfvq Av‡e`b bvgÄyÿ Kiv nq weavq Av‡e`bwU ¯wMZ Kiv nj
105.	M/s. UniMed & UniHealth Mfg. Ltd., Gazipur, Bangladesh	Zinc 25mg Capsule Zinc Acetate Dihydrate USP 83.92mg eq. to 25mg Zinc **Mineral**	Wilson's disease.	**Contra-indications:** None **Side-effects:** gastric irritation (usually transient; may be reduced if first dose taken mid-morning or with a little protein); less commonly sideroblastic anaemia and leucopenia	10mg & 20mg Tablet	BNF-71 Page-894	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
106.	M/s. UniMed & UniHealth Mfg. Ltd., Gazipur, Bangladesh	Zinc 50mg Capsule Zinc Acetate Dihydrate USP 167.84mg eq. to 50mg Zinc **Mineral**	Wilson's disease.	**Contra-indications:** None **Side-effects:** gastric irritation (usually transient; may be reduced if first dose taken mid-morning or with a little protein); less commonly sideroblastic anaemia and leucopenia	10mg & 20mg Tablet	BNF-71 Page-894	Abjgv`b Kiv ‡h‡Z cv‡i	Abjgv`b Kiv nj
107.	M/s. UniMed & UniHealth Mfg. Ltd., Gazipur, Bangladesh	Penicillamine 250mg Tablet Penicillamine USP 250mg **Antirheumatic Arthritis**	Severe active rheumatoid arthritis, Wilsons disease	**Contra-indications:** lupus erythematosus **Side-effects** : initially nausea, anorexia, fever; proteinuria, thrombocytopenia; rarely mouth ulceration, stomatitis, male and female breast enlargement, haematuria (withdraw immediately if cause unknown), alopecia, pseudoxanthoma elasticum, elastosis perforans, skin laxity; also reported pancreatitis, vomiting, cholestatic jaundice, pulmonary haemorrhage, bronchiolitis, pneumonitis, blood disorders including neutropenia, agranulocytosis, aplastic anaemia, haemolytic anaemia and leucopenia, nephrotic syndrome, glomerulonephritis, Goodpasture's syndrome, septic arthritis in patients with rheumatoid arthritis, lupus erythematosus, myasthenia gravis, polymyositis, rheumatoid arthritis, urticaria, dermatomyositis, pemphigus, Stevens-Johnson syndrome, late rashes. anaemia, haemolytic anaemia and leucopenia, nephrotic syndrome, glomerulonephritis, Goodpasture's syndrome, septic arthritis in patients with rheumatoid arthritis, lupus erythematosus, myasthenia gravis, polymyositis, rheumatoid arthritis, urticaria, dermatomyositis, pemphigus, Stevens-Johnson syndrome, late rashes.	New	BNF-71 Page-919-920	Abjgv`b Kiv ‡h‡Z cv‡i	Abjgv`b Kiv nj
108.	M/s. UniMed & UniHealth Mfg. Ltd., Gazipur, Bangladesh	Penicillamine 125mg Tablet Penicillamine USP 125mg **Antirheumatic Arthritis**	Severe active rheumatoid arthritis, Wilsons disease	Do	New	BNF-71 Page:-919-920	Abjgv`b Kiv ‡h‡Z cv‡i	Abjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RMbwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
109.	M/s. UniMed & UniHealth Mfg. Ltd., Gazipur, Bangladesh	Nintedanib 150mg Soft Capsule Nintedanib Escilate INN 180.60mg eqv. to 150mg Nintedanib **kinase inhibitor**	Nintedanib is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF).	**Contraindicatios:** None **Adverse Reaction:** Most common adverse reactions (≥5%) are: diarrhea, nausea, abdominal pain, vomiting, liver enzyme elevation, decreased appetite, headache, weight decreased and hypertension.	New	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj
110.	M/s. UniMed & UniHealth Mfg. Ltd., Gazipur, Bangladesh	Nintedanib 100mg Soft Capsule Nintedanib Escilate INN 120.400mg eq. to 100mg Nintedanib **kinase inhibitor**	Nintedanib is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF).	Do	New	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj
111.	Eskayef Bangladesh Limited	Empagliflozin 10mg Film Coated Tablet Empagliflozin INN 10mg **Antidiabetic**	It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. **Limitation of use:** It is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.	**Contraindications:** • History of serious hypersensitivity reaction to empagliflozin. • Severe renal impairment, end-stage renal disease, or dialysis. **Side effects:** The most common adverse reactions associated with empagliflozin were urinary tract infections and female genital mycotic infections.	New	USFDA	wWwmwm 245Zg mfvq Av‡e`b bvgÄyÝ Kiv nq weavq Av‡e`bU ¯wMZ Kiv †h‡Z cv‡i	wWwmwm 245Zg mfvq Av‡e`b bvgÄyÝ Kiv nq weavq Av‡e`bU ¯wMZ Kiv nj
112.	Eskayef Bangladesh Limited	Empagliflozin 25mg Film Coated Tablet Empagliflozin INN 25mg **Antidiabetic**	It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. **Limitation of use:** It is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.	**Contraindications:** • History of serious hypersensitivity reaction to empagliflozin. • Severe renal impairment, end-stage renal disease, or dialysis. **Side effects:** • The most common adverse reactions associated with empagliflozin were urinary tract infections and female genital mycotic infections.	New	USFDA	wWwmwm 244Zg mfvq Av‡e`b bvgÄyÝ Kiv nq weavq Av‡e`bU ¯wMZ Kiv †h‡Z cv‡i	wWwmwm 244Zg mfvq Av‡e`b bvgÄyÝ Kiv nq weavq Av‡e`bU ¯wMZ Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
113.	Eskayef Bangladesh Limited	Empagliflozin 5mg + Metformin 850 mg Film Coated Tablet Empagliflozin INN 5mg + Metformin BP 850 mg **Antidiabetic**	It is a combination of empagliflozin and metformin HCl indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled on a regimen containing empagliflozin or metformin, or in patients already being treated with both empagliflozin and metformin. **Limitation of use:** It is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.	**Contraindications:** • Renal Impairment, ESRD, or on dialysis • Metabolic acidosis, including diabetic ketoacidosis • History of serious hypersensitivity reaction to empagliflozin or metformin **Side effects:** • Most common adverse reactions associated with empaglifloz in (5% or greater incidence) were urinary tract infection and female genital mycotic infections. • Most common adverse reactions associated with metformin (>5%) are diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache.	Metformin 850mg Tablet		c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄyÝ Kiv †h‡Z cv‡i	c‡qvRbxq ‡idv‡iÝ Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄyÝ Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rlbl iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKlbK¨vj mve-Klgl Ui mfvi wm×vš	mfvi wm×vš
114.	Eskayef Bangladesh Limited	Empagliflozin 5mg + Metformin 1000 mg Film Coated Tablet Empagliflozin INN 5mg + Metformin BP 1000 mg **Antidiabetic**	It is a combination of empagliflozin and metformin HCl indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled on a regimen containing empagliflozin or metformin, or in patients already being treated with both empagliflozin and metformin. **Limitation of use:** It is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.	**Contraindications:** • Renal Impairment, ESRD, or on dialysis • Metabolic acidosis, including diabetic ketoacidosis • History of serious hypersensitivity reaction to empagliflozin or metformin **Side effects:** Most common adverse reactions associated with empaglifloz in (5% or greater incidence) were urinary tract infection and female genital mycotic infections. Most common adverse reactions associated with metformin (>5%) are diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache.	Metformin 1000 mg	USFDA	lWlmlm 245Zg mfvq Av‡e`b bvgÄÿ Kiv nq lealq Av‡e`bU ¯lMZ Kiv †h‡Z cv‡i	lWlmlm 245Zg mfvq Av‡e`b bvgÄÿ Kiv nq lealq Av‡e`bU ¯lMZ Kiv nj
115.	Eskayef Bangladesh Limited	Empagliflozin 12.5mg + Metformin 850 mg Film Coated Tablet Empagliflozin INN 12.5mg + Metformin BP 850 mg **Antidiabetic**	It is a combination of empagliflozin and metformin HCl indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled on a regimen containing empagliflozin or metformin, or in patients already being treated with both empagliflozin and metformin. **Limitation of use:** It is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.	**Contraindications:** • Renal Impairment, ESRD, or on dialysis • Metabolic acidosis, including diabetic ketoacidosis • History of serious hypersensitivity reaction to empagliflozin or metformin **Side effects:** • Most common adverse reactions associated with empaglifloz in (5% or greater incidence) were urinary tract infection and female genital mycotic infections. • Most common adverse reactions associated with metformin (>5%) are diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache.	Metformin 850mg Tablet		c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB lealq Av‡e`b bv gÄÿ Kiv †h‡Z cv‡i	c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB lealq Av‡e`b bv gÄÿ Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RIbwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	A|‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi mfvi wm×vš	mfvi wm×vš
116.	Eskayef Bangladesh Limited	Empagliflozin 12.5mg + Metformin 1000 mg Film Coated Tablet Empagliflozin INN 12.5mg + Metformin BP 1000 mg **Antidiabetic**	Do	Do	Metformin 1000mg Tablet	USFDA	c‡qvRb ‡bB weavq Av‡e`b bv gÄy Kiv †h‡Z cv‡i |	c‡qvRb ‡bB weavq Av‡e`b bv gÄy Kiv nj |
117.	Eskayef Bangladesh Limited	Bromhexine HCl 0.08gm + Guaifenesin 2.0gm/100ml Syrup Bromhexine HCL BP 0.08gm + Guaifenesin USP 2.0gm/100ml **Expectorant**	Secretolytic therapy in acute and chronic bronchopulmonary disease associated with abnormal mucus secretion and impaired mucus transport.	**Contraindications:** Donot use in children under 2 years of age. **Side effects:** Gastrointestinal disorders: Nausea, Vomiting, Immune system disorders: Hypersessitivity, Sweating, Headache •Vertigo (dizziness)	New		c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄy Kiv †h‡Z cv‡i |	c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄy Kiv nj |
118.	Eskayef Bangladesh Limited	Prulifloxacin 600mg Film Coated Tablet Prulifloxacin INN 600mg **Antibiotic**	•Acute uncomplicated lower urinary tract infections (simole cystitis) •Complicated Lower urinary tract infections •Acute exacerbation of chronic bronchitis	**Contraindications:** Hypersensitivity to prulifloxacin, to other quinolones antibacterial agents or to any of the excipients. Pre-pubertal children or adolescents below the age of 18 years with uncomplicated skeletal development. Patients with anamnesis of tendon diseases related to the administration of quinolones Pregnancy and lactation. **Side effects:** Epigastralgia, nausea Pruritus, skin rash.	New		c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄy Kiv †h‡Z cv‡i |	c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB weavq Av‡e`b bv gÄy Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rlbl iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKlbK¨vj mve-Kvgl Ui mfvi wm×vš	mfvi wm×vš
119.	Eskayef Bangladesh Limited	Dextromethorphan Hydrobromide 0.1gm + Guaifenesin 2.0gm + Phenylephrine HCl 0.050gm/100ml Syrup Dextromethorphan Hydrobromide USP 0.1gm + Guaifenesin USP 2.0gm + Phenylephrine HCl USP 0.050gm/100ml **Expectorant**	Helps loosen phlegm (mucus) and thin bronchial secretions to drain bronchial tubes. Temporarily relieves these symptoms occurings with a cold, nasal congestion, cough due to minor throat and bronchial irritation.	**Contraindications:** Hypersensitivity to prulifloxacin, to other certain drugs for depression, pychiatricor emotional conditions or Parkinson's disease (MOAI). **Side effects:** Fast or uneven heart rate. Severe headache, dizziness or anxiety.	New		c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB wea|q Av‡e`b bv gÄ¨Kiv †h‡Z cv‡i |	c‡qvRbxq ‡idv‡iY Ges †`‡k c‡qvRb ‡bB wea|q Av‡e`b bv gÄ¨Kiv nj |

Annex-B : Products for Import (Human)

নং	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-Kvgvwi mfvi wm×vš	mfvi wm×vš
1.	**Manufacturer:** Holopack Verpackungstechnik GmbH, BahnhofstraBe, 73453 Abtsgmund-Untergroningen , Germany **MA Holder:** Pharma Resources, GmbH, Germany **Local agent:** Zas Corporation 80/22, Mymensingh Road , Banglamotor , Dhaka-1000	Ropivacaine PhaRes Solution for Injection 40mg/20ml Ropivacaine Hydrochloride Ph. Eur 40mg/20ml **Anesthetic**	**Surgical Anaesthesia** • Epidural block for surgery, including Caesarean Section • Intrathecal block • Major nerve block • Field block (minor nerve block and infiltration) **Acute Pain Management** • Continuous epidural infusion (Ropivacaine alone or in combination with Fentanyl) or intermittent bolus administration e.g. postoperative or labour pain • Field block (minor nerve block and infiltration) • Intra-articular injection • Continuous peripheral nerve block infusion or intermittent injections, e.g. postoperative pain management • Continuous wound infusion for postoperative pain management (adults only) **Acute Pain Management in Paediatrics (Children aged 0 – 12 years)** • Caudal epidural block in neonates, infants and children up to and including 12 years • Peripheral nerve block in children aged 1 up to and including 12 years • Continuous epidural infusion in neonates, infants and children up to and including 12 years.	**Contraindication:** Ropivacaine solutions are contraindicated in patients with hypersensitivity to local anaesthetics of the amide-type. **Side effect:** The most common side effects include: • changes in your sense of taste • feeling short of breath • constipation • decreased appetite • changes in fingernails or toenails	CPP- Germany	New	Abygv`b Kiv †h‡Z cv‡i	Abygv`b Kiv nj

নং	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
2.	**Manufacturer:** Holopack Verpackungstechnik GmbH, BahnhofstraBe, 73453 Abtsgmund-Untergroningen , Germany **MA Holder:** Pharma Resources, GmbH, Germany **<u>Local agent:</u>** Zas Corporation 80/22, Mymensingh Road , Banglamotor , Dhaka-1000	Ropivacaine PhaRes Solution for Injection 75mg/10ml Ropivacaine hydrochloride 75mg/10ml **Anesthetic**	**Surgical Anaesthesia** • Epidural block for surgery, including Caesarean Section • Intrathecal block • Major nerve block • Field block (minor nerve block and infiltration) **Acute Pain Management** • Continuous epidural infusion (Ropivacaine alone or in combination with Fentanyl) or intermittent bolus administration e.g. postoperative or labour pain • Field block (minor nerve block and infiltration) • Intra-articular injection • Continuous peripheral nerve block infusion or intermittent injections, e.g. postoperative pain management • Continuous wound infusion for postoperative pain management (adults only) **Acute Pain Management in Paediatrics (Children aged 0 – 12 years)** • Caudal epidural block in neonates, infants and children up to and including 12 years • Peripheral nerve block in children aged 1 up to and including 12 years • Continuous epidural infusion in neonates, infants and children up to and including 12 years.	**Contraindication:** Ropivacaine solutions are contraindicated in patients with hypersensitivity to local anaesthetics of the amide-type. **Side effect:** The most common side effects include: • changes in your sense of taste • feeling short of breath • constipation • decreased appetite • changes in fingernails or toenails	CPP-Germany	New	Abygv`b Kiv †h‡Z cv‡i	Abygv`b Kiv nj

নং	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
3.	Ursapharm Arzneimittel GmbH. IndustriestraBe 35 66129 Saarbrucken Germany. **Local agent:** Zas Corporation 80/22, Mymensingh Road , Banglamotor , Dhaka-1000	Dexa-Gentamicin Eye Drops 5ml Bottle Dexamethasone Sodium Phosphate 1.0mg + Gentamicin Sulphate 5.0mg/ml **Antibiotic**	Infections of the anterior eye including conjunctivitis, keratitis, blepharitis, and hordeolum, caused by gentamicin-sensitive pathogens; allergic inflammation of the anterior eye with bacterial superinfection	**Contraindication:** Hypersensitivity to one of the ingredients (see composition), herpes cornea superficialis, injuries and ulcerations of the cornea, closed and open angle glaucoma, tuberculous or fungal infection of the eye. **Side Effect:** In rare cases the sensation of temporary burning in the eye has been reported. Prolonged use may result in glaucoma and cataract formation.	CPP- Germany		c‡qvRb ‡bB wea|q Av‡e`b bv gÄyÿ Ki| †h‡Z cv‡i |	c‡qvRb ‡bB wea|q Av‡e`b bv gÄyÿ Ki| nj |
4.	Ursapharm Arzneimittel GmbH. IndustriestraBe 35 66129 Saarbrucken, Germany. **Local agent:** Zas Corporation 80/22, Mymensingh Road , Banglamotor , Dhaka-1000	Kanamycin–POS Drops in 5ml Bottle (Preservative free eye drops) Kanamycin Sulphate Ph. Eur. 6.2mg/ml **Antibiotic**	Indicated for topical treatment of bacterial infections of the eyelids, conjunctiva and cornea by kanamycin sensitive germs and applied in wounds of the outer eye, burns and injuries and after surgical Interventions.	**Contraindication:** Hypersensitive against Kanamycin (Ph. Eur.) or one of the other ingredients. **Side Effect:** In rare cases, fever, intense itching of the skin [Pruritus], inflammatory skin rash [rash], the propagation of eosinophils in the blood (eosinophils belong to the group of white blood cells) [eosinophilia], painful swelling of the vessels of the skin and mucous membranes [angiedema], inflammatory allergic skin reaction [contact dermatitis, urticaria] [urticaria]) may occur.	CPP- Germany	New	Abyjgv`b Ki| †h‡Z cv‡i |	Abyjgv`b Ki| nj |

নং	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
5.	**Manufacturer:** Novartis Farmaceutica,, S.A., Spain (Novartis Bangladesh Ltd)	Farydak 10 mg Hard Capsule Panobinostat lactate anhydrous 12.576mg Eq. to Panobinostat INN 10mg **Anticancer**	FARYDAK, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma, who have received at least two prior regimens including bortezomib and an immunomodulatory agent.	**Contraindication** - Hypersensitivity to either of the active substances or to any of the excipients - Breast-feeding **Side Effects:** Very common side effects areUpper respiratory tract infection, pneumonia, decreased appetite, insomnia, dizziness, headache, hypotension, cough, dyspnea, diarrhea, nausea, vomiting, abdominal pain, dyspepsia, fatigue, edema peripheral, weight decreased, thrombocytopenia, anemia, leukopenia, neutropenia, lymphopenia, blood creatinine increased, SGPT Alanine amino transaminase (ALT) increased, SGOT Aspartate amino transaminase (AST) increased & Hypokalemia	EMA		Abygv`b Kiv †h‡Z cv‡i	Abygv`b Kiv nj
6.	**Manufacturer:** Novartis Farmaceutica,, S.A., Spain (Novartis Bangladesh Ltd)	Farydak 15 mg Hard Capsule Panobinostat lactate anhydrous 18.864mg Eq. to Panobinostat INN 15mg **Anticancer**	-do-	-do-	EMA		Abygv`b Kiv †h‡Z cv‡i	Abygv`b Kiv nj
7.	**Manufacturer:** Novartis Farmaceutica,, S.A., Spain (Novartis Bangladesh Ltd)	Farydak 20 mg Hard Capsule Panobinostat lactate anhydrous 25.152mg Eq. to Panobinostat INN 20mg **Anticancer**	-do-	-do-	EMA		Abygv`b Kiv †h‡Z cv‡i	Abygv`b Kiv nj

নং	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
8.	**Manufacturer:** GlaxoSmithKline Manufacturing S.p.A., Italy (Novartis Bangladesh Ltd)	Mekinist 0.5 mg Film-Coated tablet Trametinib Dimethyl Sulfoxide 0.5635 mg Eq. to Trametinib INN 0.5 mg **Anticancer**	Trametinib as monotherapy or in combination with Dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.	**Contraindication:** • Hypersensitivity to the active substances or to any of the excipients **Side effects:**Very common side effects areurinary tract infection, decreased appetite, fatigue, dizziness, headache, hypertension, haemorrhage, cough, diarrhea, nausea, vomiting, constipation, abdominal pain, dry mouth, rash, dry skin, pruritus, alopecia, edema peripheral, decreased appetite, neutropenia, nasopharyngitis & aspartate amino transaminase (AST) increased.	EMA		*Abygv`b Kiv †h‡Z cv‡i |*	*Abygv`b Kiv nj |*
9.	**Manufacturer:** GlaxoSmithKline Manufacturing S.p.A., Italy (Novartis Bangladesh Ltd)	Mekinist 2 mg Film-Coated tablet Trametinib Dimethyl Sulfoxide 2.254 mg Eq. to Trametinib INN 2 mg **Anticancer**	-do-	-do-	EMA		*Abygv`b Kiv †h‡Z cv‡i |*	*Abygv`b Kiv nj |*
10.	**Manufacturer:** Glaxo Operations (UK) Ltd., United Kingdom (Novartis Bangladesh Ltd)	Tafinlar 50 mg Hard Capsule Dabrafenib Mesylate Micronized 59.25mg Eq. to Dabrafenib INN 50mg **Anticancer**	Dabrafenib as monotherapy or in combination with Trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.	**Contraindication:** • Hypersensitivity to the active substances or to any of the excipients **Side effects:**Very common side effects areurinary tract infection, decreased appetite, fatigue, dizziness, headache, hypertension, haemorrhage, cough, diarrhea, nausea, vomiting, constipation, abdominal pain, dry mouth, rash, dry skin, pruritus, alopecia, edema peripheral, decreased appetite, neutropenia, arthralgia, myalgia & aspartate amino transaminase (AST) increased.	EMA		*Abygv`b Kiv †h‡Z cv‡i |*	*Abygv`b Kiv nj |*

নং	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
11.	**Manufacturer:** Glaxo Operations (UK) Ltd., United Kingdom (Novartis Bangladesh Ltd)	Tafinlar 75 mg Hard Capsule Dabrafenib Mesylate Micronized 88.88mg Eq. to Dabrafenib INN 75mg **Anticancer**	Dabrafenib as monotherapy or in combination with Trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.	**Contraindication:** • Hypersensitivity to the active substances or to any of the excipients **Side effects:**Very common side effects areurinary tract infection, decreased appetite, fatigue, dizziness, headache, hypertension, haemorrhage, cough, diarrhea, nausea, vomiting, constipation, abdominal pain, dry mouth, rash, dry skin, pruritus, alopecia, edema peripheral, decreased appetite, neutropenia, arthralgia, myalgia & aspartate amino transaminase (AST) increased.	EMA		Abygv`b Kiv †h‡Z cv‡i	Abygv`b Kiv nj
12.	Ursapharm Arzneimittel GmbH. IndustriestraBe 35 66129 Saarbrucken, Germany. **Local agent:** Zas Corporation 80/22, Mymensingh Road , Banglamotor , Dhaka-1000	Allergo-COMOD eye drops 10ml Bottle Preservative free eye drop in Comod Container Closure system Sodium Cromoglicate Ph.Eur. 20mg/ml **Antiinflammatory**	Indicated for the treatment of acute and chronic allergic conjunctivitis, for instance hay fever or vernal kerato-conjunctivitis.	**Contraindication:** Hypersensitive against sodium cromoglicate (Ph. Eur.) or one of the other ingredients. **Side Effect:** In rare cases burning, foreign-body-sensation, swelling of the conjunctiva (chemosis) and increased blood flow in the conjunctiva (conjunctival hyperaemia) may occur	CPP- Germany	2% Eye Drops	cwqvRb ‡bB wewq Av‡e`b bv gÄyi Kiv †h‡Z cv‡i	cwqvRb ‡bB wewq Av‡e`b bv gÄyi Kiv nj
13.	Ursapharm Arzneimittel GmbH. IndustriestraBe 35 66129 Saarbrucken Germany. **Local agent:** Zas Corporation 80/22, Mymensingh Road , Banglamotor , Dhaka-1000	Virupos Eye Ointment in 4.5 gm Tube (Preservative free eye Ointment) Acyclovir Ph.Eur 30mg/gm **Antiviral**	Indicated for the local treatment of keratitis caused by herpes simplex virus	**Contraindication:** Hypersensitive against aciclovir, valaciclovir or any of the other ingredients of Virupos. **Side Effect:** Immediately after application of the eye ointment a slight, quickly subsiding burning may occur. In single cases prolonged treatment (more than 14 days) may cause superficial inflammatory reactions of the lower border of the cornea and the adjoining conjunctiva (keratoconjunctivitis punctata), which do not demand an early end of the treatment and recover without any aftereffect	CPP- Germany	3% Eye Ointment	Abygv`b Kiv †h‡Z cv‡i	Abygv`b Kiv nj

নং	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
14.	**Manufacturer:** Lisapharma SpA, Address: Via Licinio, 11, 22036 Erba (CO), Italy **Supplier:** River Pharma Srl; Address: Via Marconi, 36/38 20078 San Colombano, Italy **Importer:** Benvue International Ltd. Address: 14/1, Joy Tower, Joynagar R/A, Chatteshawri Road, Chittagong, Bangladesh.	**Syaloset** Intra-articular Injection Hyaluronic acid as sodium hyluronate viscosupplement agent 64 mg /4 ml **Cartilaginous Defect Repair Agent**	It is indicated for knee osteoarthritis	**Contraindications:** Must not be injected if the joint is infected or seriously inflamed or if the patient has a skin infection or other problem in in the area where the injection is to be made. Must be administered with caution in patients with diabetes or affected by chronic pathologies. **Side Effects:** Infiltration may cause localised side effects. During the use, following symptoms may appear around the injection site: pain, heat, redness or swelling. These secondary effects may be alleviated by applying ice to the treated joint. These symptoms will normally disappear after a short period. The doctor must ensure that patients inform him of any adverse effects occurring after treatment.	FSC-Italy	New	c‡qvRb ‡bB weavq Av‡e`b bv gÄyK iv †h‡Z cv‡i	c‡qvRb ‡bB weavq Av‡e`b bv gÄyK iv nj

নং	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
15.	Manufactured by : Silver Spring Sagl, 6850 Mendrisio Switzerland **Local Agent:** Global Life Care Services& Consultation Centre, Hashim Tower, H:205/1-A, (6th Floor, Unit-F) Tejgaon-Gulshan Link Road, Tejgaon, Dhaka-1208, Bangladesh)	Goleic Injection Glycoprotein Macrophage Activating Factor (GcMAF) Immune Boosting Agent	Its an anticancer and immune boosting agent that helps in destruction of cancer cells and success can be achieved with all tumor cancers including breast, lung, prostrate, pancreatic and melanoma. Treatment with Goleic Injection (GcMAF) shows improvement in 85% cases of autism and 15% total cure, as it improves neuronal metabolic activity through cAMP signaling. It also help cure the diseases causing immune dysfunction.	**Contraindication:** It should not be given during pregnancy and lactation. Low-dose naltrexone, Externally administered heparin. Aspartame, All kinds of Corticosteroids (Prednisolon, etaprednisolon, Solu-Medrol etc) Anti-inflammatory drugs should be avoided. (NSAIDs like Ibuprofen, Diclofenac, Aspirin etc if necessary, should be taken in moderation.) Cytotoxic medications Cyclophosphamide, Etoposide, Methotrexate, should be taken carefully Morphine and analogues Tramadole, codeine, Fentanyl Oxycodon should be avoided. **Side effects :** Goleic Injection (GcMAF) has shown no side effects of its own in some cases give you minor side effects like fatigue and minor weight loss, headache ,occasional mild muscular pain, joint pain and the symptoms of a fever (3-5 hours of hot flushes)due to rebuild of immune system.	FSC- Switzerland		c‡qvRb ‡bB wea|q Av‡e`b bv gÄyK iv †h‡Z cv‡i |	c‡qvRb ‡bB wea|q Av‡e`b bv gÄyK iv nj |

নং	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-Kvgvwi mfvi wm×vš	mfvi wm×vš
16.	Manufactured by : Silver Spring Sagl, 6850 Mendrisio Switzerland **Local Agent:** Global Life Care Services& Consultation Centre, Hashim Tower, H:205/1-A, (6th Floor, Unit-F) Tejgaon-Gulshan Link Road, Tejgaon, Dhaka-1208, Bangladesh)	MicroBioMax Immune Blend Glycoprotein Macrophage Activating Factor (GcMAF) Immune Boosting Agent	Its' an anticancer and immune boosting agent that helps in destruction of cancer cells and success can be achieved with all tumor cancers including breast, lung, prostrate, pancreatic and melanoma. Treatment with Microbiomax Immune Blend (GcMAF) shows improvement in 85% cases of autism and 15% total cure, as it improves neuronal metabolic activity through cAMP signaling. It also help cure the diseases causing immune dysfunction.	**Contraindication:** Should not be given during pregnancy and lactation. Low-dose naltrexone, Externally administered heparin. Aspartame, All kinds of Corticosteroids (Prednisolon, Betaprednisolon, Solu-Medrol etc) Anti-inflammatory drugs should be avoided. (NSAIDs like Ibuprofen, Diclofenac, Aspirin etc if necessary, should be taken in moderation.) Cytotoxic medications Cyclophosphamide, Etoposide, Methotrexate should be taken carefully Morphine and analogues Tramadole, codeine, Fentanyl. Oxycodon should be avoided. **Side effects**: Microbiomax immune blend (GcMAF) has shown no side effects of its own. in some cases give you minor side effects like fatigue and minor weight loss, headache, occasional mild muscular pain, joint pain and the symptoms of a fever (3-5 hours of hot flushes)due to rebuild of immune system.	FSC-Switzerland		c‡qvRb ‡bB wea|q Av‡e`b bv gÄy Kiv †h‡Z cv‡i |	c‡qvRb ‡bB wea|q Av‡e`b bv gÄy Kiv nj |

নং	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi mfvi wm×vš	mfvi wm×vš
17.	Manufactured by : Silver Spring Sagl, 6850 Mendrisio Switzerland **Local Agent:** Global Life Care Services& Consultation Centre, Hashim Tower, H:205/1-A, (6th Floor, Unit-F) Tejgaon-Gulshan Link Road, Tejgaon, Dhaka-1208, Bangladesh)	MicroBioMax Suppository Glycoprotein Macrophage Activating Factor (GcMAF) Immune Boosting Agent	It's an anticancer and immune boosting agent that helps in destruction of cancer cells and success can be achieved with all tumor cancers including breast, lung, prostrate pancreatic and melanoma. Treatment with Microbiomax Suppositories (GcMAF) shows improvement in 85% cases of autism and 15% total cure, as it improves neuronal metabolic activity through cAMP signaling. It also helps cure the diseases causing immune dysfuction.	**Contraindication:** It should not be given during pregnancy and lactation. Low-dose naltrexone, Externally administered heparin. Aspartame, All kinds of Corticosteroids (Prednisolon, Betaprednisolon, Solu-Medrol etc) Anti-inflammatory drugs should be avoided. (NSAIDs like Ibuprofen, Diclofenac, Aspirin etc if necessary, should be taken in moderation.) Cytotoxic medications Cyclophosphamide, Etoposide, Methotrexate, should be taken carefully Morphine and analogues Tramadole, codeine, Fentanyl Oxycodon should be avoided. **Side effects**: MIcrobiomax Suppositories (GcMAF) has shown no side effects of its own.In some cases give minor side effects like fatigue and minor weight loss, headache, occasional mild muscular pain, joint pain and the symptoms of a fever (3-5 hours of hot flushes)due to rebuild of immune system.	FSC-Switzerland		c‡qvRb ‡bB wea|q Av‡e`b bv gÄy K i| †h‡Z cv‡i |	c‡qvRb ‡bB wea|q Av‡e`b bv gÄy K i| n j |

.

নং	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-Kvgvwi mfvi wm×vš	mfvi wm×vš
18.	Kedrion S.P.A Via Provincial localita` Bolognana 55027 Gallicano (LU)- Italy **Local agent:** Zas Corporation 80/22, Mymensingh Road , Banglamotor , Dhaka-1000	IMMUNOHBs 180IU/1ml Solution for Injection Human Hepatitis B Immunoglobulin I**mmunoglobulin**	-Prevention of hepatitis B virus re-infection after liver transplantation for hepatitis B induced liver failure -Immunoprphylaxis of hepatitis B -In case of accidental exposure in non-immunized subjects (including persons whose vaccination is incomplete or status unknown) -In hemodialysis patients, until vaccination has become effective -In newborn of a hepatitis B virus carrier mother -In subjects who did not show an immune response after vaccination and for whom a continuous prevention is necessary due to the continuous risk of being infected with hepatitis B	**Contraindication:** Hypersensitivity to the active substances or any of the excipients. **Side effect:** Skin reaction, Erythema, Fever, Malaise, Chill, pain at injection site.	CPP-Italy, Switzerland	New	c‡qvRb ‡bB wea\q Av‡e`b bv gÄy Kiv †h‡Z cv‡i	c‡qvRb ‡bB wea\q Av‡e`b bv gÄy Kiv nj
19.	**Manufcturer:** APS Biogroup LLc. 2235 South Central Avenue Phoenis Arizona 85004 USA **Local agent:** Global Life Services &Consultation Center. Hashim Tower, House : 205/1-A 6th floor, unit F, tejgaon- Gulshan link road Dhaaka	Immunopep Skim Colostrum a) Skim colostrum capsul APS60 (99.5gm per 100gm) b) 95 immune factors, 87 growth factors, colostrinin, IGF-1, PRP (Proline rich peptides), lactoferrin c) Medium chain triglyceride oil 0.3g sunflower lecithin (E322) 0.2gm	• Stimulate immunity • Improve digestion • Provides essential nutrients • Increasing strength and performance • Preventing sickness • Improve memory • Protection from diseases.	**Contraindication:** Immunopep is 100% Skim Colostrum. Therefore, there are no Contraindication with Immunopep. **Side Effect:** Colostrum is collected from selected Bovine sources and do not contain any additives. Immunopep has shown no side effects of its own. But ato stimulate immunity may in some cases gives minor side effects.			c‡qvRb ‡bB wea\q Av‡e`b bv gÄy Kiv †h‡Z cv‡i	c‡qvRb ‡bB wea\q Av‡e`b bv gÄy Kiv nj

নং	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-Kvgvwi mfvi wm×vš	mfvi wm×vš
20.	Manufcturer : Ajinomoto north america INC 4020.Ajinomoto Drive, USA **Local agent:** Global Life Services &Consultation Center. Hashim Tower, House : 205/1-A 6th floor, unit F, tejgaon- Gulshan link road Dhaaka	Master Amino acid pattern Purified free crystalline essential amino acid chain L-Leucine 19.6% + L- Valine 16.6% + L- Isoleucine 14.8% + L- Lysine 14.3% + L-Phenylalanine 12.9% + L-Threonine 11.1% + L-methionine 7% + L-Tryptophan 3.7%	• Weight control • Diabetic nutrition • Pregnant & nursing mothers • Clinical Nutrition • Ketogenic diet support • Countering immune weakness • Countering metabolic disorders • kidney and liver disease • Stomach and bowel illness • Rheumatism • Arthrosis • Epilepsy • Oncology	**Contraindication:** MAP is 100% Pure Protein (foodstuff). Therefore, there are no Contraindications with MAP. **Side Effect:** MAP is developed from pluses (GM-free non- gene- modified) and dose not contain any additives. MAP has shown no side effects of its own. But reuilt immune system may in some cases have some minor side effect.			c‡qvRb ‡bB wea|q Av‡e`b bv gÄyK iv †h‡Z cv‡i |	c‡qvRb ‡bB wea|q Av‡e`b bv gÄyK iv nj |
21.	**Manufactured & Packed by:** Cilag AG, Hochstrasse 201, 8200 Schaffhausen, Switzerland **<u>Local agent:</u>** **UniHealth Ltd.** House: 46, Road No. 16, Rangs Nasim Squre (6th Floor) Dhanmondi, Dhaka	Darzalex concentrate for solution for infusion Daratumumab INN 100mg/5ml **Anticancer**	DARZALEX is a human CD38-directed monoclonal antibody indicated for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.	**Contra-indication:** None **Side-effects:** The most frequently reported adverse reactions (incidence ≥20%) were: infusion reactions, fatigue, nausea, back pain, pyrexia, cough, and upper respiratory tract infection.			c‡qvRb ‡bB wea|q Av‡e`b bv gÄyK iv †h‡Z cv‡i |	Abyôv`b K iv nj |

নং	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-Kvgvwi mfvi wm×vš	mfvi wm×vš
22.	**Manufactured by:** Vetter Pharma Fertigung GmbH & Co. KG, Mooswiesen 2, 88214 Ravensburg, Germany **Packaged by:** Cilag AG, Hochstrasse 201, 8200 Schaffhausen, Switzerland **<u>Local agent:</u>** **UniHealth Ltd.** House: 46, Road No. 16, Rangs Nasim Squre (6th Floor) Dhanmondi, Dhaka	Darzalex concentrate for solution for infusion Daratumumab INN 400mg/20ml **Anticancer**	DARZALEX is a human CD38-directed monoclonal antibody indicated for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.	**Contra-indication:** None **Side-effects:** The most frequently reported adverse reactions (incidence ≥20%) were: infusion reactions, fatigue, nausea, back pain, pyrexia, cough, and upper respiratory tract infection.			c‡qvRb ‡bB wea|q Av‡e`b bv gÄyÿ Kiv †h‡Z cv‡i |	Abyôgv`b Kiv nj |
23.	Fresenius Kabi Austria GmbH, Hafnerstraße 36, Graz, 8055, Austria **Local agent :** Janata Traders, TCB Bhabon, 1 kawran Bazar,Dhaka	NEPHROSTERIL IV Infusion 250ml, 500ml L-isoleucine Ph.Eur 5.10 gm + L- leucine Ph.Eur 10.30gm + L-lysine monoacetate Ph.Eur 10.01 gm + L-lysine Ph.Eur 7.10 gm + L-methionine Ph.Eur 2.80 gm + Acetyl cysteine Ph.Eur 0.50 gm + L-cysteine Ph.Eur 0.37gm + L-phenyl alanine Ph.Eur 3.80 gm + L-threonine Ph.Eur 4.80 gm +	Balance Supply of protein elements in acute and chronic renal insufficiency as well as during peritonial and hemodialysis treatment.	**Contraindications:** Impaired amino acid metabolism, advanced functional impairment of the liver, severe cardiac insufficiency, hyperhydration, hypokalemia, hyponatremia. **Side effects:** Excessive drop rates may lead to incompatibility such as nausea, chills, and vomiting.	Germany		c‡qvRb ‡bB wea|q Av‡e`b bv gÄyÿ Kiv †h‡Z cv‡i |	c‡qvRb ‡bB wea|q Av‡e`b bv gÄyÿ Kiv nj |

		L-tryptophan Ph.Eur 1.90 gm + L-valine Ph.Eur 6.20gm + L-arginine Ph.Eur 4.90 gm + L-histidine Ph.Eur 4.30 gm + Amino-acetic acid Ph.Eur 3.20gm + L-alanine Ph.Eur 6.30 gm + L-proline Ph.Eur 4.30 gm + L-serine Ph.Eur 4.50 gm + L-Malic acid Ph.Eur 1.50 gm + Acetic acid 99% Ph.Eur 1.38 gm/Liter **Amino Acid**						

Annex-C : Products for Locally manufacture (Animal Vaccine)

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †Rwbw¡K bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë †idv‡iÝ	‡UKwbK¨vj mve-KwgwUi mfvi wm×vš	mfvi wm×vš
01.	Incepta Vaccine Ltd. (Animal Vaccine Division), Dhamrai	Anthrax Vaccine (Living) (5 doses) **(Animal Vaccine)** Anthrax Vaccine (Living) Anthrax Vaccine	Anthrax Vaccine (Living) is recommended for the active immunization of cattle, sheep, goats, horses against anthrax disease caused by Bacillus anthracis. For control of outbreaks, vaccination of all animals not showing symptoms is recommended. Not all animals will be protected by this procedure but taking action as suggested may stop further spread of the disease. It is also recommended that animals showing symptoms be isolated and treated with antibiotics as permitted.	**Contraindication:** This vaccine is not recommended for the animals that are clinically sick or severely debilitated or under conditions of severe stress and strain. Sick or weak animals will not develop adequate immunity following vaccination. **Side effect:** The vaccine causes a swelling at the site of injection. The swelling is temporary and subsides after a few days. Immunity develops within 2-4 weeks after vaccination and persists for approximately 9-12 months. Anaphylactic reactions may occur following administration of product of this nature. If noted, administer adrenaline or equivalent.	New		Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë †idv‡iÝ	‡UKwbK¨vj mve-KwgwUi mfvi wm×vš	mfvi wm×vš
02.	Incepta Vaccine Ltd. (Animal Vaccine Division), Dhamrai	Anthrax Vaccine (Living) (10 doses) **(Animal Vaccine)** Anthrax Vaccine (Living) Anthrax Vaccine	Anthrax Vaccine (Living) is recommended for the active immunization of cattle, sheep, goats, horses against anthrax disease caused by Bacillus anthracis. For control of outbreaks, vaccination of all animals not showing symptoms is recommended. Not all animals will be protected by this procedure but taking action as suggested may stop further spread of the disease. It is also recommended that animals showing symptoms be isolated and treated with antibiotics as permitted.	**Contraindication:** This vaccine is not recommended for the animals that are clinically sick or severely debilitated or under conditions of severe stress and strain. Sick or weak animals will not develop adequate immunity following vaccination. **Side effect:** The vaccine causes a swelling at the site of injection. The swelling is temporary and subsides after a few days. Immunity develops within 2-4 weeks after vaccination and persists for approximately 9-12 months. Anaphylactic reactions may occur following administration of product of this nature. If noted, administer adrenaline or equivalent.	New		Abjgv`b Kiv †h‡Z cv‡i	Abjgv`b Kiv nj
03.	Incepta Vaccine Ltd. (Animal Vaccine Division), Dhamrai	Haemorrhagic Septicaemia and Black Quarter (Inactivated) Vaccine (5 doses with aluminium hydroxide) **(Animal Vaccine)** Haemorrhagic Septicaemia and Black Quarter (Inactivated) Vaccine Haemorrhagic Septicaemia & Black Quarter Vaccine	Haemorrhagic Septicaemia and Black Quarter (Inactivated) Vaccine is recommended for cattle, calves, buffaloes and other susceptible livestock as a prophylactic measure against Haemorrhagic Septicaemia and Black Quarter Disease. The combined vaccine has advantage of protecting animals simultaneously against two Diseases.	**Contraindication:** This vaccine is not recommended for the animals that are clinically sick or severely debilitated or under conditions of severe stress and strain. Sick or weak animals will not develop adequate immunity following vaccination. **Side effect:** Generally no significant side effects are noticed after vaccination. However, in a few cases a small swelling may develop at the site of inoculation, which usually subsides within a few days.	New		Abjgv`b Kiv †h‡Z cv‡i	Abjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RIbwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë †idv‡iÝ	‡UKwbK¨vj mve-KwgwUi mfvi wm×vš	mfvi wm×vš
04.	Incepta Vaccine Ltd. (Animal Vaccine Division), Dhamrai	Haemorrhagic Septicaemia and Black Quarter (Inactivated) Vaccine (5 doses with mineral oil) **(Animal Vaccine)** Haemorrhagic Septicaemia and Black Quarter (Inactivated) Vaccine Haemorrhagic Septicaemia & Black Quarter Vaccine	Haemorrhagic Septicaemia and Black Quarter (Inactivated) Vaccine is recommended for cattle, calves, buffaloes and other susceptible livestock as a prophylactic measure against Haemorrhagic Septicaemia and Black Quarter Disease. The combined vaccine has advantage of protecting animals simultaneously against two Diseases.	**Contraindication:** This vaccine is not recommended for the animals that are clinically sick or severely debilitated or under conditions of severe stress and strain. Sick or weak animals will not develop adequate immunity following vaccination. **Side effect:** Generally no significant side effects are noticed after vaccination. However, in a few cases a small swelling may develop at the site of inoculation, which usually subsides within a few days.	New		Abjgv`b Kiv †h‡Z cv‡i	Abjgv`b Kiv nj
05.	Incepta Vaccine Ltd. (Animal Vaccine Division), Dhamrai	Haemorrhagic Septicaemia and Black Quarter (Inactivated) Vaccine (10 doses with aluminium hydroxide) **(Animal Vaccine)** Haemorrhagic Septicaemia and Black Quarter (Inactivated) Vaccine Haemorrhagic Septicaemia & Black Quarter Vaccine	Haemorrhagic Septicaemia and Black Quarter (Inactivated) Vaccine is recommended for cattle, calves, buffaloes and other susceptible livestock as a prophylactic measure against Haemorrhagic Septicaemia and Black Quarter Disease. The combined vaccine has advantage of protecting animals simultaneously against two Diseases.	**Contraindication:** This vaccine is not recommended for the animals that are clinically sick or severely debilitated or under conditions of severe stress and strain. Sick or weak animals will not develop adequate immunity following vaccination. **Side effect:** Generally no significant side effects are noticed after vaccination. However, in a few cases a small swelling may develop at the site of inoculation, which usually subsides within a few days.	New		Abjgv`b Kiv †h‡Z cv‡i	Abjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë †idv‡iÝ	‡UKwbK¨vj mve-KvgvUi mfvi wm×vš	mfvi wm×vš
06.	Incepta Vaccine Ltd. (Animal Vaccine Division), Dhamrai	Haemorrhagic Septicaemia and Black Quarter (Inactivated) Vaccine (10 doses with mineral oil) **(Animal Vaccine)** Haemorrhagic Septicaemia and Black Quarter (Inactivated) Vaccine Haemorrhagic Septicaemia & Black Quarter Vaccine	Haemorrhagic Septicaemia and Black Quarter (Inactivated) Vaccine is recommended for cattle, calves, buffaloes and other susceptible livestock as a prophylactic measure against Haemorrhagic Septicaemia and Black Quarter Disease. The combined vaccine has advantage of protecting animals simultaneously against two Diseases.	**Contraindication:** This vaccine is not recommended for the animals that are clinically sick or severely debilitated or under conditions of severe stress and strain. Sick or weak animals will not develop adequate immunity following vaccination. **Side effect:** Generally no significant side effects are noticed after vaccination. However, in a few cases a small swelling may develop at the site of inoculation, which usually subsides within a few days.	New		Abygv`b Kiv †h‡Z cv‡i	Abygv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë †idv‡iÝ	‡UKwbK¨vj mve-KwgwUi mfvi wm×vš	mfvi wm×vš
07.	Eon Pharmaceuticals Ltd., Chandan, Joydevpur, Gazipur	Ketoprofen 1500 mg + Paracetamol 1500 mg Bolus (For Veterinary Use Only) Ketoprofen USP 1500 mg + Paracetamol BP 1500mg Analgesic	Ketoprofen is a non-steroidal anti-inflammatory agent (NSAID), prescribed for mild to moderate pain, fever and inflammation. It stops the production of a substance that causes pain, fever, and inflammation. Paracetamol is used to treat mild to moderate pain (from headaches, menstrual periods, toothaches, backaches,osteoarthritis or cold/flu aches and pains) and to reduce fever.	**Contra-indication:** Ketoprofen is contraindicated in conditions like Peptic ulcer, Bronchospasm, Rhinitis, Renal insufficiency. **Side-effect:** Ketoprofen causes upset stomach, constipation, diarrhoea, dizziness, lightheadedness, drowsiness, loss of appetite or headache may occur. Paracetamol usually has no side effects.	New		c‡qvRb ‡bB wea|q Av‡e`b bv gÄyK iv †h‡Z cv‡i |	c‡qvRb ‡bB wea|q Av‡e`b bvgÄyK iv nj |
08.	Eon Pharmaceuticals Ltd., Chandan, Joydevpur, Gazipur	Azithromycin 5.0gm + Diprophylline 5.0gm + Chlorpheniramine Maleate 0.500gm Powder (For Veterinary Use Only) Azithromycin BP 5.0 gm+ Diprophylline BP 5.0gm+ Chlorpheniramine Maleate BP 0.500gm Antibiotic	It is mainly used for poultry's snore cough, eyelid swelling, nasal discharge and other respiratory tract disease symptoms caused by *Newcastle disease*, *mycoplasma chlamydia*, *Rickettsia spp* or *mixed virus infection*. Repairing respiratory tract mucosa cell rapidly, preventing inflammatory secretion exudation.	**Contra-indication:** It is contraindicated in animals with hyper sensitivity to any active ingrediants. Do not mixes use this product with acidic material. **Side-effect:** Itching, severe allergic reactions, irritation, fungal infection, sweating, hives and blistering. Hearing loss and/or tinnitus, abnormalities in taste and smell sensation.	New		c‡qvRb ‡bB wea|q Av‡e`b bv gÄyK iv †h‡Z cv‡i |	c‡qvRb ‡bB wea|q Av‡e`b bvgÄyK iv nj |
09.	Eon Pharmaceuticals Ltd., Chandan, Joydevpur, Gazipur	Ceftriaxone Sodium 2.0gm + Sulbactum Sodium 1.0gm/Vial Injectable Solution (For Veterinary Use Only) Ceftriaxone sodium USP 2.0gm + Sulbactum sodium USP 1.0gm/Vial	Infections caused by pathogens sensitive to Ceftriaxone Injection, e.g.: sepsis; meningitis; abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts); -infections of the bones, joints, soft tissue, skin and of wounds; -	**Contra-indication:** Ceftriaxone Injection is contraindicated in patients with known hypersensitivity to cephalosporin antibiotics. In patients hypersensitive to penicillin, consider the possibility of allergic cross -reactions. **Side-effect:**	New		c‡qvRb ‡bB wea|q Av‡e`b bv gÄyK iv †h‡Z cv‡i |	c‡qvRb ‡bB wea|q Av‡e`b bvgÄyK iv nj |

		Antibiotic	infections in patients with impaired defence mechanisms; renal and urinary tract infections; respiratory tract infections, particularly pneumonia, and ear, nose and throat infections; -genital infections, including gonorrhoea. Perioperative, prophylaxis of infections.	pain, tenderness, hardness, or warmth in the place where ceftriaxone was injected, headache, dizziness, sweating, flushing, diarrhea. Some side effects can be serious, such as: rash, bloody, watery stools, fever, stomach cramps, stomach pain or bloating, nausea and vomiting, heartburn, chest pain				
10.	Eon Pharmaceuticals Ltd., Chandan, Joydevpur, Gazipur	Gentamicin 400mg + Ciprofloxacin HCl 500mg + Ribavirin 200mg/100ml Solution (For Veterinary Use Only) Gentamicin USP 400mg + Ciprofloxacin HCl USP 500mg + Ribavirin INN 200mg/100ml Antibiotic	In chickens, prevention and treatment of chronic respiratory disease (CRD), mycoplasmosis, Gastrointestinal and respiratory infections caused by micro-organisms sensitive to Doxycycline and/or Gentamicin like *Bordetella, Campylobacter, Chlamydia, E. coli, Klebsiella, Haemophilus, Mycoplasma, Pasteurella, Rickettsia, Salmonella, Staphylococcus and Streptococcus* spp. Gram-negative bacteria including *Pseudomonas*, *Proteus*, *Serratia*, and the Gram-positive *Staphylococcus*. in poultry.	**Contra-indication:**use of other drug may induce ototoxicity or nephrotoxicity. **Side-effect:** The important side effects are vestibular auditory otoxicity and nephrotoxicity. In case of long term use it may particularly toxic to the auditory & renal system.	New		c‡qvRb ‡bB wea/q Av‡e`b bv gÄyÿ K i v †h‡Z cv‡i	c‡qvRb ‡bB wea/q Av‡e`b bvgÄyÿ K i v nj
11.	Eon Pharmaceuticals Ltd., Chandan, Joydevpur, Gazipur	Ofloxacin 1g + Ornidazole 2.5g + Loperamide 0.0075g Bolus (For Veterinary Use Only) Ofloxacin USP 1.0 gm+ Ornidazole USP 2.50gm + Loperamide USP 0.0075gm Antibiotic	It is indicated against severe diarrhoea and dysentery, it reduces peristaltic movement of the gut, it enhances absorption of drug, reduces water and electrolyte loss from body and ensures early and complete recovery.	**Contra-indication:** Contraindicated in hypersensitivity associated with the use of any member of the quinolone group of antimicrobial agents. **Side-effect:** Less serious side effects may include Nausea, vomiting, diarrhea, headache	New		c‡qvRb ‡bB wea/q Av‡e`b bv gÄyÿ K i v †h‡Z cv‡i	c‡qvRb ‡bB wea/q Av‡e`b bvgÄyÿ K i v nj

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †Rlbw¡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë †idv‡iÝ	‡UKwbK¨vj mve-Kwgwdi mfvi wm×vš	mfvi wm×vš
12.	Eon Pharmaceuticals Ltd., Chandan, Joydevpur, Gazipur	Thiamine Hydrochloride100 mg/ml Inject able Solution (For Veterinary Use Only) Thiamine Hydrochloride USP 100 mg/ml Vitamin	Thiamine is indicated in the treatment or prevention of thiamine deficiency states. Symptoms of thiamine deficiency may be manifested as gastrointestinal (anorexia, salivation), neuromuscular/CNS signs (ataxia, seizures, loss of reflexes), or cardiac effects (brady- or tachyarrhythmias).	**Contra-indication:** Thiamine injection is contraindicated in animals hypersensitive to it or any component of it. **Side-effect:** Hypersensitivity reactions have occurred after injecting this agent. Some tenderness or muscle soreness may result after IM injection.	New		Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj

Annex-D : Products for Import (Veterinary)

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi mfvi wm×vš	mfvi wm×vš
1.	Manufacturer: SP veterinaria, S.A., Spain **Owner/Distributor.:** Haychem (Bangladesh) Limited, Rabbee House, Building #B, apartment# B-1, House # CEN(B)-11, Road#99, Gulshan-2, Dhaka-1212	Amoxicilin trihidrate 500mg/gm Water Soluble powder Amoxicilin trihidrate 500mg/gm **Antibiotic**	For the treatment and control of Pigs : Infectious Processes caused by Streptococcus suis, except nervous and artcular forms. Poultry : Pasteurellosis and colibacillosis, caused by sensitive strains to amoxicillin. Lactating calves : Pasteurellosis and colibacillosis, caused by sensitive strains to amoxicillin and salmonellosis.	**Contraindications:** Do not administer to animals with allergy to β-lactamic antibiotics, Do not administer to rabbits, guinea pigs, hamsters and equids. oral route to animals with functional rumen. **Side effects:** Hypersensitivity reactions with different states of severity, from an urticaria to an anaphylactic shock, Gastro- intestinal symptoms (Vomits, diarrhoea), Suprainfections from resistant bacteria deriving from its continuous use.	SPAIN	10%, 15% & 30% Powder	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj
2.	Manufacturer: Lexington Enterprises PTE LTD Singapore. **Owner/Distributor.:** (Century Agro Limited Chandana Chowrasta, Gazipur, Bangladesh)	CEC (Ciprofloxacin 6.50% + Enrofloxacin HCl 2.50% + Colistin sulfate 0.25%)/ 1000ml **Antibiotic**	For the treatment and control of Prevent & controlls all kinds of bacterial diseases, Improves growth & body weights, It should be used mainly as growth promoter and to control mild infections only, During serious outbreaks potential antibiotics should be use, Mycoplasmosis, E. coil, coryza, fow cholera, Salmonellosis, It is act against allgram positive and gram negative organisms, mix infection, for prevention and treatment of Chronic Respiratory Disease Disease (CRD) and associated symptoms viz cough, seezing, nasal discharge, tracheal rales, gasping, unthriftiness etc.	**Contraindications:** Hypersensitivity to ciprofloxacin, Administration to animals with a serious impaired hepatic and/or renal function, Concurrent administration of tetracyclines, chloramphenicol, macrolides and lincosamides **Side effects:** Hypersensitivity reactions, Administration tojuvenile animals can lead to arthropathy.			c‡qvRb ‡bB wea|q Av‡e`b bv gÄyi Kiv †h‡Z cv‡i	c‡qvRb ‡bB wea|q Av‡e`b bvgÄyi Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi mfvi wm×vš	mfvi wm×vš
3.	Manufacturer: Samu Median Co. Ltd. Korea. **Owner/Distributor.:** (Tushin Agro Pharma, Meher Tower (7th floor) 164. Sonargnon road, hatirpool, Dhaka)	Coccibait Solution Amprolium 240gm + Ethopabate 15.2gm/Litre **Antibiotic**	For the treatment of coccidiosis in Chicken and turkey	**Contraindications:** None. **Side effects:** Coccibait is safe and has no negative effect on weight gain or feed conversion.	Korea	New	c‡qvRb ‡bB weavq Av‡e`b bv gÄy Kiv †h‡Z cv‡i	c‡qvRb ‡bB weavq Av‡e`b bvgÄy Kiv nj
4.	Manufacturer: Lexington Enterprises PTE LTD Singapore. **Owner/Distributor.:** (Century Agro Limited Chandana Chowrasta, Gazipur, Bangladesh)	Lincosep (Lincomycin HCl 2.2% + Spectinomycine HCl 2.2%)/ 100ml **Antibiotic**	For the treatment and control of Prevention and treatment of chronic respiratory disease (CRD), Infection caused by E. Coli, Salmonella and Mycoplasma, It can be used generally for enteric and control of diarrhea.	**Contraindications:** Do not use in poultry eggs for human consumption, horses, ruminating animals, guinea pigs and rabbits, animals known to be hypersensitive to the active ingredients, , co-administer with penicillins, cephalosporins, quinolones and/or cycloserine, seriously impaired renal functions. **Side effects:** Hypersensitivity reactions.			c‡qvRb ‡bB weavq Av‡e`b bv gÄy Kiv †h‡Z cv‡i	c‡qvRb ‡bB weavq Av‡e`b bvgÄy Kiv nj
5.	Manufacturer: Samu Median Co. Ltd. Korea. **Owner/Distributor.:** (Tushin Agro Pharma, Meher Tower (7th floor) 164. Sonargnon road, hatirpool, Dhaka)	Neoxy vet Powder Neomycin Sulfate 100gm + Oxytetracycline HCl 100gm/kg **Antibiotic**	For the treatment of following Gastrointestinal and respiratory infections caused by Bacteria, Mycoplasma, Rickettsia and Chlamydia spp. **Poultry:** Chronic Respiratory Disease (CRD), Compound Chronic Respiratory Disease (CCRD), Bacterial Enteritis, Colibacillosis, Salmonellosis etc. **Cattle, Goats and Sheep :** Bacterial Enteritis, Pneumonia, Mastitis, Colibacillosis and Actinobacillosis.	**Contraindications:** Do not use in animals with known hypersensitivity to the active ingredient. **Side effects:** Hypersensitivity reaction.	Korea	New	Abygv`b Kiv †h‡Z cv‡i	Abygv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi mfvi wm×vš	mfvi wm×vš
6.	**Manufacturer:** MERIAL 29, avanue Tony Garnier 69007 Lyon, France **Owner/Distributor.:** (Advance Animal Science Co. Ltd.; 2/10 Block-B, Lalmatia, Dhaka-1207)	BIORAL H120 NeO Effervescent Tablet Vaccine Freeze dried live attenuated virus of Infectious Bronchitis disease- H120 Strain **Bronchitis Vaccine**	It is used for the active immunization of chicken against infectious Bronchitis- H120	**Contraindications:** None. **Side effects:** Vaccination with BIORAL H120 NEO Effervescent Tablet vaccine is satisfactory and has no tendency to revert the virulence after seven passages in chicken.	FSC-France	New	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj
7.	**Manufacturer:** MERIAL 29, avanue Tony Garnier 69007 Lyon, France. **Owner/Distributor.:** (Advance Animal Science Co. Ltd.; 2/10 Block-B, Lalmatia, Dhaka-1207)	Gallivac IB88 NEO Effervescent Tablet Vaccine Live vaccine against Infectious Bronchitis caused by a coronavirus variant, strain CR88121. Each dose contains at least 4.0 $\log_{10}$ EID_{50} EID_{50} = 50% eg infective dose **Bronchitis Vaccine**	Active immunization of chickens against infectious Bronchitis caused by the Coronavirus variant of group CR88.	**Contraindications:** None. **Side effects:** Vaccination with GALLIVAC IB88 NEO vaccine is satisfactory and has no tendency to revert the virulence after seven passages in chicken.	FSC-France	New	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj
8.	**Manufacturere** OX-Compania De Tratamiento De Aguas S.L. Spain **Eskayef Bangladesh Limited**	OX-VIRIN (vet) Hydrogen Peroxide 25% + Peracetic Acid 5% **Disinfectant**	It is an ecological and effective broad-spectrum peroxyacid-based detergent with proven efficacy against bacteria, viruses, fungi, bacterial and fungal spores, ciliated protozoa and algae.	**Contraindications:** Gastric Lavage, neutralization, activated charcol. **Side effects:** Not Known	New	Spain	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj
9.	Manufacturer: Lexington Enterprises PTE LTD Singapore. **Owner/Distributor.:** (Century Agro Limited Chandana Chowrasta, Gazipur, Bangladesh)	Cough Nil Cough syrup Bromhexine HCL 80mg + Menthol 10mg + Ammonium chloride 2200mg + Levocetrizine dihydrochloride 5mg + Sodium citrate 1100mg/ 100ml **Expectorant**	For the treatment and control of Respiratory tract infections, Coryza, Bronchitis, Enhance the bio availability of antibiotics in the respiratory infection tretment, to prevent and tear respiratory symptoms during outbreak of CRD, Infections coryza & other respiratory diseases, to prevent & treat sneezing, coughing and labored breathing in infections/	**Contraindications:** Skin disease and allergic condiotions **Side effects:** No undesirable effects are to be expected when the prescribed dosage regimen is followed. Difficulty in Breathing, Vomiting, Diarrhea, Fever, Allergy			c‡qvRb ‡bB weavq Av‡e`b bv gÄyi Kiv †h‡Z cv‡i	c‡qvRb ‡bB weavq Av‡e`b bvgÄyi Kiv nj

			noninfectious causes.					

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi mfvi wm×vš	mfvi wm×vš
10.	Laboratorios Hipra S.A., Spain (Nasco Agro Product)	HIPRAPOX Vaccine 1000 dose/vial with 1000 doses of solvents. *Live Fowl-Pox Virus,* *Strain FPV92……10^4 – $10^{4.2}$ EID_{50} /Dose **Fowl-Pox Vaccine**	To prevent Fowl-Pox, both in the cutenous or diptheritic forms in chickens (boilers, layers and breederd) and turkeys	**Contraindications**: None has been described **Side effects:** After 7-10 days post-vaccination, one or two nodules should appear at the injection site which transform into scabs (“take”), indicating that the bird has been vaccinated. the scabs will disappear within 2-3 weeks after the vaccination.	CPP-Spain		Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj
11.	Manufacturer : Ningbo SanshengPharmacutical com. Ltd, China **Local agents:** Agro based technology center, 85/A tejkunipara, taejgaon, Dhaka	Compound GnRHA Liquid Injection Grade (Ovlin) (For fish use only) DOM 100mg+S-GnRHa 0.2mg/10ml **Hormone**	It is used to induce breeding in both fresh water and marine water fish. It substitutes the pituitary with advantages of high estrus rate, shorten response time and decrease side-effects.	**Contraindications:** Not Known **Side effects:** Undetected	FSC-China		c‡qvRb ‡bB wea|q Av‡e`b bv gÄyi Kiv †h‡Z cv‡i	c‡qvRb ‡bB wea|q Av‡e`b bvgÄyi Kiv nj
12.	Manufacturer : Ningbo SanshengPharmacutical com. Ltd, China **Local agents:** Agro based technology center, 85/A tejkunipara, taejgaon, Dhaka	Compound S-GnRHa Powder for Injection Grade (Ovupin) (For fish use only) DOM 100mg+S-GnRHa 0.2mg/Vial **Hormone**	It is used to induce breeding in both fresh water and marine water fish. It substitutes the pituitary with advantages of high estrus rate, shorten response time and decrease side-effects.	**Contraindications:** Not Known **Side effects:** Undetected	FSC-China		c‡qvRb ‡bB wea|q Av‡e`b bv gÄyi Kiv †h‡Z cv‡i	c‡qvRb ‡bB wea|q Av‡e`b bvgÄyi Kiv nj
13.	Manufacturer : Ningbo SanshengPharmacutical com. Ltd, China **Local agents:** Agro based technology center, 85/A tejkunipara, taejgaon, Dhaka	Human Chorionic gonadotrophin (HCG) for Injection (For fish use only) Human Chorionic gonadotrophin (HCG) **Hormone**	Accelerate ovulation and formation of corpus luteum and to increase animal sexual desire. Also can be used for delay of ovulation, ovarian cyst, inducing estrus and breeding of cultured fish.	**Contraindications:** Not Known **Side effects:** Undetected	FSC-China		c‡qvRb ‡bB wea|q Av‡e`b bv gÄyi Kiv †h‡Z cv‡i	c‡qvRb ‡bB wea|q Av‡e`b bvgÄyi Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi mfvi wm×vš	mfvi wm×vš
14.	**Manufacturer:** MERIAL Selectt INC 1168 Airport Parkway, gainesville, GE 30503, U.S.A. **Owner/Distributor.:** (Advance Animal Science Co. Ltd.; 2/10 Block-B, Lalmatia, Dhaka-1207)	Trovac-AIV H5 AVIAN INFLUENZA- Fowl Pox Vaccine. Live Fowl Po`x Vector. H5 Subtype **Influenza Vaccine**	This vaccine is recommended for initial use in healthy one-day-old chickens. Chickens vaccinated any time after one day of age should not have received a prior fowl pox vaccination. Vaccinates have been proven to remain immune to fowl pox for ten weeks and immune to avian influenza subtype H5 for 20 weeks after the initial vaccination. This vaccine may be combined with Merial Select's Marek's Disease Vaccine, Serotypes 2&3, Live Virus, product codes MHSF-3115 and MHSF-3175. It is essential that the chickens be maintained under good environmental conditions, and that exposure to disease viruses be reduced as much as possible.	**Contraindications:** Do not vaccinate diseased birds. Vaccinate all birds on the premises at one time. Administer a minimum of one dose for each bird. Avoid stress conditions during and following vaccination. Do not place chickens in contaminated facilities. Exposure to disease must be minimized as much as possible. Side effects: Not Known	FSC-USA	New	c‡qvRb ‡bB weavq Av‡e`b bv gÄyi Kiv †h‡Z cv‡i	c‡qvRb ‡bB weavq Av‡e`b bvgÄyi Kiv nj
15.	**Manufacturer:** MERIAL 4 Chemin du Calquet 31000 Toulouse, France. **Owner/Distributor.:** (Advance Animal Science Co. Ltd.; 2/10 Block-B, Lalmatia, Dhaka-1207)	FRONT LINE Plus for Dog Topical Spray Fipronil 10% + and methoprene USP 9% **Insecticide**	For Prevention and treatment against Fleas, Ticks and chewing lice for Dogs and Puppies. For external use. Frontline Plus Kill 100% of Fleas and ticks within 48hrs. The products kill parasites through contact, not via pet's bloodstream. On spread all over the pet's body. The product is absorbed into the skin and distributed with the natural oils all over pet's body.	**Contraindications:** None. Exclusively for external use. **Side effects:** No remarkable toxicity or effects were observed during clinical Trial.	FSC-France	New	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj

Annex-E : Products for Import (Medical Devices)

bs	c¯ZKvi‡Ki bvg	ewYR¨K bvg	‡gvW‡Kj wWfvB‡mi bvg	K¨v‡UMvi	Class	wb‡`kbv/e¨envi	Contraindication & Side-effect	FSC/CPP	‡UKwbK¨vj mve-KwgwUi mfvi wm×vš	mfvi wm×vš
1.	**Manufacturer :** Boston Scientific Corporation, USA **Local Agent :** Vastech Limited, Nurjehan Tower (6th Floor), 80/22 Mymensingh Road, Dhaka	Radial Jaw 4 Single use Large Capacity Biopsy Forcep	Biopsy Forcep	Biopsy Forcep	**Class : B**	It is specifically designed to collect tissue endoscopically for histologic examination. These forceps should not be used for any purpose other than their intended function. For Hot Biopsy Forceps : These Single-Use Hot Biopsy Forceps are intended to be used through an endoscope to cauterize and remove polyps and/or tissue specimens throughout the alimentary tract. The alimentary tract to include the esophagus, stomach, duodenum, jejunum, ileum and colon.	**Contraindications:** None Known. **Adverse events:** Complications associated with the use of the single-use biopsy forceps may include: Bleeding, Perforation, Infection, Pheumothorax (Specific to Pulmonary Forceps)	CFG from USA	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |
2.	**Manufacturer :** Boston Scientific Corporation, USA **Local Agent :** Vastech Limited, Nurjehan Tower (6th Floor), 80/22 Mymensingh Road Dhaka	MULTIBITE Biopsy Forcep	Biopsy Forcep	Biopsy Forcep	**Class : B**	It is designed specifically to collect tissue endoscopically for histologic examinations. These instruments are intended for endoscopic gastrointestinal biopsy and should not be used for any purpose other than their intended function.	**Contraindications:** When gastrointestinal endoscopy or biopsy is otherwise contraindicated. **Adverse events:** None known	CFG from USA	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |
3.	**Manufacturer :** Boston Scientific Corporation, USA **Local Agent :** Vastech Limited, Nurjehan Tower (6th Floor), 80/22 Mymensingh Road Dhaka	Tandem XL Triple Lumen ERCP Cannula	ERCP Cannula	Cannula	**Class : B**	It is used to inject contrast medium to obtain a cholangiogram of the biliary duct system. The contrast medium is injected through the cannula and fluoroscopy or x-ray is performed to obtain the cholangiogram.	**Contraindications:** Only those contraindications specific to endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy (ES). **Adverse Events:** Possible complications that may result from cholangiographic procedures include, but may not be limited to: Perforation Hemorrhage, Hematoma, Septicemia/Infection Cholangitis, Pancreatitis, Allergic reaction to contrast medium	CFG from USA	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	ewYR¨K bvg	‡gvW‡Kj wWfvB‡mi bvg	K¨v‡UMvi	Class	wb‡`kbv/e¨envi	Contraindication & Side-effect	FSC/CPP	mfvi wm×vš	mfvi wm×vš
4.	**Manufacturer :** Boston Scientific Corporation, USA **Local Agent :** Vastech Limited, Nurjehan Tower (6th Floor), 80/22 Mymensingh Road Dhaka	Contour ERCP Cannula	ERCP Cannula	Cannula	**Class : B**	It is used to inject contrast medium to obtain a cholangiogram of the biliary duct system. The contrast medium is injected through the cannula and fluoroscopy or x-ray is performed to obtain the cholangiogram.	**Contraindications:** Only those contraindications specific to endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy (ES). **Side Effects:** Possible complications that may result from cholangiographic procedures include, perforation; hemorrhage; hematoma; septicemia/ infection; cholangitis, pancreatitis; allergic reaction to contrast medium.	CFG from USA	Abygv`b Kiv †h‡Z cv‡i |	Abygv`b Kiv nj |
5.	**Manufacturer :** Boston Scientific Corporation, USA **Local Agent :** Vastech Limited, Nurjehan Tower (6th Floor), 80/22 Mymensingh Road Dhaka	CRE Wireguided wire Balloon Dilatation Catheter	Endoscopic Balloon Dilatation Catheters	Catheter	**Class: B**	It is intended for use in adult and adolescent populations to endoscopically dilate strictures of the alimentary tract like esophageal, pyloric, duodenal, and colonic.	**Contraindications:** None Known. **Side Effects:** Possible adverse events that may result from an alimentary tract balloon dilatation procedure include, but may not be limited to: perforation, hemorrhage, hematoma, sepsis/infection, allergic reaction to contrast medium	CFG from USA	Abygv`b Kiv †h‡Z cv‡i |	Abygv`b Kiv nj |
6.	**Manufacturer :** Boston Scientific Corporation, USA **Local Agent :** Vastech Limited, Nurjehan Tower (6th Floor), 80/22 Mymensingh Road Dhaka	Optiflo Hemostasis catheter	Hemostasis Catheter	Catheter	**Class : B**	It is used endoscopically to introduce a sclerosing agent or vasoconstrictor into selected sites to control actual or potential bleeding lesions in the digestive system.	**Contraindications:** Contraindications for this device are those applicable to injection therapy and include, but may not be limited to, those patients allergic to sclerosing or vasoconstricting agents and with patients with lesions inappropriate for injection therapy. **Side Effects:** Possible complications include, but may not be limited to: bleeding, post-injection ulceration with delayed bleeding; perforation; aspiration pneumonia; pleural effusion; other respiratory difficulties; hepatic failure; septicemia; chest pain; esophageal ulcers; esophageal stricture; and dysphagia. • Check for proper position of Optiflo Hemostasis Catheter using direct endoscopic vision. Injecting in an improper location or too deeply may lead to patient injury.	CFG from USA	Abygv`b Kiv †h‡Z cv‡i |	Abygv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	ewYR¨K bvg	‡gvW‡Kj wWfvB‡mi bvg	K¨v‡UMvi	Class	wb‡`kbv/e¨envi	Contraindication & Side-effect	FSC/CPP	mfvi wm×vš	mfvi wm×vš
7.	**Manufacturer :** Boston Scientific Corporation, USA **Local Agent :** Vastech Limited, Nurjehan Tower (6th Floor), 80/22 Mymensingh Road Dhaka	Resolution Clip Device	Endoscopic Clip	Endoscopic Clip	**Class : B**	It is indicated for clip placement within the Gastro-intestinal (GI) tract for the purpose of: 1. Endoscopic marking, 2. Hemostasis for: Mucosal/sub-mucosal defects < 3 cm, Bleeding ulcers, Arteries < 2 mm, Polyps < 1.5 cm in diameter, Diverticula in the colon, Prophylactic clipping to reduce the risk of delayed bleeding post lesion resection, 3. Anchoring to affix jejunal feeding tubes to the wall of the small bowel, 4. As a supplementary method, closure of GI tract luminal perforations < 20 mm that can be treated conservatively	**Contraindications:** • Do not use this device when hemostasis cannot be verified visually with an endoscopic field of view. • Arteries greater than 2 mm • Polyps greater than 1.5 cm in diameter • Mucosal/Submucosal defects greater than 3 cm **Side Effects:** • Limited studies indicate that the use of clips in the presence of bacterial contamination may increase or prolong infection. • Re-bleeding may occur if the clips detach within 24 hours. • Although rates of occurrence are low, recurrent bleeding, ineffective clipping or endoscopic complications could result in the need for surgery.	CFG from USA	Abjgv`b Kiv †h‡Z cv‡i	Abjgv`b Kiv nj
8.	**Manufacturer :** Boston Scientific Corporation, USA **Local Agent :** Vastech Limited, Nurjehan Tower (6th Floor), 80/22 Mymensingh Road Dhaka	Captivator Single-Use Polypectomy Snare	Polypectomy Snare	Polypectomy Snare	**Class : B**	It is indicated for use endoscopically for the removal and or cauterization of diminutive polyps, sessile polyps, pedunculated polyps and tissue from within the gastrointestinal tract.	**Contraindications:** Contraindications for these devices are those specific to endoscopic Polypectomy and tissue resection. **Side Effects:** Adverse events include, but are not limited to: perforation, fulguration, immediate or delayed hemorrhages, transmural burns, characterized by abdominal pain, fever, and transient illeus	CFG from USA	Abjgv`b Kiv †h‡Z cv‡i	Abjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	ewYwR¨K bvg	‡gvW‡Kj wWfvB‡mi bvg	K¨v‡UMwi	Class	wb‡`kbv/e¨envi	Contraindication & Side-effect	FSC/CPP	mfvi wm×vš	mfvi wm×vš
9.	**Manufacturer :** Boston Scientific Corporation, USA **Local Agent :** Vastech Limited, Nurjehan Tower (6th Floor), 80/22 Mymensingh Road Dhaka	RF 3000 Radio Frequency Generator	RF Generator	RF Generator	**Class :** C	It is intended for thermal coagulation of tissue with electrodes. The generator delivers isolated RF output of up to 200 watts to the electrode. Full power is available in the impedance range of 25 ohm to 100 ohm at a constant RF voltage; lower power are available outside this range. RF ablation system designed to provide complete, predictable thermal ablation. Utilizing an impedance-based feedback loop, the RF 3000 Ablation System is designed to provide improved clinical outcomes for patients with metastatic or primary liver disease.	**Contraindications:** Not Known **Side Effects:** Not Known	CFG from USA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj
10.	**Manufacturer :** Boston Scientific Corporation, USA **Local Agent :** Vastech Limited, Nurjehan Tower (6th Floor), 80/22 Mymensingh Road Dhaka	Expect Endoscopic Ultrasound Aspiration Needle	Endoscopic Ultrasound Aspiration Needle	Ultrasound Aspiration Needle	**Class: B**	It is designed to sample targeted submucosal and extramural gastrointestinal lesions through the accessory channel of a curvilinear echoendoscope.	**Contraindications:** Contraindications for this device are those specific to the primary endoscopic procedure to be performed in gaining access to the desired site. Relative contraindications to submucosal and extramural aspiration include, but are not limited to: coagulopathy. **Side Effects:** Complications associated with the use of the Expect Needle may include: Bleeding, Perforation, Pancreatitis, Infection Peritonitis, Inflammation, Aspiration, Fever, Allergic Reaction to Medication, Hypotension, Respiratory Depression or Arrest, Cardiac Arrhythmia or Arrest, Tumor Seeding	CFG from USA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	ewYR¨K bvg	‡gvW‡Kj wWfvB‡mi bvg	K¨v‡UMvi	Class	wb‡`kbv/e¨envi	Contraindication & Side-effect	FSC/CPP	mfvi wm×vš	mfvi wm×vš
11.	**Manufacturer :** Boston Scientific Corporation, USA **Local Agent :** Vastech Limited, Nurjehan Tower (6th Floor), 80/22 Mymensingh Road Dhaka	SpyGlass DS with Spybite	Direct Visualization System	Visualization System	**Class : B**	It is intended to provide direct visualization and to guide both optical and accessory devices for diagnostic and therapeutic applications during endoscopic procedures in the pancreatico-biliary system including the hepatic ducts.	**Contraindications** Contraindications associated with the use of this device include: • Patients for whom ERCP is medically contraindicated. • Contraindications specific to endoscopic pancreatico-biliary duct exploration and cannulation. **Side Effects:** Possible complications include, but my not be limited to: Pancreatitis, Perforation, Hemorrhage, Hematoma, Septicemia/infection, Cholangitis, Allergic reaction to contrast medium, Mucous membrane damage	CFG from USA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj
12.	**Manufacturer:** NIPRO Medical Industries Ltd., Japan **Manufacturing site:** Nipro Asia PTE LTD Operating under NIPRO Corporation, Osaka, japan 2-19-64, Matsubara, tatebayashi-shi, Gunma, 374-8518, JAPAN **Local Agent:** Utshab lifecare limited ½ Eskaton Garden Road, Ramna Dhaka	Spinal Needle	Spinal Needle	Spinal Needle	**Class: D**	It is puncture needle used for the administration of anesthetics into spinal subarachnoid space, and for the collection of cerebrospinal fluid (liquor cerebrospinal).	**Contraindications:** None **Side Effects:** None	Japan	Av‡e`bwU ¯wMZ Kiv nj	Av‡e`bwU ¯wMZ Kiv nj

bs	c¯ZKvi‡Ki bvg	ewYR¨K bvg	‡gvW‡Kj wWfvB‡mi bvg	K¨v‡UMi	Class	wb‡`kbv/e¨envi	Contraindication & Side-effect	FSC/CPP	mfvi wm×vš	mfvi wm×vš
13.	**Manufacturing site:** Somahlution, LLC 225 Chmney corner Lane Suite 2001 jupiter, FL 33458, USA **Local Agent:** Biocard Limited House # 35/10/C, Road No. 2, Shyamoli, Mohammadpur	**DuraGraft** Vascular Conduit Solution	Vascular Conduit Solution	Solution	**Class : B**	It is intended for the preservation, storage and flushing of vascular conduits, which is a pivotal step in cardiac and peripheral bypass surgeries. As the only clinically proven Endothelial Damage Inhibitor, DuraGraft is critical to successful patient outcomes.	**Contraindications:** Not known **Side Effects:** Not known	The Netherland	*1. cwZôvb‡K †gvW‡Kj wWfvBmwUi BDRvi WvUv Ges wKwbK¨vj WvUv `wLj Ki‡Z n‡e|*  *2. †gvW‡Kj wWfvBmwUi* Safety, Eficacy and usefulness *Gi welq wb¤œwjwLZ `ÿZv Rb KwWqvK mvRb Gi gZvg‡Zi wfwË‡Z cieZ‡Z wm×vš Mp,vZ n‡e -* *K. Wvt jyKvi Avgvb, KwWqvK mvRb, BDbvB‡UW nvmcvZvj, XvKv|* *L. KwWqvK mvRb, wmGgGBP, XvKv|*	*1. cwZôvb‡K †gvW‡Kj wWfvBmwUi BDRvi WvUv Ges wKwbK¨vj WvUv `wLj Ki‡Z n‡e|*  *2. †gvW‡Kj wWfvBmwUi* Safety, Eficacy and usefulness *Gi welq wb¤œwjwLZ `ÿZv Rb KwWqvK mvRb Gi gZvg‡Zi wfwË‡Z cieZ‡Z wm×vš Mp,vZ n‡e -* *K. Wvt jyKvi Avgvb, KwWqvK mvRb, BDbvB‡UW nvmcvZvj, XvKv|* *L. KwWqvK mvRb, wmGgGBP, XvKv|*

bs	c¯ZKvi‡Ki bvg	ewYR¨K bvg	‡gvW‡Kj wWfvB‡mi bvg	K¨v‡UMi	Class	wb‡`kbv/e¨envi	Contraindication & Side-effect	FSC/CPP	mfvi wm×vš	mfvi wm×vš
14.	**Manufacturing site:** HELENA Laboratories 1530 Lindbergh Dr Beaumont, USA **Local Agent:** Spac Med Enterprise BSEC Bhaban, Level-9, 102 Kazi Nazrul Islam Avenue, Kawran Bazar, Dhaka	**Actalyke** ACT Tube	Activated Clotting Time (ACT) Tubes	Tube	**Class : B**	It is used to perform the Activated Clotting Time (ACT) test, a whole blood coagulation assay used at the patient site to monitor heparin therapy.	Contraindications: None Side Effects: None	CFG of USA	*Abyjgv`b Kiv †h‡Z cv‡i |*	*Abyjgv`b Kiv nj |*
15.	**Manufacturer**: Microvention Europe, France **Production Ste**: MicroVention Inc., USA **Local Agent:** Unitrade Corporation 2/5 Humayun Road, Mohammadpur, Dhaka	SOFIA Distal access Catheter	Distal access Catheter	Catheter	**Class: D**	It is Intended for general intravascular use, including the neuro and peripheral vasculature. It can be used to facilitate the introduction of diagnostic and therapeutic agents. It is not intended for use in coronary arteries.	**Contraindications:** There are no known contraindications. **Potential Complications:** Potential complications include, but are not limited to: vessel or aneurysm perforation, vasospasm, hematoma at the site of entry, embolism, ischemia, intracerebral/intracranial hemorrhage, pseudo aneurysm, seizure, stroke, infection, vessel dissection, thrombus formation, and death.	FSC-France EC Certificate	*Abyjgv`b Kiv †h‡Z cv‡i |*	*Abyjgv`b Kiv nj |*
16.	**Manufacturer**: Microvention Europe, France **Production Ste**: MicroVention Inc., USA **Local Agent:** Unitrade Corporation 2/5 Humayun Road, Mohammadpur, Dhaka	Sofia Plus Catheter	Catheter	Catheter	**Class: D**	It is Intended for general intravascular use, including the neuro and peripheral vasculature. It can be used to facilitate the introduction of diagnostic and therapeutic agents. It is not intended for use in coronary arteries	**Contraindications:** There are no known contraindications. **Potential Complications:** Potential complications include, but are not limited to: vessel or aneurysm perforation, vasospasm, hematoma at the site of entry, embolism, ischemia, intracerebral/intracranial hemorrhage, pseudo aneurysm, seizure, stroke, infection, vessel dissection, thrombus formation, and death.	FSC-France EC Certificate	*Abyjgv`b Kiv †h‡Z cv‡i |*	*Abyjgv`b Kiv nj |*

bs	c¯ZKvi‡Ki bvg	ewYR¨K bvg	‡gvW‡Kj wWfvB‡mi bvg	K¨v‡UMi	Class	wb‡`kbv/e¨envi	Contraindication & Side-effect	FSC/CPP	mfvi wm×vš	mfvi wm×vš
17.	**Manufacturer**: Microvention Europe, France **Production Ste**: MicroVention Inc., USA **Local Agent:** Unitrade Corporation 2/5 Humayun Road, Mohammadpur, Dhaka	Sofia tm Guiding Catheter	Guiding Catheter	Catheter	**Class: D**	The SOFIA Distal Access Catheter is intended for general intravascular use, including the neuro and peripheral vasculature. It can be used to facilitate the introduction of diagnostic and theraeutic agents. It is not intended for use in coronary arteries. Moreover, it is intended for use in removal/ aspiration of emboli and thrombi from selected blood vessels in the arterial system, including the peripheral and neurovasculatures.	**Contraindications:** There are no known contraindications. **Potential Complications:** Potential complications include, but are not limited to: vessel or aneurysm perforation, vasospasm, hematoma at the site of entry, embolism, ischemia, intracerebral/intracranial hemorrhage, pseudo aneurysm, seizure, stroke, infection, vessel dissection, thrombus formation, and death.	FSC-France EC Certificate	Abjgv`b Kiv †h‡Z cv‡i	Abjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	ewYwR¨K bvg	‡gvW‡Kj wWfvB‡mi bvg	K¨v‡UMvi	Class	wb‡`kbv/e¨envi	Contraindication & Side-effect	FSC/CPP	mfvi wm×vš	mfvi wm×vš
18.	**Manufacturer**: Microvention Europe, France **Production Ste**: MicroVention Inc., USA **Local Agent:** Unitrade Corporation 2/5 Humayun Road, Mohammadpur, Dhaka	Fred (Flow Re-Direction endoluminal device) Intraluminal Support Device	Intraluminal Support Device	Intraluminal Support Device	**Class: D**	The FRED system is intended for endovascular emboilzatioon of intracranial neurovascular aneurysms. The FRED system may also be used with embolic coils for the treatment of intracranial; neurovascular lesions.	**Contraindications:** Use of the FRED system is contraindicated under these circumstances: • Patients in whom anticoagulant, antiplatelet therapy or thrombolytic drugs are contraindicated • Patients with known hypersensitivity to nickel-titanium • Patients in whom angiography demonstrated inappropriate anatomy that does not permit passage or deployment of the FRED system **Potential complications:** Possible complications include but are not limited to the following: Bleeding or Hemorrhage including intracerebral, retroperitoneal or other locations Complications of arterial puncture including pain, local bleeding (hematoma) or injury to the artery or adjacent nerves, Device migration, Distal Embolization, Headache, Incomplete aneurysm occlusion, Neurologic deficits including stroke and/or death, Perforation or dissection of the vessel(s), Pseudoaneurysm formation, Rupture or perforation of aneurysm, Transient ischemic attack (TIA) or ischemic stroke, Vasospasm, Vessel occlusion, Vessel stenosis or thrombosis	FSC-France EC Certificate	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	ewYwR¨K bvg	‡gvW‡Kj wWfvB‡mi bvg	K¨v‡UMvi	Class	wb‡`kbv/e¨envi	Contraindication & Side-effect	FSC/CPP	mfvi wm×vš	mfvi wm×vš
19.	**Manufacturer**: Microvention Europe, France **Production Ste**: MicroVention Inc., USA **Local Agent:** Unitrade Corporation 2/5 Humayun Road, Mohammadpur, Dhaka	Fred Jr. (Flow Re-Direction endoluminal device) Intraluminal Support Device	Intraluminal Support Device	Intraluminal Support Device	**Class: D**	The FRED Jr. system is intended for endovascular embolization of intracranial neurovascular aneurysms. The FRED Jr. system may also be used with embolic coils for the treatment of intracranial neurovascular lesions.	**Contraindications:** Use of the FRED Jr. system is contraindicated under these circumstances: • Patients in whom anticoagulant, antiplatelet therapy or thrombolytic drugs are contraindicated Patients with known hypersensitivity to nickel-titanium, Patients in whom angiography demonstrated inappropriate anatomy that does not permit passage or deployment of the FRED Jr. system **Potential complications:** Possible complications include but are not limited to the following: Bleeding or Hemorrhage including intracerebral, retroperitoneal or other locations Complications of arterial puncture including pain, local bleeding (hematoma) or injury to the artery or adjacent nerves, Device migration, Distal Embolization, Headache, Incomplete aneurysm occlusion, Neurologic deficits including stroke and/or death, Perforation or dissection of the vessel(s), Pseudoaneurysm formation, Rupture or perforation of aneurysm, Transient ischemic attack (TIA) or ischemic stroke, Vasospasm, Vessel occlusion, Vessel stenosis or thrombosis	FSC-France EC Certificate	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	ewYR¨K bvg	‡gvW‡Kj wWfvB‡mi bvg	K¨v‡UMi	Class	wb‡`kbv/e¨envi	Contraindication & Side-effect	FSC/CPP	mfvi wm×vš	mfvi wm×vš
20.	**Manufacturer**: Microvention Europe, France **Production Ste**: MicroVention Inc., USA **Local Agent:** Unitrade Corporation 2/5 Humayun Road, Mohammadpur, Dhaka	LVIS Intraluminal support device system	Intraluminal support device	Intraluminal support device	**Class: D**	The LVIS intraluminal Support Device is intended for use with embolic coils for the treatment of intracranial neurovascular diseases. The LVIS is also intended to be used in the peripheral vasculature.	**Contraindications:** Use of the LVIS device is contraindicated under these circumstances: • Patients in whom anticoagulant, anti-platelet therapy or thrombolytic drugs are contraindicated; • Patients with known hypersensitivity to metal, such as nickel-titanium and metal jewelry; patients with anatomy that does not permit passage or deployment of the LVIS device; Patients with an active bacterial infection; • Patients with a pre-existing stent in place at the target aneurysm. **Potential Complications:** Possible complications include but are not limited to the following: Hematoma at the puncture site, Perforation or dissection of the vessel(s), Intravascular spasm, Hemorrhaging, Rupture or perforation of aneurysm, Coil herniation, Device migration, Neurologic insufficiencies including stroke and death, Ischemia, Vascular occlusion, Vessel stenosis, Incomplete aneurysm occlusion, Pseudoaneurysm formation, Distal Embolization, Headache, Infection, Reaction to contrast agents including severe allergic reactions and renal failure.	FSC-France EC Certificate	Abjgv`b Kiv †h‡Z cv‡i |	Abjgv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	ewYR¨K bvg	‡gvW‡Kj wWfvB‡mi bvg	K¨v‡UMi	Class	wb‡`kbv/e¨envi	Contraindication & Side-effect	FSC/CPP	mfvi wm×vš	mfvi wm×vš
21.	**Manufacturer**: Microvention Europe, France **Production Ste**: MicroVention Inc., USA **Local Agent:** Unitrade Corporation 2/5 Humayun Road, Mohammadpur, Dhaka	LVIS Jr. intraluminal support device	Intraluminal support device	Intraluminal support device	**Class: D**	The LVIS Jr. intraluminal Support Device is intended for use with embolic coils for the treatment of intracranial neurovascular diseases, The LVIS jr. is also intended to be used in the peripheral vasculature.	**Contraindications:** Use of the LVISR Jr. device is contraindicated under these circumstances: • Patients in whom anticoagulant, anti-platelet therapy or thrombolytic drugs are contraindicated; Patients with known hypersensitivity to metal, such as nickel-titanium and metal jewelry; Patients with anatomy that does not permit passage or deployment of the LVISR Jr. device; Patients with an active bacterial infection **Potential Complications:** Possible complications include but are not limited to the following: Hematoma at the puncture site, Perforation or dissection of the vessel(s), Intravascular spasm, Hemorrhaging, Rupture or perforation of aneurysm, Coil herniation, Device migration, Neurologic insufficiencies including stroke and death, Ischemia, Vascular occlusion, Vessel stenosis, Incomplete aneurysm occlusion, Pseudoaneurysm formation, Distal Embolization, Headache, Infection, Reaction to contrast agents including severe allergic reactions and renal failure	FSC-France EC Certificate	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	ewYwR¨K bvg	‡gvW‡Kj wWfvB‡mi bvg	K¨v‡UMvi	Class	wb‡`kbv/e¨envi	Contraindication & Side-effect	FSC/CPP	mfvi wm×vš	mfvi wm×vš
22.	**Manufacturer**: Microvention Europe, France **Production Ste**: MicroVention Inc., USA **Local Agent:** Unitrade Corporation 2/5 Humayun Road, Mohammadpur, Dhaka	PHIL liquid embolic system	liquid embolic system	liquid embolic system	**Class: D**	The PHIL device is intended for use in the embolization of lesions in the peripheral and neurovasculature, including arteriovenous malformations and hypervascular tumors.	**Contraindications:** The use of the PHIL device is contraindicated when any of the following conditions exist: When patient has severe iodine allergy. When optimal microcatheter placement is not possible. When provocative testing indicates intolerance to the occlusion procedure. When vasospasm stops blood flow. Not for use with premature infants (<1,500 g) or individuals with significant liver and kidney function impairment. **Potential Complications:** Potential complications include, but are not limited to: Hematoma, Arterial thrombosis, Ischemic events due to embolic migration, vasospasm, thrombosis, Hemorrhagic accidents: vascular rupture – perforation, Hemodynamic changes induced by the embolization may result in hemorrhagic complications, These ischemic or hemorrhagic complications may result in various functional neurological deficits, stroke, and possibly death.	FSC-France EC Certificate	Abjgv`b Kiv †h‡Z cv‡i |	Abjgv`b Kiv nj |
23.	**Manufacturer**: Microvention Europe, France **Production Ste**: MicroVention Inc., USA **Local Agent:** Unitrade Corporation 2/5 Humayun Road, Mohammadpur, Dhaka	Eric Retrieval device	Retrieval device	Retrieval device	**Class: D**	The ERIC Retrieval Device is intended for use in the revascularization of acute ischemic stroke caused by intracranial occlusive vessels of patients who are ineligible for IV t-PA or who fail IV t-PA therapy.	**Contraindications:** Patients with known hypersensitivity to nickel-titanium. Patients with stenosis proximal to the thrombus site that may prevent safe recovery of the ERIC™ Retrieval Device. Patients with angiographic evidence of carotid dissection. **Potential complications:** Potential complications include, but are not limited to: vessel or aneurysm perforation, vasospasm, hematoma at the site of entry, embolism, ischemia, intracerebral/ intracranial hemorrhage, pseudo aneurysm, seizure, stroke, infection, vessel dissection, thrombus formation, and death.	FSC-France EC Certificate	Abjgv`b Kiv †h‡Z cv‡i |	Abjgv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	ewYR¨K bvg	‡gvW‡Kj wWfvB‡mi bvg	K¨v‡UMi	Class	wb‡`kbv/e¨envi	Contraindication & Side-effect	FSC/CPP	mfvi wm×vš	mfvi wm×vš
24.	**Manufacturer**: Microvention Europe, France **Production Ste**: MicroVention Inc., USA **Local Agent:** Unitrade Corporation 2/5 Humayun Road, Mohammadpur, Dhaka	CASPER RX Carotid Artery Stent system	Carotid Artery Stent system	Carotid Artery Stent system	**Class: D**	The Carotid Artery Stent System is indicated for use in patients with atherosclerotic disease of the carotid arteries.	**Contraindications:** The Casper Carotid Stent System is contraindicated for use in: • Patients in whom anticoagulant, antiplatelet therapy or thrombolytic drugs is contraindicated • Patients with known hypersensitivity to nickel-titanium • Patients with severe vascular tortuosity or anatomy that would preclude the safe introduction of a guide catheter, sheath, embolic protection system or stent system • Patients with uncorrected bleeding disorders • Lesions in the ostium of the common carotid artery. **Side Effects:** Possible complications include but are not limited to the following: Arrhythmia, Aneurysm and pseudoaneurysm formation, Abrupt vessel closure, Allergic reactions (including to antiplatelet agents, contrast medium or stent materials), Arteriovenous fistula, Bleeding from anticoagulation/antiplatelet medication, Bradycardia and hypotension, Carotid artery spasm, Coronary ischemia, Death, Disseminated intravascular coagulation, Emboli (air, tissue, plaque, thrombus, device or other), Emergency artery bypass graft surgery, Hematoma, Hemorrhagic or embolic stroke/TIA, Infection and/or pain at insertion site/Sepsis, Intimal tear/dissection, Myocardial Infarction (MI), New or worse encephalopathy, Renal failure/insufficiency, Respiratory arrest, Stent misplacement, Tissue necrosis, Vessel injury/dissection/perforation/rupture /trauma, Vessel occlusion or thrombosis, Vessel spasm or recoil	FSC-France EC Certificate	Abjgv`b Kiv †h‡Z cv‡i |	Abjgv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	ewYR¨K bvg	‡gvW‡Kj vWfvB‡mi bvg	K¨v‡UMi	Class	wb‡`kbv/e¨envi	Contraindication & Side-effect	FSC/CPP	mfvi wm×vš	mfvi wm×vš
25.	**Manufacturer :** Eucare Pharmaceuticals PVT. Ltd. Plot No. AC-25B, Sidco Industrial Estate, Thirumusivakka, Chennai **Local Agent :** Lima Enterprise 90/91, Nazimuddin Road, Dhaka-1000	Sterile Kollagen sheet	Biological skin dressing	dressing	**Class: B**	It is used in the follwing areas: - Non infected 2nd degree superficial and deep dermal burns, - 3rd degree burns as a temporary civer after escharectomy/ tangential excision. - Traumatic loss of skin coover. - Temporary wound cover in major open fracture wounds preparatory to flap cover. - Chronic skin ulcers. - Shallow pressure sores. - Leprosy ulcers. - Dermabrasion areas. - Protective cover widely meshed autografts.	**Contraindications:** Grossly infected wound may reject the collagen cover. Avoid in patients hypersensitive to collagen. The product will not be sterile when the packing isdamaged during transit. Store at normal room temperatures. **Side Effects:** Not Known.	FSC-India	c`wUi cixÿv I we‡kl‡bi wi‡cvU Ges we‡klÁ gZvg‡Zi wfwË‡Z cieZx‡Z wm×vš MnY Kiv n‡e|	c`wUi cixÿv I we‡kl‡bi wi‡cvU Ges we‡klÁ gZvg‡Zi wfwË‡Z cieZx‡Z wm×vš MnY Kiv n‡e|
26.	Soveta Baltica UAB Kalvariju 125, Lt 08221 Vilnius Lithuania. **<u>Local agent:</u>** Zas Corporation 80/22, Mymensingh Road Banglamotor , Dhaka-1000	Sofargen Spray, Non Sterile	Wound Dressing Spray	dressing	**Class: B**	Sofargen Spray is indicated for the local treatment of small skin lesions such as abrasions, excoriations, cuts, superficial wounds and dermatological affections in general.	**Contraindication:** Patients with known hypersensitivity to any ingredients of it. **Side effect:** Temporary irritation or burning sensation may occur, although without consequences and rare local allergic reactions.	FSC-Lithunia	Abyjgv`b Kiv †h‡Z cv‡i|	Abyjgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	ewYwR¨K bvg	‡gvW‡Kj wWfvB‡mi bvg	K¨v‡UMvi	Class	wb‡`kbv/e¨envi	Contraindication & Side-effect	FSC/CPP	mfvi wm×vš	mfvi wm×vš
27.	**Manufacturer :** Medvance (Thailand) Ltd., 129/43 Factory land,Moo 3, Phaholyothin Road, Thailand **Local Agent :** Space Med Enterprise BSEC bhaban (Level-9), 102 Kazi nazrul islam Avenue, Kawran Bazar, Dhaka-1215.	Heart Lung Pack	Heart Lung Pack	Heart Lung Pack	**Class: C**	It is used in the following areas: Perfusion products are used to temporarily replace the functions of the heart and lungs during cardiac and thoracic surgery procedures.	**Contraindications:** Not Konwn. **Side Effects:** Not Known.	FSC-Thailand	CE- Certificate `wL‡j i k‡Z Abyjgv`b Kiv †h‡Z cv‡i	CE-Certificate `wL‡j i k‡Z Abyjgv`b Kiv nj	

Annex-F

Products for Locally Manufacture (Herbal):

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †R‡bwiK bvg	wb‡`kbv	Contra-indication & Side effect	Status (New Molecule/ Existing)	Reference	nvevj GWfvBRix KwgwU (Jla wbqšY KwgwUi †UKwbK¨vj mve KwgwUi mfvi wm×vš)	mfvi wm×vš
1.	Incepta Herbal & Nutricare Ltd.	Ispaghula Husk 3.5 gm + Mebeverine HCl 135 mg / Sachet Effervescent Granules Ispaghula Husk BP 3.5 gm + Mebeverine HCl BP 135 mg / Sachet	For the treatment of irritable bowel syndrome	**Contraindications:** 1. Contraindicated in cases of intestinal obstruction or faecal impaction 2. Hypersensitivity to ispaghula or mebeverine **Side Effects:** Ispaghula/psyllium husk contains potent allergens. The exposure to these allergens is possible through oral administration, contact with the skin and, in the case of powder formulations, also by inhalation. As a consequence to this allergic potential, individuals exposed to the product can develop hypersensitivity reactions such as rhinitis, conjunctivitis, bronchospasm and in some cases, anaphylaxia. Cutaneous symptoms as exanthema and/or pruritus have also been reported. Special attention should be given to individuals manipulating the powder formulations routinely.	New	BNF: 71 Page No: 77	Abjgv`b Kiv †h‡Z cv‡i|	Abjgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †R‡bwiK bvg	wb‡`kbv	Contra-indication & Side effect	Status (New Molecule/ Existing)	Reference	nvevj GWfvBRix KwgwU (Jla wbqšY KwgwUi †UKwbK¨vj mve KwgwUi mfvi wm×vš)	mfvi wm×vš
2.	Radiant Nutraceuticals Limited (Herbal Division)	Hibiscus Flower 200mg Capsule Hibiscus Flower (Hibiscus sabdariffa)	Prevent recurrent cystitis, Improve the quality of life of women suffering from UTIs, Helps lower body temperature, Upper respiratory tract infection (dissolve phlegm), Laxative, Diuresis, Hypertension	**Contraindication:** None listed **Side effect:** None listed	New	PDR for herbal medicines; Page: G-14, 394 European Pharmacopoeia , Page: 2376 Herbal Medicines Compendium – USP Monograph of Hibiscus sabdariffa Flower	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj|
3.	Radiant Nutraceuticals Limited (Herbal Division)	Cranberry 500mg Capsule Vaccinium macrocarpon (Cranberry)	Reduction in UTI occurrence, Kidney stones, Treatment of UTI		Existing	The ABC clinical guide to herbs; p-73	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †R‡bwiK bvg	wb‡`kbv	Contra-indication & Side effect	Status (New Molecule/ Existing)	Reference	nvevj GWfvBRix Kwgw U (Jla wbqšY Kwgw Ui †UKwbK¨vj mve Kwgw Ui mfvi wm×vš)	mfvi wm×vš
4.	Total Herbal &Nutraceuticals	Cranberries Syrup Cranberries Extract 30 gm /100ml (Vaccinium macrocarponAiton)	1) Urinary Tract Infection -UTI, (2) Cranberries have also been used for blood disorders, (3) PreventLiver problems, (4) Removing Kidney stones,(5) Prevent Loss of appetite (6) Scurvy and in the preparation of wound dressings. (7) Antioxidant activity	**Contra Indication**contraindications of cranberry may be present with renal insufficiency and in persons with the potential for developing Uric acid or calcium oxalate stones. **Side Effect:** Not known	New	*(1)ABC Clinical Guide to herbs,Page no: 73-80* (2)PDR for Herbal medicines 4th edition Page no: 20-21.	Abyjgv`b Kiv †h‡Z cv‡i|	Abyjgv`b Kiv nj|
5.	Total Herbal &Nutraceuticals	Cranberries Sachet Cranberries Extract 2 gram (Vaccinium macrocarponAiton)	1) Urinary Tract Infection -UTI, (2) Cranberries have also been used for blood disorders, (3) Prevent Liver problems, (4) Removing Kidney stones, (5) Prevent Loss of appetite (6) Scurvy and in the preparation of wound dressings. (7) Antioxidant activity	**Contra Indication**contraindications of cranberry may be present with renal insufficiency and in persons with the potential for developing Uric acid or calcium oxalate stones. **Side Effect:** Not known	New	*(1)ABC Clinical Guide to herbs,Page no: 73-80* (2) PDR for Herbal medicines 4th edition Page no: 20-21.	Abyjgv`b Kiv †h‡Z cv‡i|	Abyjgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †R‡bwiK bvg	wb‡`kbv	Contra-indication & Side effect	Status (New Molecule/ Existing)	Reference	nvevj GWfvBRix Kwgw U (Jla wbqšY Kwgw Ui †UKwbK¨vj mve Kwgw Ui mfvi wm×vš)	mfvi wm×vš
6.	Radiant Nutraceuticals Limited (Herbal Division)	Liver Tonic 500mg Tablet Capers (Capparis spinosa) , Chicory (Cichorium intybus) ,Black nightshade (Solanum nigrum) , Arjuna (Terminalia arjuna) , Negro coffee (Cassia occidentalis) , Yarrow (Achillea millefolium) , Tamarisk (Tamarix gallica) , Mandur bhasma	Liver dysfunction like viral hepatitis, alcoholic liver disease, pre-cirrhotic conditions and early cirrhosis, anorexia, loss of appetite and liver damage due to radiation therapy, fatty liver, Jaundice and loss of appetite during pregnancy. As an adjuvant during prolonged illness and convalescence, adjuvant to hemodialysis and as an adjuvant to hepatotoxic drugs like anti-tubercular drugs, statins, chemotherapeutic agents and antiretrovirals)	**Contraindication:**None listed **Side effect:** None listed	New	The ABC clinical guide to herbs; p-379	Abygv`b Kiv †h‡Z cv‡i	Abygv`b Kiv nj|
7.	Radiant Nutraceuticals Limited (Herbal Division)	Liver Tonic 500mg Capsule Capers (Capparis spinosa) , Chicory (Cichorium intybus) ,Black nightshade (Solanum nigrum) , Arjuna (Terminalia arjuna) , Negro coffee (Cassia occidentalis) , Yarrow (Achillea millefolium) , Tamarisk (Tamarix gallica) , Mandur bhasma	Liver dysfunction like viral hepatitis, alcoholic liver disease, pre-cirrhotic conditions and early cirrhosis, anorexia, loss of appetite and liver damage due to radiation therapy, fatty liver, Jaundice and loss of appetite during pregnancy. As an adjuvant during prolonged illness and convalescence, adjuvant to hemodialysis and as an adjuvant to hepatotoxic drugs like anti-tubercular drugs, statins, chemotherapeutic agents and antiretrovirals)	**Contraindication:** None listed **Side effect:** None listed	New	The ABC clinical guide to herbs; p-379	Abygv`b Kiv †h‡Z cv‡i	Abygv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †R‡bwiK bvg	wb‡`kbv	Contra-indication & Side effect	Status (New Molecule/ Existing)	Reference	nvevj GWfvBRix KwgwU (Jla wbqšY KwgwUi †UKwbK¨vj mve KwgwUi mfvi wm×vš)	mfvi wm×vš
8.	Radiant Nutraceuticals Limited (Herbal Division)	Ginoba 240mg ER Tablet Ginkgo biloba L. (Ginkgo Biloba Extract)	Neurology:Cerebral insufficiency: The German Commission E approved ginkgo for the following symptoms resulting from demential syndromes: memory deficit, poor concentration, depression, dizziness, tinnitus, and headache. Treatment of attention and memory loss that occur with Alzheimer's disease and multi-infarct dementia. Vertigo and tinnitus (ringing in the ear) of vascular and involutional origin. Vascular Disease: Peripheral vascular disease: improvement of pain-free walking distance in Peripheral Arterial Occlusive Disease in Stage II according to Fontaine (intermittent claudication) in a regimen of physical therapeutic measures, in particular walking exercise approved by Commission E. Other Potential Uses: Sexual dysfunction secondary to selective serotonin reuptake inhibitor (SSRI) use. Control of acute altitude sickness and vascular reactivity to cold exposure. Protective action in hypoxia. Acute cochlear deafness.	**Contraindication:** Ginkgo should not be used in persons who have a history of allergy to ginkgo. It is also contraindicated in bleeding disorders due to increased bleeding potential associated with chronic use (6–12 months) or before elective surgery. The 120 mg dosage should not be used in children under 12 years. Clinicians are advised to use all necessary precautionary measures in administering ginkgo extracts for treatment of depressive mood and headache not associated with demential syndromes since these conditions have not been sufficiently investigated. **Side effect:** Rare cases of stomach or intestinal upsets, headaches, or allergic skin reactions have been documented. Ginkgo has also been reported to cause dizziness and palpitations. In higher than recommended doses, diarrhea, nausea, vomiting, restlessness, and weakness may occur. Several case reports of bleeding associated with ginkgo use have been reported, including two reports of subdural hematoma, one report of subarachnoid hemorrhage, one report of intracerebral hemorrhage, and one report of anterior chamber bleeding in the eye (hyphema).	Existing	The ABC clinical guide to herbs; p-185	Abyjgv`b Kiv †h‡Z cv‡i|	Abyjgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †R‡bwiK bvg	wb‡`kbv	Contra-indication & Side effect	Status (New Molecule/ Existing)	Reference	nvevj GWfvBRix KwgwU (Jla wbqšY KwgwUi †UKwbK¨vj mve KwgwUi mfvi wm×vš)	mfvi wm×vš
9.	Radiant Nutraceuticals Limited (Herbal Division)	Pycnogenol 75mg Capsule Pycnogynol/French Maritime Pine Extract	Pine bark extract demonstrates antioxidant and anti-inflammatory actions and has been studied for a wide range of clinical conditions, including chronic venous insufficiency, cardiovascular conditions, and erectile dysfunction. However, many clinical studies have been limited in size, with nonrandomized or open-label designs conducted by a limited pool of researchers.	**Contraindication**: Pycnogenol seems to increase the immune system. By increasing the immune system pycnogenol might decrease the effectiveness of medications that decrease the immune system. Some medications that decrease the immune system include azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3 (OKT3, Orthoclone OKT3), mycophenolate (CellCept), tacrolimus (FK506, Prograf), sirolimus (Rapamune), prednisone (Deltasone, Orasone), corticosteroids (glucocorticoids), and others. **Side Effect:** None known at therapeutic dosage levels. At high dosages diarrhea or mild gastrointestinal upset may occur.	Existing	The ABC clinical guide to herbs; p-369	Abyjgv`b Kiv †h‡Z cv‡i|	Abyjgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †R‡bwiK bvg	wb‡`kbv	Contra-indication & Side effect	Status (New Molecule/ Existing)	Reference	nvevj GWfvBRix KwgwU (Jla wbqšY KwgwUi †UKwbK¨vj mve KwgwUi mfvi wm×vš)	mfvi wm×vš
10	M/s. Hamdard Laboratories (Waqf) Bangladesh Ltd.	Fenugreek Trigonella foenum-graecum 500mg Capsule (Methi)	It exhibits hypoglycemic effect and indicated for effective management and treatment of diabetes. It is also used for the treatment of loss of appetite, inflammation of the skin, fever, vomiting, anorexia, cough, bronchitis, colitis, and cold pain in the lower abdomen.	**Contraindication**: The Drug should not be used during Pregnancy. **Side Effect:** Health risk or Side Effects following the proper administration of designated therapeupic dosages are not recorded.	New	*PDR for Herbal Medicines* (Herbal Monographs), 4th Edition, USA. Fenugreek; pp. 319-320.	Abyjgv`b Kiv †h‡Z cv‡i|	Abyjgv`b Kiv nj|
11	Total Herbal &Nutraceuticals	Fenugreek Extract Fenugreek Extract 610mg Tablet	1) Aphrodisiac: 2) Blood Glucose Control, 3) Increase Free Testosterone 5) Supports Growth Hormone, 6) Improve of Muscle 7) Reduce body weight. 8) Reduce ttriglycerides 9) Good for Breast Feeding Mothers	**Contra Indication:** None documented. However, the potential for preparations of fenugreek to interact with other medicines administered concurrently, particularly those with similar or opposing effects, should be considered. **Side Effect:** Not known	New	1) British Herbal Pharmacopeia 1996, Page no: 80-81 3)The Complete Commisssion E Monograph, Page no:130 3)PDR for Herbal medicines 4th edition Page no:304.	Abyjgv`b Kiv †h‡Z cv‡i|	Abyjgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †R‡bwiK bvg	wb‡`kbv	Contra-indication & Side effect	Status (New Molecule/ Existing)	Reference	nvevj GWfvBRix KwgwU (Jla wbqšY KwgwUi †UKwbK¨vj mve KwgwUi mfvi wm×vš)	mfvi wm×vš
12	M/s. Hamdard Laboratories (Waqf) Bangladesh Ltd.	Azadirachta indica 475mg (Neem) Capsule	The special preparation of standardized extract of Azadirachta *indica* makes the product as a perfect natural remedy for balancing the body. It acts as a rejuvenator and expels toxins from the body. It also acts as a blood purifier for beautiful & healthy skin, combats acne and pimples, boosts up immune system, reduces blood sugar and lowers blood cholesterol level. It has anti-allergic property and it is also very effective in skin infection and rashes.	**Contraindication**: There is no known Contraindication. **Side Effect:** No health hazards or side effects are known in conjunction with the proper administration of designated therapeupic dosages.	New	*PDR for Herbal Medicines* (Herbal Monographs), 4th Edition, USA. Neem; pp. 599-600.	Abyjgv`b Kiv †h‡Z cv‡i|	Abyjgv`b Kiv nj|
13	M/s. Hamdard Laboratories (Waqf) Bangladesh Ltd.	Piper methysticum 400mg Capsule (kava Kava)	Nervous excitement, mental stress, anxiety and insomnia.	**Contraindication**: Kava is Contraindicated in patients with endogenous depression because it may increase the danger of suicide. **Side Effect:** *General:* No health hazards are known in conjunction with the proper administration of designated therapeutic dosages.Administration of the herb leads to rare cases of allergic reactions and gastrointestinal complaints. Slight morning tiredness can appear at the beginning of the therapy. Motor reflexes and judgment when driving may be reduced while taking the herb. *Central Nervous System:* Dyskinesia and	New	*PDR for Herbal Medicines* (Herbal Monographs), 4th Edition, USA. Kava Kava; pp. 489-496.	Abyjgv`b Kiv †h‡Z cv‡i|	Abyjgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †R‡bwiK bvg	wb‡`kbv	Contra-indication & Side effect	Status (New Molecule/ Existing)	Reference	nvevj GWfvBRix Kwgw U (Jla wbqšY Kwgw Ui †UKwbK¨vj mve Kwgw Ui mfvi wm×vš)	mfvi wm×vš
				choreoathetosis of the limbs, trunk, neck and facial musculature have been reported secondary to the administration of kava (Schelosky, 1995; Spillane, 1997). *Endocrine:* Following long-term use of high doses of Kava extract, weight loss was reported (Mathews, 1988).				
14	M/s. Hamdard Laboratories (Waqf) Bangladesh Ltd.	Rosmarinus officinalis 500mg Capsule (Rosemary)	Blood pressure, dyspeptic complaints, loss of appetite, headaches, migraine, and rheumatism.	**Contraindication**: Rosemary preparations should not be used during pregnancy. **Side Effect:** *General:* No health hazards or side effects are known in conjunction with the proper administration of esignated therapeutic dosages. Contact allergies have been observed on occasion.	New	*PDR for Herbal Medicines* (Herbal Monographs), 4th Edition, USA. Rosemary; pp. 709-710.	Abygv`b Kiv †h‡Z cv‡i	Abygv`b Kiv nj|
15	M/s. Hamdard Laboratories (Waqf) Bangladesh Ltd.	Vitis vinifera 50mg Capsule (Grape Seed)	Peripheral venous insufficiency (such as nocturnal cramps, paraesthesias, sensation of warmth), cyanosis, edema, weakness due to polyurea, night vision, ocular stress, post-operative edema.	**Contraindication**: There is no known Contraindication. **Side Effect:** No health hazards or side effects are known in conjunction with the proper administration of designated therapeutic dosages.	New	*PDR for Herbal Medicines* (Herbal Monographs), 4th Edition, USA. Grape Seed; pp. 405-410.	Abygv`b Kiv †h‡Z cv‡i	Abygv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †R‡bwiK bvg	wb‡`kbv	Contra-indication & Side effect	Status (New Molecule/ Existing)	Reference	nvevj GWfvBRix KwgwU (Jla wbqšY KwgwUi †UKwbK¨vj mve KwgwUi mfvi wm×vš)	mfvi wm×vš
16	Total Herbal &Nutraceuticals	KELP Extract KELP Powder (Bladderwrack) 300 mg Tablet	1) Kelp are used for the regulation of thyroid function. 2) Hypothyroidism, 3) Supports Goiter, 4) Prevent Arthritis, 5) Prevent Rheumatism,6) Reduces Obesity.7) Reduces Diabetes	**Contra Indication**Brown Kelp should not be used by individuals with afamilial disposition to thyroid illness or hyperthyroidism. **Side Effect:** Not known	New	1) PDR for Herbal medicines 4th edition Page no: 122 and Page no: 446-447, 2) British Pharmacopeia –Volume 4, Herbal	Abygv`b Kiv †h‡Z cv‡i|	Abygv`b Kiv nj|
17	Total Herbal &Nutraceuticals	Couch Grass Couch GrassRhizome Extract325 mg Capsule	1) Infections of the urinary tract 2) Removes kidney stones 3) Removes bladder stones	**Contra Indication:** No flushing-out therapy if edema is present due to cardiac or renal insufficiency **Side Effect:** Not known	New	1.British Pharmacopeia Voluem 4, Copy Attached 2. PDR for Herbal Medicine, Fourth Edition, Page:771-772 3. The Complete German Commission E Monograph, Page no:118	Abygv`b Kiv †h‡Z cv‡i|	Abygv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †R‡bwiK bvg	wb‡`kbv	Contra-indication & Side effect	Status (New Molecule/ Existing)	Reference	nvevj GWfvBRix KwgwU (Jla wbqšY KwgwUi †UKwbK¨vj mve KwgwUi mfvi wm×vš)	mfvi wm×vš
18	M/S Acme Laboratories Ltd. (Herbal & Nutraceuticals Division)	Peppermint oil (Menthol) Liquid Peppermint oil (Menthol) 20ml/100ml	It is used in Catarrh of the upper respiratory tract and inflammation of the upper mucosa.	**Contra Indication:** It should not be applied to the faces of infants or small children, particularly not in the nasal area. **Side Effect:** It is a weak potential for sensitization due to its menthol content. Hypersensitivity reactions may include skin rash, adbominal pain, heartburn and perianal burning.	New	PDR for Herbal Medicine, 3rd Edition, P-629,630,631	Abyjgv`b Kiv †h‡Z cv‡i|	Abyjgv`b Kiv nj|